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Never be too big to ask questions,  
never know too much to learn something new. 
  
- Augustine Mandino –
 ABSTRACT 
 
 
Medicines information (MI) is an essential part of rational pharmacotherapy. 
Intensified clinical research and more matured pharmacovigilance systems 
have produced more information on therapeutic effects of pharmacotherapies 
to facilitate more detailed profiling of their benefits and risks. In turn, more 
open communication on medications with patients has been facilitated by 
drug safety issues, patients’ right to know about their treatments and by a 
significant increase in electronic information sources. Even though a wide 
variety of evidence-based MI sources for patients and consumers is currently 
available, the coordination between MI sources and their providers has been 
limited. The need for coordination has become more evident as the number of 
MI sources and providers has substantially increased over time. 
Improved communication on medicines to patients and consumers has 
been a strategic priority in developing MI practices in the European Union, 
including Finland, during the 2000s. To enhance the coordination of MI 
practices in Finland, the Finnish Medicines Agency Fimea published the first 
national MI strategy in 2012. The primary goal of the national MI strategy is 
to influence MI practices in all social and healthcare settings to reach the 
ultimate goal of well-informed patients who adhere to their medication.  
This thesis examines MI practices and policies in Finland during the 
2000s. The primary goal of the thesis is to support the strategic development 
of MI and the implementation of the national MI strategy. The thesis 
comprises three independent studies (I–III) in which both quantitative and 
qualitative research methods were applied. They investigated development 
targets for MI practices in Finland based on a systematic review of the existing 
literature (I), assessed long-term trends in the receipt of MI among the 
Finnish adults (II), and evaluated how well the ultimate goal of the national 
MI strategy regarding well-informed adherent patients with chronic diseases 
had been achieved at the midpoint of the strategy period in 2015 (III). 
The systematic review on MI research conducted in Finland during 
2000–2016 found 126 studies that covered a wide range of approaches 
applying various research methods (Study I). More than half of the studies 
were qualitative (54% of all studies, n=68), although surveys were the most 
commonly used individual method (47%, n=59). Twelve studies were 
interventions and only six studies applied a theory. Patient counselling in 
community pharmacies was the most commonly studied topic (19%, n=24). 
Regardless of some methodological pitfalls, MI research provides a 
multifaceted understanding of MI practices and their development needs in 
Finland. Research should shift towards larger research lines having a stronger 
 theory base and study designs. Future research should be focused on the 
effectiveness of MI in different healthcare settings, along with the use of 
electronic MI sources and services, MI literacy, MI needs among patients and 
healthcare professionals (HCPs). 
Based on the nationally representative repeated postal survey “Health 
Behaviour and Health among the Finnish Adult Population” conducted by the 
National Institute for Health and Welfare during 1999–2014, physicians, 
community pharmacists and package leaflets were the main MI sources 
among adult medicine users aged 15–64 years (n=18862) throughout the 
study period (Study II). The use of the Internet as a MI source increased the 
most noticeably, being used by 1% of the adult medicine users in 1999 and 16% 
in 2014. The number of medicine users who did not receive MI from HCPs 
more than doubled (17% to 38%), and the number of medicine users who did 
not receive MI from any sources increased by sevenfold (4% to 28%) during 
the study period. It is necessary to continue research on trends in the receipt 
of MI at the population level and to identify population groups requiring 
special attention, such as senior citizens with multiple medications. Further 
evidence is also needed on factors contributing to a growing number of 
medicine users not receiving MI. 
According to the interviews among stakeholder representatives (n=79, 
71%) involved in the implementation of the national MI strategy, the 
medication use processes for patients with chronic diseases requires 
development at every level of implementation (i.e., macro, meso, micro) 
(Study III). Medication counselling and other care advice by HCPs, 
particularly by community pharmacists, were the best implemented actions in 
general. The major actions needing development at the infrastructure level 
(macro) concern the coordination of care, transfer of patient information 
between care units, lack of reconciled medication lists, and local and national 
agreements on the responsibilities of patients and HCPs involved in the 
medication use process; at the HCP level (meso), focus on implementing the 
entire medication use process in primary and social care, particularly in 
geriatric units; and at patient level (micro), related to limited patient 
involvement in their care, lack of patients’ adherence to treatment and the 
inability of patients to retrieve information. Patients need to be better involved 
in implementing their treatment by improving empowerment and partnership 
to achieve the goal of well-informed adherent patients. 
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 TIIVISTELMÄ 
 
 
Lääkeinformaatio on keskeinen osa rationaalista lääkehoitoa. Kliinisten 
lääketutkimusten lisääntyminen ja lääketurvatoiminnan kehittyminen ovat 
lisänneet tietämystä lääkkeiden vaikutuksista. Lääkitysturvallisuuden 
edistämistyö, potilaan oikeus saada tietoa käyttämistään lääkkeistä ja 
sähköisten lääkeinformaatiolähteiden määrän merkittävä kasvu ovat 
mahdollistaneet potilaille avoimemman tiedonsaannin lääkehoidoista. 
Vaikka näyttöön perustuvia lääkeinformaatiolähteitä potilaille ja kuluttajielle 
on nykyisin saatavilla yhä enemmän, koordinaatio informaatiolähteiden ja 
niiden tuottajien välillä on ollut puutteellista. 
Potilaiden ja kuluttajien lääkeinformaation saannin parantaminen on 
ollut strateginen tavoite Euroopan unionissa 2000-luvulla. Tähän liittyen 
Lääkealan turvallisuus- ja kehittämiskeskus Fimea julkaisi ensimmäisen 
kansallisen lääkeinformaatiostrategian vuonna 2012. Strategialla halutaan 
vaikuttaa lääkeinformaatiokäytänteisiin kaikkialla sosiaali- ja terveyden-
huollossa, jotta saavutettaisiin tavoite hyvin informoiduista ja lääkehoitoi-
hinsa sitoutuneista potilaista. 
Väitöskirjatutkimuksessa tutkittiin lääkeinformaatiokäytänteiden 
kehittymistä Suomessa 2000-luvulla sekä sitä, miten Euroopan unionin 
linjaukset ovat näkyneet siinä. Tutkimus jakautui kolmeen osatyöhön, joissa 
tutkittiin 1) lääkeinformaatiokäytänteiden kehittymistä Suomessa tutkimus-
tiedon valossa 2000-luvulla, 2) aikuisväestön lääkeinformaation saannin 
kehittymistä vuosina 1999–2014 ja 3) kansallisen lääkeinformaatiostrategian 
toteutumista kolme vuottta sen käynnistymisen jälkeen vuonna 2015.       
Ensimmäinen osatyö toteutettiin järjestelmällisenä kirjallisuus-
katsauksena Suomessa vuosina 2000–2016 julkaistuista lääkeinformaatiotut-
kimuksista (n=126). Yli puolet (54 %, n=68) tutkimuksista oli laadullisia, 
vaikkakin kysely oli yleisimmin käytetty yksittäinen tutkimusmenetelmä (47 
%, n=59). Interventiotutkimuksia oli yhteensä 12. Kuudessa tutkimuksessa oli 
hyödynnetty teoriaa viitekehyksenä. Lääkeneuvonta avohoidon apteekeissa 
oli yleisimmin tutkittu teema (19 %, n=24). Huolimatta joistakin tutkimus-
menetelmällisistä puutteista, lääkeinformaatiotutkimus antaa kattavan 
käsityksen Suomen lääkeinformaatiokäytänteistä ja kehitystarpeista. Jatkos-
sa lääkeinformaatiotutkimuksen tulisi suuntautua laajempiin tutkimuskoko-
naisuuksiin, jotka pohjautuisivat vahvemmin teorioihin ja teoriasta johdettui-
hin tutkimusasetelmiin. Lääkeinformaation vaikuttavuutta eri terveydenhuol-
toympäristöissä, sähköisten lääkeinformaatiolähteiden ja palvelujen käyttöä, 
lääkeinformaation lukutaitoa sekä kuluttajien ja terveydenhuollon 
ammattilaisten lääketiedon tarpeita tulisi tutkia syvällisemmin. 
 Toinen osatyö perustui Terveyden ja hyvinvoinnin laitoksen valta-
kunnallisesti edustavaan vuosittaiseen postikyselyyn ”Suomalaisen aikuis-
väestön terveyskäyttäytyminen ja terveys” (AVTK) vuosiväliltä 1999–2014. 
Tulosten perusteella lääkärit, farmaseutit ja proviisorit sekä pakkausselosteet 
olivat yleisimmät lääkeinformaation lähteet aikuisilla lääkkeiden käyttäjillä 
(15–64-vuotiaat, n=18862) koko tutkimusajanjakson ajan. Eniten kasvoi 
internetiä lääketiedon lähteenä käyttävien osuus:  vuonna 1999 osuus oli 1 % 
vastaajista ja vuonna 2014 osuus oli 16 %. Tutkimusajanjakson aikana niiden 
lääkkeen käyttäjien määrä yli kaksinkertaistui (17 %:sta 38 %:iin), jotka 
ilmoittivat, etteivät olleet saaneet tietoa käyttämistään lääkkeistä terveyden-
huollon ammattilaisilta. Vastaavasti niiden lääkkeiden käyttäjien määrä 
seitsenkertaistui (4 %:sta 28 %:iin), jotka ilmoittivat, etteivät olleet saaneet 
mistään informaatiolähteestä tietoa käyttämistään lääkkeistä. Lääkeinfor-
maation saannin trendejä väestötasolla tulee seurata jatkossakin ja tunnistaa 
potilasryhmät, joilla on erityistarpeita lääkeinformaation saannissa, kuten 
iäkkäät monilääkityt potilaat. Lisäksi tietoa tarvitaan niistä tekijöistä, jotka 
vaikuttavat kasvavaan määrään lääkkeiden käyttäjiä, jotka jäävät ilman tietoa. 
Kansallisen lääkeinformaatiostrategian toteutumista tutkittiin haastat-
telemalla strategian toteuttamiseen osallistuvien sidosryhmien edustajat 
(n=79, osallistumisprosentti 71). Tulosten perusteella pitkäaikaissairaiden 
lääkehoitoprosessi vaatii kehittämistä prosessin jokaisella toteutustasolla 
(makro-, meso- ja mikrotaso). Lääkeneuvonta, erityisesti apteekeissa, ja 
terveydenhuollon ammattilaisten toteuttama muu hoidon ohjaus olivat 
parhaiten toteutuneet toimenpiteet. Toimintaympäristön (makrotaso) 
merkittävimmät kehittämistarpeet koskivat lääkehoidon koordinointia, 
potilastiedon siirtymistä hoitoyksiköiden välillä, ajantasaisen lääkitystiedon 
saatavuutta sekä paikallisia ja kansallisia sopimuksia potilaiden ja 
terveydenhuollon ammattilaisten tehtävistä ja vastuista lääkehoito-
prosessissa. Terveydenhuollon ammattilaisilla (mesotaso) suurimmat 
kehittämistarpeet tunnistettiin perusterveydenhuollossa ja sosiaalihuollossa 
tapahtuvassa lääkehoidon toteutuksessa, erityisesti vanhustenhuollon 
yksiköissä. Ensisijaisina puutteina potilailla (mikrotaso) esille nostettiin 
potilaiden rajoittunut osallistuminen omaan hoitoonsa, puutteellinen hoitoon 
sitoutuminen sekä riittämättömät tiedonhakutaidot luotettavan 
lääkeinformaation etsimiseen. Potilaita tulisi ottaa enemmän mukaan hoidon 
toteuttamiseen vahvistamalla potilaiden voimaantumista omaan hoitoonsa 
sekä tukemalla potilaiden kumppanuutta, jotta saavutettaisiin tavoite hyvin 
informoiduista ja hoitoonsitoutuneista potilaista. 
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GLOSSARY 
ADHERENCE 
Adherence can be defined as “the extent to which a person’s behaviour, e.g., 
taking medicines, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from healthcare professionals”.1 
Adherence requires that patients are active partners with healthcare 
professionals in their own care, and that they have open communication with 
healthcare professionals in order to ensure an effective clinical practice. 
 
CLINICAL PRACTICE GUIDELINES 
Clinical practice guidelines are independent, evidence-based guidelines that 
are intended as a basis for treatment decisions, and can be used by physicians, 
other healthcare professionals and patients.2 These guidelines cover 
important issues related to health, medical treatment as well as the prevention 
of diseases. In Finland, the national guidelines are called the Current Care 
Guidelines. 
 
CONCORDANCE 
Concordance refers to mutual understanding of the treatment as a result of a 
negotiation between the patient and the healthcare professional that respects 
the patient’s wishes, beliefs and underlying knowledge.3,4 Concordance views 
the patient as being the equal of the healthcare provider and as having a right 
to make informed decisions. Concordance is related to ‘empowerment’ and 
‘patient-centred care’. 
 
DRUG SAFETY 
Drug safety covers knowledge and assessment of pharmacological properties 
and effects, quality of the manufacturing process, labelling and information 
relating to medicines as a product.5 
 
ELECTRONIC MEDICINES INFORMATION 
In this thesis, electronic medicines information covers all information related 
to medicines and medicine use provided in electronic form, e.g., the Internet, 
mobile applications in smartphones and multimedia. 
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EMPOWERMENT 
In the context of health, empowerment is a process through which people gain 
greater control over decisions and actions affecting their health by developing 
skills, knowledge, competence and opportunities to influence the factors 
affecting their health and well-being.6 
 
HEALTH EDUCATION 
Health education comprises consciously constructed opportunities for 
improving health knowledge and health literacy.7 It fosters the motivation, 
skills and confidence necessary to take action to improve health. Health 
education includes the communication of information concerning the 
underlying social, economic and environmental conditions impacting on 
health, as well as individual risk factors and risk behaviours, and the use of the 
healthcare services. 
 
HEALTHCARE PROFESSIONAL (HCP) 
A person who is trained and licensed to provide healthcare to humans, and to 
maintain health in humans through the application of the principles and 
procedures of evidence-based medicine and caring, including physicians, 
dentists, pharmacists, nurses, midwifes; excluding veterinarians.8,9 
 
HEALTH LITERACY 
Health literacy is linked to literacy and entails people’s knowledge, motivation 
and competences to access, understand, appraise, and apply health 
information in order to make judgements and take decisions in everyday life 
concerning healthcare, disease prevention and health promotion to maintain 
or improve quality of life during the life course.10 A recent definition is as 
follows: ‘the degree to which individuals can obtain, process, understand, and 
communicate about health-related information needed to make informed 
health decisions’.11 
 
MEDICATION SAFETY 
Medication safety covers the principles and functions of healthcare 
professionals and organisations to ensure safe medicine use and protect 
patients from harm.5 
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MEDICATION USE PROCESS 
A patient’s medication use process is an operative chain comprising the 
assessment of medication need, the choice and dispensing of the medicine, its 
dosage and administration, the patient’s motivation, advice and commitment 
to the therapy, organisation of the treatment follow-up and the evaluation of 
the outcome, as well as ensuring that the patient, the organisations and 
persons involved in the treatment are well-informed of the medication use 
process.3 
 
MEDICINAL PRODUCT 
A medicinal product is a substance or combination of substances presented 
for treating or preventing disease in human beings which may be administered 
with a view to making a medical diagnosis or to restoring, correcting or 
modifying physiological functions is likewise considered a medicinal 
product.12 There are also veterinary products for animals, but this thesis 
focuses on medicinal products for human use. In this thesis, ‘medicine’, 
‘medication’ and ‘pharmacotherapy’ are used to describe this term when 
appropriate. 
 
MEDICINES EDUCATION 
Medicines/Medication education refers to teaching about the rational 
medicine use.4,13-15 It is a planned individual and/or group interactive and 
collaborative learning experience and process with the aim of providing 
information that increases and influences people’s knowledge, skills and 
competences regarding medicines and their use. The learning process is 
individualised in that it accounts for the person’s different information needs, 
such as children or the elderly. In this thesis, the term ‘medicines education’ 
is used. 
 
MEDICINES INFORMATION (MI) 
Medicines information covers medicines-related information accessible to 
consumers and healthcare professionals in diversified forms, such as in 
written, verbal or electronic form.16 Medicines information includes statutory 
and product specific-information on medicines; written and online medicines 
information materials targeted at patients and healthcare professionals; 
medicines information tools, databases and information systems used in daily 
practice by healthcare professionals; medicines information provided by 
medicines information centres; and oral patient education and counselling. 
Medicines information should be designed according to target audience, e.g., 
medicines information targeted to healthcare professionals and to consumers 
is different.  
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MEDICINES INFORMATION CONTEXT 
In this thesis, medicines information context refers to the circumstances in 
which communication in regard to medicines occurs or medicines information 
exists. The medicines information context is influenced by the source of 
information (e.g., healthcare professionals, package leaflets, the Internet), 
information user (e.g., consumer, medicine user) and mode of information 
(written, verbal, electronic).17-19 
 
MEDICINES INFORMATION LITERACY 
Multiple concepts exist to define health literacy in the context of medicine use, 
such as ‘medication literacy’, ‘pharmacotherapy literacy’, ‘pharmacy health 
literacy’.20 A recently published definition is as follows: ‘the degree to which 
individuals can obtain, comprehend, communicate, calculate and process 
patient-specific information about their medicines to make informed 
pharmacotherapy and health decisions in order to safely and effectively use 
their medications, regardless of the mode by which the content is delivered 
(e.g., written, oral and visual)’.20 In this thesis, the term ‘medicines 
information literacy’ is used.  
 
MEDICINES INFORMATION PRACTICES 
In this thesis, medicines information practices refers to actual medicines 
information performance at a national level (macro level) such as the 
practices of authorities to provide reliable medicines information to 
consumers and healthcare professionals, at an organisational level (meso 
level) such as practices of healthcare organisations and institutions to ensure 
adequate medicines information resources for healthcare professionals and at 
patient care level (micro level) such as practices of healthcare professionals to 
communicate on medicines with patients. 
 
MEDICINES INFORMATION STRATEGY 
Medicines information strategy is a policy guideline which provides 
recommendations on how medicines information could be developed, 
provided and organised nationally or regionally for healthcare professionals 
and patients.16 
 
MEDICINES POLICY 
Medicines policy is a part of the social welfare and health policy.3 Medicines 
policy aims at ensuring that appropriate medicines are reliably and equally 
available in health facilities, medicines are prescribed and dispensed 
appropriately, and that medicines are affordable and are protected against 
catastrophic expenditure.21 In this thesis, ‘medicines information policy’ 
refers to policy aims in regards to medicines information which are in line with 
national medicines policy with supporting rational pharmacotherapy.3,22 
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PACKAGE LEAFLET (PL) 
A package leaflet is a legal document approved as part of the marketing 
authorisation of each medicinal product within the European Union.12 It 
contains statutory medicine-specific information for the medicine user and it 
should be based on the Summary of Product Characteristics. Package leaflets 
are currently also available online and audio format. Previously the term 
‘patient information leaflet’ has been used in the European Union. 
 
PATIENT 
Patient refers to a person awaiting or being under medical or healthcare 
treatment or using medical or health care services.8,23 This concept includes 
anyone who is taking medicines, including non-prescription medicines as self-
medication. In this thesis, the term ‘patient’ is also used when referring to the 
person receiving medicines information.24,25 Depending on the context, other 
terms are used in this thesis, such as ‘medicine users’ when referring to actual 
users of medicines and ‘general public’, ‘public’ or ‘consumers’ when referring 
to people in general (i.e., not necessary actual patients). 
 
PATIENT COUNSELLING/MEDICATION COUNSELLING 
Patient counselling is closely related to the concepts of ‘medication 
counselling’, ‘patient education’, ‘pharmacist-patient-communication’, 
‘patient information’ and ‘advice-giving’. These concepts have been used to 
refer to the verbal communication in regard to medicines between healthcare 
professionals and patients where the healthcare professionals take the 
patients’ personal needs and situation into consideration and supports their 
coping with the medications.3,4,26 Patient counselling is seen as an approach 
that focuses on enhancing problem solving for the patient to improve or 
maintain quality of health and quality of life. This conceptualisation 
emphasises that counselling should be a dialogue between patient and 
healthcare professionals. 
 
PHARMACOVIGILANCE 
Pharmacovigilance is defined as the science and activities relating to the 
detection, assessment, understanding and prevention of adverse drug 
reactions or any other drug-related problem.27 It is an essential component of 
patient care and the rational medicine use. It is also variously referred to as 
adverse drug reaction monitoring, drug safety surveillance, side effect 
monitoring, spontaneous reporting, post-marketing surveillance or variations 
of these. Pharmacovigilance involves the safety monitoring of all medicines 
including herbal and complementary remedies, vaccines and biological 
substances. 
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RATIONAL PHARMACOTHERAPY 
Rational pharmacotherapy is effective, safe, high quality, economical and 
equal.28 The prerequisites of successful pharmacotherapy improve when 
patients participate in the planning and implementation of their own 
pharmacotherapy as partners, when the regimen of pharmacotherapies is 
jointly agreed, and when patients receive support in the medicine use. 
 
SIGNIFICANCE OF MEDICINES INFORMATION 
In this thesis, the significance of medicines information refers to medicines 
information as a factor contributing to the outcomes and effectiveness of 
pharmacotherapies. It covers the ways of designing and using medicines 
information so that it facilitates optimising positive outcomes and minimising 
negative outcomes of medicinal products in patient care. 
 
SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) 
Summary of Product Characteristics is a legal document approved as part of 
the marketing authorisation of each medicinal product.29 It contains the basis 
of information for healthcare professionals on how to use medicines safely and 
effectively. Package leaflets should be drawn up in accordance with the 
Summary of Product Characteristics. 
 
WRITTEN MEDICINES INFORMATION (WMI) 
In this thesis, written medicines information refers to medicine-specific 
information in printed form for patients, such as statutory package leaflets.30 
Written medicines information is commonly produced by pharmaceutical 
manufacturers, government bodies or third parties. 
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ABBREVIATIONS 
ADR Adverse drug reaction 
CMR Comprehensive medication review 
DRP  Drug-related problem 
EHR   Electronic health record 
EU   European Union 
EUPC   Effect, Use, Problems, Checkups Method 
Fimea   Finnish Medicines Agency 
HCP   Healthcare professional 
mHealth   Mobile health 
MI   Medicines information 
MI Network  National Medicines Information Network (Finland) 
MIC   Medicines information centre 
OC  Oral contraceptive 
OTC  Over-the-counter medicine, non-prescription medicine 
PL  Package leaflet (for patients) 
QALY  Quality-adjusted life-year 
QaM  Questions to Ask about Your Medicines campaign  
RCT  Randomised controlled trial 
SmPC  Summary of Product Characteristics (for HCPs) 
UK  United Kingdom 
USA  United States of America 
USP   United States Pharmacopeia 
WHO   World Health Organization 
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1 INTRODUCTION 
Medicines are among the most common interventions in healthcare to protect, 
maintain and restore people’s health.1,31 However, even in developed 
countries, approximately half of medicine users are estimated to fail to take 
their medications as prescribed.1 Easy access to medicines information (MI) 
is one of the key facilitators in empowering people to engage in appropriate 
and safe medicine use.32 
Patients’ access to MI has significantly improved during the last few 
decades.16,18,19,22,33-35 Drug safety issues, patients’ right to know about 
medicinal interventions that they are exposed to and tendency to empower 
patients in taking more responsibility for self-management of their diseases 
have been driving forces for more open access to MI.16,18,22,24  The shift “from 
paper to cyber” has led to the improved availability of MI to patients via the 
Internet and electronic applications in smartphones and other electronic 
devices. These novel information technology innovations are fast evolving 
towards systems enabling customised MI, interactive communications and 
follow-up treatments.16,33,34,36-38 Improved communication concerning 
medicines has also been a strategic priority in national and international 
medicines policies, e.g., within the European Union (EU).3,22,25,39-42 
In Finland, MI to patients and better coordination of MI have been 
among the key public health and health policy goals since the 1980s.19,43,44 The 
landmarks towards more open access to MI among patients have been 
pharmacists’ duty to counsel on prescription and non-prescription medicines 
since 1983, and the first computerised system to produce MI leaflets for 
patients in 1986.18,43 At the turn of the millennium, package leaflets (PLs) 
became mandatory in all EU countries, including Finland.45 Since the early 
2000s, the Internet and other electronic MI sources have become more 
common and eventually revolutionised access to statutory MI, e.g., by making 
PLs available online in written and audio format.18 In fact, the MI context has 
changed substantially over time and novel information technology 
innovations create new ways of communicating on medicines. 
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In order to coordinate MI practices and enhance public-private 
partnerships in Finland, the Finnish Medicines Agency Fimea published the 
first national MI strategy in 2012.22 The primary goal of the national MI 
strategy is to influence system- and organisation-based MI practices in all 
social and healthcare environments in order to reach the ultimate goal of the 
well-informed patient who adheres to the therapy. To implement the national 
MI strategy by 2020, a National Medicines Information Network (MI 
Network) was established involving the key stakeholders providing and 
producing MI. The MI Network also includes various patient organisations 
representing diversified patient groups. This type of networking is ground-
breaking in Finland and also unique globally, even beyond the EU. Finland 
can be considered as a textbook example in developing MI practices 
strategically.16 
This thesis aims to examine MI practices and policies in Finland during 
the 2000s. The primary goal is to collect and provide information to support 
the strategic development of MI at the national level and assist in 
implementing the first national MI strategy. The literature review of the thesis 
(Chapter 2) describes the significance and outcomes of MI in patient care and 
the strategic development of MI practices in the EU, particularly in Finland. 
Furthermore, the results of the systematic literature review of the recent 
research on the use of MI sources in adult medicine users are presented. The 
empirical part (Chapters 3–7) investigates development targets for MI 
practices in Finland based on a systematic review of the existing literature 
(Original publication I), assesses long-term trends in the receipt of MI among 
the Finnish adults (Original publication II), and evaluates to what extent the 
ultimate goal of the national MI strategy about well-informed adherent 
patients with long-term medications had been achieved at the midpoint of the 
MI strategy period in 2015 (Original publication III). This thesis is a part of a 
larger MI-related line of research of the Clinical Pharmacy Group at the 
Faculty of Pharmacy, University of Helsinki.
2 Review of the literature 
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2 REVIEW OF THE LITERATURE 
The literature review of the thesis comprises three sections (Figure 1). The first 
section discusses the evolution of medicines information (MI) targeted at 
patients and consumers. The historical overview is presented through the 
different MI sources in written, verbal and electronic forms, focusing in 
particular on the changes in the European Union (EU). This section also 
presents the significance of MI in influencing potential outcomes and 
effectiveness of pharmacotherapies in patient care. 
In the second section, the strategic development of MI at the national 
and international level over the last few decades is demonstrated with special 
reference to the developments within the EU. Particular focus is on the first 
national MI strategy in Finland, its roots and implementation. 
The third section presents the use of MI sources among adult medicine 
users during the period of 2000–2018. Understanding the current practices 
in using MI sources is essential for evaluating the use, accessibility and 
significance of MI and developing further reliable MI services targeted to 
consumers and various medicine user groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure and contents of the literature review of the thesis. 
 
Section I: 
EVOLUTION AND SIGNIFICANCE OF MEDICINES INFORMATION IN PATIENT CARE 
 
• Evolution of statutory MI to meet practice needs 
• Evolution of formulations of MI to improve its potential outcomes in patient care 
• MI as a facilitator of evidence-based pharmacotherapy 
 
 
Section II: 
STRATEGIC DEVELOPMENT OF MEDICINES INFORMATION 
 
• Drivers for the strategic development of MI in the EU 
• Strategic development of MI practices in the EU 
• Development, implementation and evaluation of the first national MI strategy in Finland 
 
Section III:  
USE OF MEDICINES INFORMATION SOURCES IN ADULTS 
 
• Receipt of MI from various sources among adult medicine users in general and among different 
medicine user groups 
• Motives for searching MI, barriers to receiving MI, reliability and satisfaction with MI received 
• Factors affecting the receipt of MI 
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2.1 EVOLUTION AND SIGNIFICANCE OF MEDICINES 
INFORMATION IN PATIENT CARE 
In the first part of this section, the evolution of MI to patients and the 
background for statutory MI are described (Figure 1). In this review, MI refers 
to statutory and general product-specific information on medicines accessible 
to patients and healthcare professionals (HCPs) in written, verbal and 
electronic formats. 
The second part focuses on the significance of MI in patient care and its 
effects on the outcomes of pharmacotherapies (Figure 1). In this thesis, 
pharmacotherapy is illustrated to have two essential components: 1) a 
medicinal product of acceptable quality ensured through marketing 
authorisation, 2) accompanied by statutory and other MI ensuring its rational 
use in patient care (Figure 2). These two integrated components generate the 
effectiveness of pharmacotherapy which can be measured as various 
outcomes, such as behavioural, clinical, humanistic or economic outcomes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Illustration of significance of medicines information (MI) as a factor contributing to 
outcomes and effectiveness of pharmacotherapies 
 
 
The significance of MI refers to ways of using MI as a vehicle for 
optimising positive outcomes and minimising negative outcomes of medicinal 
products. These outcomes can be direct or indirect behavioural outcomes 
(e.g., medication adherence), clinical outcomes (e.g., normalisation of blood 
pressure or glucose level), humanistic outcomes (e.g., quality of life, 
satisfaction of treatment) or economic outcomes (e.g., cost savings in 
medicines or use of health services). 
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Although the therapeutic effect is due to the medicine use, the 
prerequisite of that effect is research-based evidence on the clinical 
characteristics of the medicinal substance and preparation: for what ailment 
and how the preparation works, for whom it is suitable and for how long it 
should be used and in what dose in order to obtain the optimum therapeutic 
effect. MI should provide answers to the above-mentioned questions, making 
it a key element in a successful pharmacotherapy outcome, although its impact 
on the outcomes of pharmacotherapies is difficult to assess. 
 
2.1.1 EVOLUTION OF MEDICINES INFORMATION IN PATIENT CARE 
 
This historical overview presents the evolution of MI targeted to patients since 
the most significant worldwide medicine disasters had occurred after World 
War II (1939–1945) (Figure 3).  
In the late 1950s, the thalidomide catastrophe demonstrated the 
importance of reliable MI in the worst possible way.19,27,46-48 Pregnant women 
prescribed thalidomide for treating morning sickness became the victims 
during 1956–1962. Soon after thalidomide had extended to a wider use 
altogether in 46 countries, the number of miscarriages increased in pregnant 
women in the early 1960s, and more severe and debilitating malformations 
occurred in more than 10,000 newborns and children. At that time, the effects 
of the medicines were poorly known as pharmaceutical companies were not 
obliged to generate clinical evidence, e.g., about adverse reactions of the 
medicines they were selling. Even though HCPs did not have available 
adequate information about medicines they prescribed and dispensed them to 
patients.  
After the thalidomide catastrophe, many countries started to more 
systematically gather information about the adverse drug reactions (ADRs) 
(Figure 3).19,27,46,49 This led to the establishment of marketing authorisation 
and pharmacovigilance systems in many developed countries to prevent the 
harmful effects of medicines. In the EU, marketing authorisation holders were 
also obligated to make MI available to both HCPs in the form of Summary of 
Product Characteristics (SmPCs) and for patients in the form of package 
leaflets (PLs) based on the SmPC.12,49 
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Figure 3. Evolution of medicines information (MI) to patients since the 1960s. 
 
 
Written medicines information (WMI) has been an integral part of 
improving the receipt of MI among patients since the first legal requirements 
on the mandatory medicines information leaflets came into force in the USA 
and the UK during the 1970s (Figure 3).50,51 The leaflets in medicinal packages 
also gradually became more common in other countries over the 1980s, and 
the uniform legislation for PLs in the EU was enacted in the 1990s.18,19,49,52 In 
1992, the European Commission issued a Directive on the labelling of 
medicinal products for human use and PLs.45 Since 1999, a comprehensive PL 
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has been required to be included in all medicinal packages in the EU member 
states.45,52 The legislation requires that PLs supplied by the manufacturers of 
the medicinal products should be compiled in accordance with the SmPCs in 
a form comprehensible to the patients.45,53 The readability of PLs must be 
ensured. During the 2000s, patients have been increasingly involved in the 
development of PLs and their quality.54-61 A significant milestone in 
developing the quality of PLs took place in 2004 when a new legal obligation 
was introduced to all marketing authorisation holders.62 A Directive requires 
that PLs reflect the results of consultations relating to user testing of PLs with 
target user groups. As a result, user testing on PLs was implemented across 
the EU to identify the shortcomings of PLs and to improve their quality and 
readability.59,63-66 
In the early 1960s the first medicines information centres (MICs) were 
established in the USA and Europe, and they became more common globally 
during the 1970s (Figure 3).67-69 MICs are information service units 
maintained by pharmacists and other HCPs, originally designed to assist 
HCPs in their clinical practice.70-73 Later, a growing number of MICs also 
started to provide health and MI to consumers and co-operating 
organisations. Many of the MICs are integrated with clinical services and they 
usually operate in hospitals, healthcare centres, pharmaceutical training 
organisations (e.g., universities) or pharmacies. Currently, MICs provide 
objective and reliable MI in multiple formats, such as by telephone, email, chat 
and one-to-one meetings with HCPs. Additionally, MICs can conduct research 
and maintain reporting systems for ADRs and medication errors. 
Since the 1960s, medication counselling provided by HCPs gradually 
evolved from medicine-centred, paternalistic, physician-privileged duty 
towards more patient-centred and interactive communication involving 
pharmacists and the entire healthcare team with the goal of empowering 
medicine users to self-manage their diseases and pharmacotherapies (Figure 
3).14,26,43,74 Although medication counselling has been recognised as an 
essential part of rational pharmacotherapy for a long time, not until 1994 were 
the first pharmacopeia-level guidelines and recommendations for medication 
counselling published by the United States Pharmacopeia (USP).14,15,26 The 
USP Medication Counselling Behavior Guidelines were established to ensure 
the quality of MI, to promote public health and to develop authoritative 
information about rational medicine use.15 During 1994–1997, the USP 
developed a comprehensive medication counselling assessment tool for HCPs 
to assess and improve their counselling skills in different medication 
2 Review of the literature 
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counselling contexts.14 The tool was based on an extensive inventory of 
existing tools used in medical, nursing and pharmacy schools primarily in the 
USA. Of that tool, a pharmacist-specific tool was developed and 
validated.4,15,26,75,76 The implementation of the USP’s guidelines has been 
promoted by such international professional organisations as the 
International Pharmaceutical Federation (FIP) and International 
Pharmaceutical Students’ Federation (IPSF).4,77 
Multimedia-based interventions have been used in patient education 
since the 1970s, but their use in healthcare became more common in the 1990s 
(Figure 3).78 Multimedia education provides information using multiple 
media formats, including textual data and graphic presentations with the use 
of audio, visual, animation or video recordings or interactive programmes, 
such as CDs, DVDs or computer-playable files delivered via portable media or 
internet resources.78,79 
Since the early 1990s, digitalisation and the development of electronic 
communications (e.g., the Internet) generated novel information technologies 
applicable to almost every area of life, including healthcare and well-being 
(Figures 3 and 4).80 The growing shift “from paper to cyber” through novel and 
innovative ways of communicating, such as social media services, was rapid 
during the 2000s.37,81-86 This has dramatically changed consumers’ 
information-seeking behaviours and has enabled a more diversified and easier 
access to health information and MI.87 Along with the expanding availability 
of electronic information sources, patients have had the opportunity to 
communicate with HCPs, as well as with other patients interactively (e.g., 
chat-based MI services provided by community pharmacies) and orally via 
telecommunications software applications (e.g., via Skype).34,37,88-92 
Furthermore, various parties producing MI (e.g., authorities, pharmaceutical 
companies, patient organisations) started to provide MI to patients in 
electronic and audio form, such as online PLs.18 
The use of more advanced mobile health (mHealth) technologies and 
interventions grew rapidly over the 2010s, such as personalised smartphone 
applications assisting in disease management (Figures 3 and 4).93,94 In 2014, 
there were over 400 smartphone applications available worldwide for patients 
purely targeted to improve medication adherence.95 Multimedia-based 
interventions also adapted to support patients in managing with their 
diseases, such as videogames in self-management of diabetes.96,97 
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Figure 4. Evolution of digitalisation and electronic communication used by patients and 
consumers to seek medicines information (MI) and communicate about their medicines 
since the 1990s. 
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2.1.2 SIGNIFICANCE OF MEDICINES INFORMATION IN PATIENT 
CARE 
 
Optimum content and format of MI has been under continuous development 
and investigation since it became evident through severe medicine disasters 
that MI is essential for preventing risks related to medicine use.19,27,46-48 This 
inventory describes the attributes which have been associated with MI in 
order to improve its significance in patient care in terms of outcomes of 
pharmacotherapies (Figure 5). Evidence for this qualitative review has been 
compiled from meta-analyses and systematic reviews published over the past 
ten years (2009–2019) (Table 1).96,98-111 Publications focusing on interventions 
exploring the significance of written, verbal or electronic MI in patient care 
were included. Also included were studies in which the context of the study 
indicated that MI was part of the intervention, e.g., prescribing medicines by 
physicians and services provided by community pharmacists. However, this 
review does not reflect the complete body of literature as included studies were 
not collected systematically. 
The significance of MI in patient care has been studied since the early 
1970s (Table 1).96,98-111 Figure 5 summarises the attributes extracted from the 
included meta-analyses (n=5) and systematic reviews (n=10) facilitating the 
significance of MI in patient care in terms of improved outcomes. The 
attributes were different for written, verbal and electronic MI. In addition to 
the MI-related attributes that modify the significance of MI, there are other 
modifying factors. These factors were categorised to: 1) patient-related 
factors, such as health information and MI literacy skills; remembering, 
interpretation and understanding of MI, disease and its state, health locus of 
control, educational level, coping style and demographics; and 2) availability 
and accessibility of MI to patients. 
The outcome measures used in the studies presented in Table 1 to assess 
the significance of MI in patient care fell into the following four categories: 1) 
behavioural outcomes, such as medication adherence; 2) clinical outcomes, 
such as blood pressure, haemoglobin level and health status; 3) humanistic 
outcomes, such as knowledge about medicines, patient’s quality of life and 
satisfaction with care or MI received; and 4) economic outcomes, such as 
direct medicine cost savings to patients (Figure 5).96,98-111 Of these outcomes, 
behavioural outcomes have been most commonly studied, particularly 
medication adherence, whereas economic outcomes have been only 
marginally studied (Table 1). 
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Figure 5. Medicines information (MI)-related factors and other factors that are found to 
contribute to the outcomes of pharmacotherapies. The figure is a qualitative synthesis of the 
literature presented in Table 1. 
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Behavioural outcomes 
• Increases adherence to medication 
• Prevents ADRs and medication 
errors 
• Allows patients to make informed 
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role in their treatments 
• Empowers patients to self-manage 
their medication and health 
 
 
 
 
Economic outcomes 
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to patients 
Humanistic outcomes 
• Increases patient satisfaction to 
treatment and self-efficacy 
• Improves quality of life 
• Increases knowledge of medicines 
 
Clinical outcomes 
• Improves clinical outcomes, such as 
blood pressure and cholesterol 
 
 
• Patient-related factors: Health and MI literacy skills; remembering, interpretation and understanding 
of MI, disease and its state, health locus of control, education level, coping style and demographics 
• Availability and accessibility of MI to patients 
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A MI-related issue that has not gained sufficient attention as a factor 
influencing outcomes of pharmacotherapies is conflicting information (Figure 
5). Given that these days patients seek and receive MI from multiple sources, 
they may encounter conflicting MI.112-115 Over half (51–80%) of adults with 
chronic disease112,113 and almost a quarter (23%) of pregnant women have 
reported receiving conflicting information about their medicines.115 Other 
than own physician, media (e.g., television, radio) and the Internet are the 
most common sources of conflicting MI to patients.112 ADRs, duration of 
treatment and dosage are the most frequent topics about which patients have 
received conflicting information.112,113 Conflicting MI may increase anxiety, 
cause unnecessary concern about medicine use, and as a consequence, 
decrease medication adherence.112,115 Although the extent to and conditions 
under which patients receive conflicting MI has been recently documented, 
this phenomenon should be further studied systematically and better taken 
into account in education of HCPs and in the strategic development of MI and 
MI services targeted to patients.
  
   
Table 1. Meta-analyses (n=5) and systematic reviews (n=10) on the significance of medicines information (MI) in patient care. Studies are presented according 
to the study methods in alphabetical order by the names of the authors. 
 
 
META-ANALYSES (n=5) 
Authors 
Publication 
yearRef. 
Aspect studied 
Method 
Number of studies 
Publication period 
Types of 
interventions 
Outcome 
measuresa 
Key outcomes on significance of MI 
Chisholm-Burns 
et al.  
2010101 
Pharmacist-led 
direct patient 
care nterventions 
• Meta-analysis/ 
systematic review 
• 71 RCTs and 
227 other studies 
• 1973–2009 
Main interventions: 
Patient education 
Medicines utilisation 
review 
Chronic disease 
management 
B,C,H Pharmacist-led counselling interventions significantly reduced glycated haemoglobin (HbA1c) values (mean difference 
between the pharmacist intervention group and the comparison group 0.8%); low density lipoprotein cholesterol  
by 6.3 mg/dL; systolic blood pressure by 7.8 mmHg; and diastolic blood pressure by 2.9 mmHg. Pharmacist-led 
interventions were found to positively affect patients’ knowledge in 20 out of 35 studies;  medication adherence in 26 
out of 54 studies; patient satisfaction in 20 out of 41 studies; medication errors in 9 out of 11 studies; and on ADRs in 9 
out of 15 studies. Effects on the quality of life were mixed (12 out of 31 studies) or intervention had no effects (14 out 
of 31 studies). 
Deters et al.  
2018102 
Community 
pharmacist-led 
interventions for 
diabetics 
• Meta-analysis 
• 6 RCTs 
• 2007–2015 
Personal visits 
Printed leaflets  
Telephone calls 
B,C Community pharmacist-led counselling interventions significantly improved adherence and glycemic control in patients 
with type 1 and 2 diabetes. These interventions reduced glycated haemoglobin (HbA1c): mean difference was 0.66%. The 
most effective intervention components were interdisciplinary and patient-centred, such as sending feedback to the 
physician, setting individual goals with the patient and analysing the medication of the patient and identifying drug- 
related problems (DRPs). 
Omboni et al.  
2018108 
Effectiveness of 
pharmacists’ 
interventions on 
the management 
of cardiovascular 
diseases 
• Meta-analysis 
• 22 meta-
analyses/ 
systematic 
reviews 
• 2003–2016 
Patient education 
Medication 
management 
Measurement and 
management of 
disease risk factors 
B,C,H,E Pharmacists’ interventions were associated with a significant reduction in blood pressure and serum cholesterol levels 
and a reduction in the risk of smoking. They had a positive or no effect on the reductions of risk behaviours and control 
of risk factors for coronary heart disease. Limited evidence was available on the effectiveness of pharmacist-led 
interventions on patient satisfaction, adherence, knowledge and economic outcomes. A multidisciplinary approach, 
including medical input plus a pharmacist, specialist nurse or both, and a greater involvement of community rather than 
hospital pharmacists, represented the most efficient and modern healthcare delivery model. 
Van Camp et al.  
2013109 
Nurse-led 
interventions to 
enhance 
adherence to long-
term medication 
• Meta-analysis/ 
systematic review 
• 10 RCTs 
• 2006–2011 
Electronic messages 
Individual and group 
session counselling 
Nurse care 
management 
B Nurse-led individual counselling appeared effective in improving adherence to long-term medications. Nurse-led 
counselling in groups and via electronic messages also enhanced adherence but further research is needed on the 
effectiveness of these interventions. Nurse-led counselling conducted over a longer period (6 to 12 months) tended to 
have a greater impact than 3 months of counselling. Long-term interventions were more sustainable compared to the 
short-term interventions. Complex interventions, such as tailored counselling combined with social support, education 
and/or reminders, seemed to enhance adherence more compared to using single interventions. 
Zolnierek et al.  
2009111 
Physician-led 
interventions on 
patient 
medication 
adherence 
• Meta-analysis 
• 127 studies 
• 1976–2007 
Counselling B Physician-led counselling significantly positively affected medication adherence among their patients. There was a 19% 
higher risk of non-adherence among patients whose physician communicated poorly than among patients whose 
physician communicated well. Training physicians in communication skills improved patient adherence by 12%. Physician 
communication skills training had less effect on adherence the more serious a patient’s disease was, and more effect if 
the physicians trained were paediatricians. 
 
 
  
   
 
SYSTEMATIC REVIEWS (n=10) 
Authors 
Publication 
yearRef. 
Aspect studied 
Method 
Number of studies 
Publication period 
Types of 
interventions 
Outcome 
measuresa 
Key outcomes on significance of MI 
Antoine et al.  
201498 
Pharmacist-led 
counselling 
interventions for 
oral medicines in 
type 2 diabetics 
• Systematic 
review 
• 6 RCTs 
• 2003–2011 
 
Counselling 
Educative group 
activities 
Nutrition consultation 
Telephone calls 
B,C,H A pharmacist-led counselling intervention improved adherence to type 2 diabetes medications in all 6 studies, but a 
statistically significant effect was shown in only 2 studies. Education provided regularly compared to a single education 
session tended to improve adherence. Adherence was primarily measured by self-reports and prescription refill rates. 
Pharmacist-led intervention significantly improved blood pressure and blood glucose levels in 5 out of 6 studies. The 
involvement of a pharmacist contributed to an improvement of knowledge and self-care activities in 3 out of 6 studies. 
Blalock et al.  
201299 
Community 
pharmacist-led 
interventions on 
patient health 
outcomes 
• Systematic 
review 
• 12 RCTs and 9 
other studies 
• 1973–2011 
Community 
pharmacists-
delivered patient 
care services 
B,C,H Community pharmacists-led interventions showed statistically significant improvement in medication adherence in 6 out 
of 12 studies and in appropriate medicines use in 3 out of 5 studies. Pharmacists-led interventions had the best effects 
on lowering blood pressure. Interventions showed no effects on cholesterol level, safety outcomes or quality of life. 
There was insufficient or unclear evidence on the significance of pharmacist-led interventions on patient satisfaction, 
knowledge and healthcare utilisation. 
Celio et al. 
2018100 
Pharmacist-nurse 
collaborations  
in medication 
adherence-
enhancing 
interventions 
• Systematic 
review 
• 5 RCTs, 9 other 
studies and  
7 conference 
abstracts 
• 1996–2016 
 
Multiprofessional 
interventions and 
educational 
programmes 
B,C,E Pharmacists and nurses are in a strategic position to identify patients for adherence interventions. Pharmacists 
specifically ensure treatment efficacy, security and access, and provide MI and lifestyle advice. Nurses clinically co- 
managed patients with physicians and provided patients with information on their diseases. Five studies described 
significant improvements in clinical outcomes (e.g., blood pressure), while 4 studies showed significant improvements in 
both medication adherence and clinical outcomes. Effective team communication and well-defined roles between HCPs 
were key components to enhance adherence. Economic outcomes of the multiprofessional support programme was 
explored in only one RCT study in which cost-savings per patients were higher and quality-adjusted life-year (QALY) per 
patients were increased compared to the control group. Collaborative pharmacist-nurse medication adherence 
enhancing interventions are rare, and they are often at an early developmental stage. More evidence is needed on the 
effective models of collaborative practice among pharmacists, nurses, physicians and other HCPs to support and 
reinforce medication adherence in different chronic patient groups. 
Ciciriello et al.  
201396 
Multimedia 
educational 
interventions for 
patients about 
prescription and 
OTC medicines 
• Systematic 
review 
• 24 RCTs 
• 1982–2011 
Computer-based 
programmes 
Slide-tape audio visual 
presentations 
Videos 
B,C,H Multimedia education about medicines was more effective than no education or non-standardised education provided 
by HCPs as part of usual clinical care in improving knowledge and skill acquisition (inhaler technique). There is some 
evidence that multimedia education is at least equivalent to other forms of education, including written education and 
education provided by HCPs. Multimedia education can be considered as an adjunct to usual care rather than as sole 
education. Multimedia education can be considered as an alternative to education provided by HCPs when MI provided 
by HCPs is not available. 
Jose et al. 
2018103 
Negative impacts 
of side effects 
information for 
patients 
• Systematic 
review 
• 17 RCTs 
• 1982–2017 
Medicine-specific 
information on 
safety-related 
aspects provided in 
verbal and/or 
written formatb 
B,C,H Only limited evidence was found to indicate that informing patients about the side effects of medicines has a significant 
negative impact on the patient (e.g., increased reporting of side effects, anxiety for side effects or medicines use), 
treatment process or treatment outcomes. Sharing information about side effects of medicines had significantly 
increased occurrence or reporting of side effects among medicine users in 4 out of 17 studies. Anxiety of negative events 
of medicines were observed in 2 out of 4 studies. No significant impact was observed on compliance to medication or 
negative clinical outcomes (e.g., disease relapse). 
 
 
  
   
Authors 
Publication 
yearRef. 
Aspect studied 
Method 
Number of studies 
Publication period 
Types of 
interventions 
Outcome 
measuresa 
Key outcomes on significance of MI 
Kuntz et al. 
2014104 
Patient-centred 
interventions to 
improve 
medication 
management and 
adherence 
• Systematic 
review 
• 43 RCTs and  
17 other studies 
• 2007–2013 
Patient education and 
counselling 
Pharmacy services 
Decision aids 
Shared decision-
making 
Case management 
Feedback 
interventions 
B,C,E,H Educational interventions were most effective when combined with coaching or behavioural and social support. 
Educational interventions often resulted in greater knowledge and better medication adherence, self-efficacy and self 
monitoring skills. Educational intervention produced no significant long-term impact on adherence in 5 out of 16 studies. 
One study noted that educational interventions might be most cost-effective among less-adherent patients.  
Effects of pharmacy service interventions on medication adherence were mixed, but more often positive. Patients were 
often satisfied with their interactions with pharmacists and with potential cost savings. 
Decision aids and shared decision-making interventions increased knowledge, participation, confidence in decision- 
making and satisfaction with care among patients. Three studies showed that patients’ understanding of risk was 
improved and decisional conflict lessened. Increased patient knowledge did not change the patient decision-making 
process, and there was little evidence that treatment choice or patient beliefs changed even when patients were more 
informed about benefits and risks of their medicines. 
Case management interventions delivered by nurses or care teams, such as assessment of barriers to medication-taking 
among patients, significantly improved medication adherence and clinical outcomes, but they had no effect on quality of 
life. 
Feedback interventions carried out by pharmacists or physicians, such as discussions with the patient to inform changes 
to the regimen, increased patient satisfaction regarding care and concordance between patient preferences and 
prescribed regimens in 2 out of 5 studies. 
Milosavljevic  
et al.  
2018105 
Impact of 
community 
pharmacist-led 
interventions on 
health outcomes 
• Systematic 
review 
• 16 RCTs and 
6 other studies 
• 1973–2015 
Counselling 
Focus groups 
Monitoring DRPs 
Pharmacists’ home 
visits 
Take-home videos and 
WMI 
Telephone calls 
B,C,E,H 
 
Pharmacist-led counselling interventions improved patients’ medication adherence and disease control. Interventions 
contributed best to asthma and blood pressure control, management of cholesterol and chronic obstructive pulmonary 
disease. Studies did not find an effect of interventions on glycated haemoglobin levels or depressive symptom control. 
The results of the pharmacist-led interventions to economic outcomes were mixed. 
Mullen et al. 
2018106 
Best practices for 
prescription 
medicines 
labelling and 
educational 
materials 
• Systematic 
review 
• 49 RCTs 
• 1976–2016 
WMI 
Pharmacy-generated 
container labelling 
Supplemental 
instructions 
Multimedia tools (e.g., 
audio-visual and 
computer-based 
materials) 
B,H Strongest evidence on best practices: 
For WMI: Materials written at lower reading level (≤ 5th grade) resulted in greater perceived clarity, increased 
comprehension and fewer medication errors. Use of plain and simplified language enhanced patients’ medication 
adherence, attitudes, navigability and comprehension of WMI and reduced worry regarding the treatment. Typographic 
cues (e.g., use of bolding, bullet points, underlining) and standardised formats enhanced patients’ comprehension.  
For container labelling: Standardised warning icons paired with simplified text increased attendance to and 
comprehension of medicine warnings compared to warning text on its own. Combined use of standardised icons for 
dosing intervals (e.g., morning, noon evening, bedtime), numeric characters to describe quantitative information, explicit 
dosing instructions, simple terminology and ≥ 12-point font size increased patient comprehension. 
For supplemental instructions: Use of explicit dosing instructions, plain and simplified text and grid format improved 
adherence, but study findings were mixed. 
For multimedia tools: Short and targeted educational videos resulted in improved short and long-term knowledge and 
enhanced beliefs on medications compared to longer video interventions or written materials. Videos did not appear to 
influence adherence. Interactive computer or web-based programmes had a positive impact on knowledge about 
medicines and self-efficacy. Incorporation of visual aids (e.g., animations) in multimedia tools did not appear to have an 
impact on patients’ behaviour, knowledge or adherence. 
  
   
Authors 
Publication 
yearRef. 
Aspect studied 
Method 
Number of studies 
Publication period 
Types of 
interventions 
Outcome 
measuresa 
Key outcomes on significance of MI 
Nicolson et al.  
2009107 
WMI on patient 
outcomes in 
relation to 
prescription and 
OTC medicines 
• Systematic 
review 
• 25 RCTs 
• 1972–2002 
WMI (e.g., PLs, 
supplementary 
leaflets) 
Non-print WMI (e.g., 
WMI  
    on websites) 
B,H WMI significantly improved knowledge about a medicine in 6 out of 12 studies compared with no WMI. Patients 
provided with WMI had significantly higher knowledge of side effects in 3 out of 6 studies compared with those given no 
WMI. Patients given WMI expressed greater satisfaction with the information provided, reported less worry about the 
treatment and understood the information better, but the significance of these outcomes on medicines use should be 
further studied. Three studies found that those who had received WMI were more adherent to their medication. No such 
difference was found when biological markers were used to assess adherence. Eight studies compared the effects of 
presenting WMI in different ways: Programmed instructions significantly increased understanding of medicine use 
compared with the standard format handout. Providing information on the risk of side effects as a numerical description 
was significantly more effective in helping people make a correct estimation of risk than giving the same information as a 
verbal description. People were significantly less favourable to the treatment when information about the risks of the 
medicine was given after information about the benefits of the medicine. Studies that evaluated the effects of WMI on 
clinical outcomes were not found. 
Zapata et al. 
2013110 
Women’s 
understanding of 
written 
instructions on 
an oral 
contraceptive 
(OC) pill 
• Systematic 
review 
• 3 RCTs and 6 
other studies 
1983–2009 
Impact of WMI (e.g., 
PLs, brochures) on 
patients’ 
understanding of 
what to do after 
forgetting to take an 
OC pill 
B,H Providing WMI on missed pill instructions with contraceptive counselling significantly improved knowledge of how to 
manage missed pills for up to 3 months compared to contraceptive counselling alone. Findings indicated a wide 
variability in women having correct knowledge, with 37–94% knowing what to do after missing one pill, 16–83% knowing 
what to do after missing two pills and 3–72% knowing what to do after missing three pills. Many women missing pills did 
not intend to follow recommended actions per missed pill instructions despite understanding the guidance. Graphic- 
based missed pill instructions were better than text only instructions and less information resulted in improved 
comprehension. 
aSignificance of medicines information (MI) in patient care and medicines use has been measured as behavioural (B), clinical (C), economic (E) or humanistic (H) outcomes; bRegular or specific patient 
information leaflets or standardised information sheet/handouts.  
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SIGNIFICANCE OF WRITTEN MEDICINES INFORMATION (WMI) 
 
Studies that explored the significance of WMI in patient care focused on WMI 
on prescription and OTC medicines,107 prescription medicines labelling,106 the 
impact of information on side effects on medicine use103 and patients’ 
understanding of dosage instructions in PLs related to oral contraceptives 
(OCs)110 (Table 1). There is reasonable evidence that WMI can significantly 
improve patients’ knowledge about medicines.107,110 However, there is also 
some evidence, although partly limited or contradictory, that WMI can have 
an effect on changing the patient’s attitudes or behaviours, such as improving 
medication adherence.103,107,110 Patients who are able to use WMI in addition 
to verbal MI have reported being less concerned about their medication and 
have expressed better knowledge, understanding and satisfaction with MI 
provided than patients who received only verbal MI.107,110 Moreover, 
adherence to the medicines’ instructions is found to be higher among patients 
provided with WMI, even they have reported slightly more side effects than 
those who have not received WMI.107 
The strongest evidence on best practices of WMI has been shown when 
plain and simplified language has been used combined with typographic cues 
(e.g., bolding, bullets points, underlining), graphic-based instructions and 
quantitative descriptions (Figure 5, Table 1).106,110 For example, providing 
information of the risk of ADRs as a numerical description is significantly 
more effective in supporting patients to make correct risk estimations than 
giving the same information as a verbal description (e.g., “10 out of 100 
medicine users are expected to experience particular adverse drug reactions” 
instead of providing a general expression that “adverse drug reaction is 
common”.107 Furthermore, patients are found to be significantly less likely to 
take their medicine when information about the risks of medicine is given 
after information about the benefits of medicine. Adjusting the reading level 
(≤ 5th grade) in WMI on prescription medicines has found to result in greater 
perceived clarity, increased comprehension and fewer medication errors 
among patients.106 There is evidence that standardised warning icons or 
pictograms paired with simplified text in labels of medicine containers 
increase attendance to and comprehension of medicine warnings compared to 
warning text on its own.106 
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SIGNIFICANCE OF VERBAL MEDICINES INFORMATION 
 
The significance of verbal interventions in patient care provided by HCPs, 
such as medication education and counselling has been a widely studied topic 
(Figure 5, Table 1).98-102,104,105,108,109,111 Medication counselling provided by 
physicians, pharmacists and nurses has been shown to improve medication 
adherence in many patient groups, such as diabetics.98,99,102,105,111 Nurse-led 
counselling in groups and via electronic messages may also enhance 
adherence but more evidence is needed on the effectiveness of these 
interventions.109 
The most effective intervention components in verbal MI to enhance 
medication adherence have been found to be HCPs’ competent 
communication skills and patient-centred approach, interdisciplinary and 
effective team communication, well-defined roles between HCPs, regularly 
provided counselling and promotion of self-management (Figure 5, Table 
1).98,100,102,108,111 Combining interventions, such as tailored counselling 
combined with social support, education and/or reminders, enhance 
adherence more than using a single intervention.104,109 
Many of the pharmacist-led verbal MI interventions have been shown to 
have a statistically significant impact on clinical outcomes, such as lowering 
blood pressure and blood glucose levels, and enhancing glycemic control 
(Figure 5, Table 1).98,99,101,102,108 The best effects of the pharmacists’ verbal MI 
interventions have been seen on blood pressure control, but the evidence of 
their effectiveness on patient satisfaction, knowledge, quality of life and 
healthcare utilisations is insufficient or contradictory.99,101,105,108 Pharmacist-
led interventions have also been proven to have positive effects on safety 
outcomes, such as preventing ADRs and medication errors.101 The significance 
of pharmacist-led verbal MI interventions to economic outcomes is 
mixed.105,108  
Case management interventions by nurses or care teams, such as the 
assessment of barriers to medication-taking among patients, have been 
indicated to significantly improve medication adherence and clinical 
outcomes, but not quality of life (Table 1).104 In some cases, feedback 
interventions carried out by pharmacists or physicians, such as discussions 
with the patient to inform about the changes to the regimen, increase patient 
satisfaction with their care and concordance between patient preferences and 
prescribed regimens.104 There is robust evidence that informing patients about 
potential ADRs by educational verbal MI interventions does not increase the 
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reporting of ADRs in most of the cases and does not impact negatively on 
medication adherence or clinical outcomes.103 
 
SIGNIFICANCE OF MULTIMEDIA-BASED MEDICINES INFORMATION 
 
There is limited but optimistic evidence that multimedia-based MI 
interventions are more effective than no education or non-standardised 
education provided by HCPs as part of usual clinical care in improving skill 
acquisition (e.g., inhaler technique among asthmatics) and knowledge about 
medicines (Table 1).96 Multimedia-based education could be used alongside 
MI provided by HCPs, but not as a replacement for medication counselling or 
WMI. Studies related to the best-practices for MI on prescription medicines 
have found that short and targeted educational videos improve short- and 
long-term knowledge compared to longer video interventions or written 
materials.106 Interactive computer or web-based programmes have shown a 
positive impact on knowledge and self-efficacy. Incorporation of visual aids, 
such as animations, in multimedia tools have not been indicated to impact on 
patients’ behaviour, knowledge or medication adherence. 
2.2 STRATEGIC DEVELOPMENT OF MEDICINES 
INFORMATION 
This section focuses on the strategic development of MI in the EU, especially 
in the 2000s. Finland is used as a textbook example country as the 
development of MI practices there has been systematic and long-term. In 
particular, the focus is in the development, implementation and evaluation of 
the Finnish first national MI strategy.22 
 
2.2.1 STRATEGIC ACTIONS TO ENHANCE MEDICINES INFORMATION 
TO PATIENTS IN THE EUROPEAN UNION DURING THE 2000s 
 
The availability and quality of MI has been key topic of debate globally as an 
integral prerequisite for rational pharmacotherapy since the 1960s.27,46 To 
ensure patients have access to high-quality and balanced MI, adequate 
coordination and organisation of MI practices between public and private 
stakeholders are required.16,25,32,116 
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Since the early 2000s, developing the coordination of MI has been one 
of the strategic aims to improve the access of MI to patients and to enhance 
the implementation of rational pharmacotherapy in the EU. In 2001, the High 
Level Group on Innovation and Provision of Medicines, known as the G10 
Medicines Group, was set by the European Commission to enhance 
competitiveness in the pharmaceutical industry and to encourage high levels 
of health protection.24 In 2002, the G10 Medicines Group published 
recommendations for action to improve the quality and access of MI to 
patients. In 2005, the European Commission established the High Level 
Pharmaceutical Forum, known as the Pharmaceutical Forum, to continue the 
implementation of the recommendations published by the G10 Medicines 
Group.25 The Pharmaceutical Forum was mandated to assess current MI 
practices in the EU countries and develop a set of core quality principles for 
improving quality of MI.25 
In 2008, the Pharmaceutical Forum concluded in its recommendations 
that patients in different EU countries do not have equal access to MI (Table 
2).25 Variation in MI practices particularly concerned the use of the Internet 
as a source of MI and cooperation between public and private sector MI 
providers. The Pharmaceutical Forum’s recommendations on information to 
patients emphasised the responsibility and cooperation of various actors in 
MI (e.g., HCPs, patients and representatives of the pharmaceutical industry) 
in the production of the reliable MI (Table 2). Furthermore, the 
recommendations proposed that the EU member states should establish long-
term strategic work to coordinate MI practices nationwide. 
Within the EU, the UK has been a pioneer country for the long-term 
national development of MI practices, especially WMI to patients.16,39,51 The 
work done in the UK has had a spillover effect on the EU regulations 
concerning WMI, particularly PLs (e.g., structure and content, availability in 
braille format, user testing of readability).45,53,62 Many of the UK initiatives 
have had their roots in the developments in the USA, a long-term research 
cooperation between British, American and Australian MI researchers being 
the vehicle for transfer.117 
  
Table 2. Recommendations of the High Level Pharmaceutical Forum (Pharmaceutical Forum) on information to patients published in 2008 addressed to the 
European Commission, interested stakeholders and the European Union member states.25 All the recommendations are subject to the European and national 
legal provisions. 
 
 
RECOMMENDATIONS AND ACTIONS FOR IMPLEMENTATION 
 
 
Recommendation 1: ENHANCE QUALITY OF INFORMATION 
Actions for implementation: 
1. The Forum recognises that the mandate of the Pharmaceutical Forum is part of a broader health information context, as identified by a number of important elements which Member States and the Commission should 
commit themselves to taking into consideration when developing work in this field. 
2. All the relevant players, including national competent authorities, the Commission, public health stakeholders and industry, should ensure high quality information and thereafter should commit themselves to 
implementing and using the core quality principles and their methodology of use for the development of information, and to identifying poor quality information.  
3. The Forum recognises the added value for patients and citizens of providing information on medical conditions jointly with information on treatment options. All the relevant players should ensure that the identified key 
elements for information to patients on medical conditions and treatment options are taken into consideration when information to patients is produced, assessed and improved. 
4. The Commission should consider using the EU Health Portal to raise the visibility of good information sources and ensure that all principles developed by the Forum are applied. Member States and stakeholders, with the 
assistance of the Commission, should commit themselves to continuing to share information about new initiatives regarding information that are in line with the principles. 
5. The Commission together with the Member States and the relevant stakeholders should consider developing a common approach to quality assurance of information. 
6. The ban on advertising of prescription medicines to the general public should continue. 
 
 
Recommendation 2: INCREASE ACCESSIBILITY AND DISSEMINATION OF INFORMATION 
Actions for implementation: 
7. Member States, stakeholders and the Commission should accelerate their engagement toward generation of information to citizens in effective communication formats (electronic and non-electronic means), taking 
account of local traditions, healthcare systems and languages. To initiate the process, Member States, stakeholders and the Commission are invited to implementing the specific recommendations identified to increase 
accessibility and dissemination of health information in the various healthcare settings. 
8. The Commission should commit itself to making visible the best practices identified in the Member States and to promoting cooperation between the Member States and the relevant stakeholders to further exchange 
experiences. 
9. The European Medicines Agency should continue, and be financially enabled to continue, its efforts in improving the database on medicinal products authorised in the EU as foreseen in Article 57, 1(l) of Regulation (EC) 
No 726/2004 and its cooperation with Member States and stakeholders with regard to information on medicinal products. 
 
 
Recommendation 3: GENERATION OF INFORMATION BY MAKING THE BEST USE OF ALL ACTORS 
Actions for implementation: 
10. Member States, the Commission and other stakeholders should take note of existing partnerships and collaborations between the various parties that mobilise knowledge and resources for producing and disseminating 
information to patients. 
11. Member States, the Commission and other stakeholders should exchange information about the different approaches existing across Europe in the choice of partners, structures and responsibilities. They should also 
consider whether further collaborations could be created. 
12. Where such partnerships and collaborations are set up, Member States and stakeholders should commit themselves to respecting the minimum ethical requirements of i) transparency, ii) disclosure of financial and 
other support and iii) definition of responsibilities as identified in the Forum process. 
13. The Commission should raise the visibility of existing partnerships and collaborations, for instance by using the EU Health Portal, which respect the ethical guidance and produce information in line with the core quality 
principles. 
 
 
Recommendation 4: CONTINUED MOMENTUM ON INFORMATION TO PATIENTS 
Actions for implementation: 
14. The members of the Pharmaceutical Forum are invited to disseminate the outcomes of the Forum to all interested parties and citizens, e.g., through workshops. 
15. Member States and the relevant stakeholders are expected to ensure that the recommendations are followed up at national level. Member States and the Commission in cooperation with the relevant stakeholders 
should within the next two years undertake a first review of what exists, and what has been created and/or improved following the recommendations from the Pharmaceutical Forum in the field of information to patients. 
16. Further cooperation and sharing of experiences at EU level is needed, and thus the Commission should set up a process building on the Information to Patients working group to evaluate the direct outcomes and follow-
up of the Pharmaceutical Forum. 
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Among the most remarkable milestones in the UK guiding the 
development of national MI practices has been the shift from compliance to 
concordance.1,118,119 It was initiated in mid-1990s through extensive research 
by the Royal Pharmaceutical Society of Great Britain (RPSGB) to identify the 
root causes of poor compliance.118,119 However, instead of root causes, the 
researchers ended up with an entirely new approach to medicine taking and 
recommended to disregard compliance as a concept.14,119,120 
The new concept, concordance, refers to mutual understanding of the 
treatment as a result of a negotiation between the patient and the HCPs 
professional that respects the patient’s wishes, beliefs and underlying 
knowledge.3,4,119 Concordance views the patient as being the equal of the 
healthcare provider and as having a right to make informed decisions. 
Concordance is related to empowerment and patient-centred care, thus it is 
not a synonym of compliance.1,121-123 To implement concordance-based 
practices in the UK, a national long-lasting strategic Partnership in Medicine 
Taking programme was initiated by the National Health Service (NHS) in 
1997.119 The programme was supported in many ways, e.g., by the 
development of an instrument to operationalise the concept of concordance to 
assess HCPs’ attitudes towards it.124,125 This instrument and its modifications 
have been applied beyond the UK, for instance in Finland.120,126,127 
In 2004, the UK created a national health information strategy, Better 
Information, Better Choices, Better Health,  as a 3-year action plan at local 
and national levels with a vision of putting information at the centre of 
healthcare within the UK.40 The strategy was designed to influence the way 
people seek and use health information in informing their healthcare 
decisions. The strategy included 25 activities which were outlined to improve 
access to health information, signposting and quality of information, and open 
up the relationship between HCPs and patients, organisational roles and 
responsibilities and communications and support.  
During the compilation of the first national MI strategy in Finland, in 
2010 a Master’s thesis was conducted at the University of Helsinki in 
cooperation with the University of Bath to evaluate the implementation of the 
various actions of the UK’s national health information strategy.128 An 
evaluation found that the best implemented activities were primarily those 
which were already underway when the strategy was compiled, e.g., websites 
available nationally to provide general health information and information 
about prescription medicines. The weakest accomplished activities were those 
which were considered unnecessary during the strategy or where there was no 
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clearly addressed responsible stakeholder to implement the activity, e.g., a 
web-based search engine for health information. The planned 3-year 
timescale was possibly too short to deliver all of the activities planned in the 
strategy. 
In the UK, the idea of the strategic development of MI was adopted from 
the USA in which public and private stakeholders had been brought together 
already by the beginning of 1970s as a consequence of a failure to oblige 
package inserts in pharmaceutical products.129 The initiative was blocked by 
the drug industry, which led to the formation of a coordinating body of MI to 
consumers named National Council of Patient Information and Education 
(NCPIE) in 1982.130 NCPIE has been facilitating research and development of 
MI practices to consumers, primarily in the USA. However, it has also had 
spillover effects to other countries, including in Europe, e.g., through the 
WHO EuroPharm Forum: one of its programmes to enhance community 
pharmacists’ involvement in patient care and health promotion was adopted 
from NCPIE (Questions to Ask About Your Medicines campaign).131,132 
 
2.2.2 DEVELOPMENT OF MEDICINES INFORMATION IN FINLAND 
 
As in many other countries, the roots of MI to patients in Finland are in the 
realisation of drug safety risks in the 1960s (Figure 6). Already by 1961, the 
first nationwide MIC with a call centre service specialising in prevention and 
treatment of acute poisonings was founded in the Helsinki University 
Hospital.18 In the early 1970s, a debate was raised on patients’ rights to know 
about the medicines they take and the need to also involve pharmacists in 
medication counselling to enhance rational medicine use.17,43,74 At that time, 
the perceptions of HCPs, particularly those of physicians, were paternalistic 
on patients’ role in their own care, even though the rights of the patients were 
recognised in principle. The debate led to the administrative regulation in 
1973 that allowed community pharmacists to participate in medication 
counselling. Prior to this, medication counselling was limited to physicians’ 
duty and pharmacists were only allowed to provide MI at the request of the 
patients. 
In the 1980s, the request for active medication counselling became even 
more dominant along with public health orientation in healthcare 
developments which emphasised health education (Figure 6).43 Efforts were 
made to coordinate and organise MI practices in healthcare.17,43 Pharmacists’ 
statutory obligation to provide counselling to patients while dispensing 
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prescription medicines and selling non-prescription medicines came into 
force in 1983. The first major action to improve the coordination of MI 
between the various actors in healthcare, particularly between physicians and 
community pharmacists, took place in 1986 when the multidisciplinary 
guidelines for MI, called Lääkeinformaation pelisäännöt in Finnish, were 
published. Together with the increased availability of MI targeted to patients, 
the need for reliable WMI sources increased. The first medicines compendium 
for consumers, called Kodin Lääkeopas in Finnish, was published in 1984, 
and the first computerised database system to produce medicines information 
leaflets to patients in community pharmacies was launched in 1986.18 There 
were no uniform regulations for the statutory PLs in the EU until 1999 when 
PLs became mandatory in all EU member states, including Finland.19 The first 
national clinical practice guidelines for HCPs and patients, called Käypä hoito 
-suositukset in Finnish, were published in Finland in 1997.133-135 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIntegrated into the online health library (Terveyskirjasto), bROHTO initially worked as a project in 1998–2001, and after that it operated as the Centre for Pharmacotherapy Development ROHTO under the Ministry of Social Affairs and Health (2002–2008), cService provided by the 
Hospital District of Helsinki and Uusimaa (HUS), dService provided by the University Pharmacy which is owned by University of Helsinki, eOwned by the University of Kuopio/the University of Eastern Finland, fOwned by the University of Eastern Finland and Pharmaceutical 
Information Centre in 2012–2014, owned by Pharmaceutical Information Centre since 2015, and provided MI service to consumers until 2017, gWebsite portal owned by the University of Kuopio/the University of Eastern Finland during 2002–2011, since 2012 owned by the 
Finnish Medicines Agency Fimea, hOwned by Duodecim Publishing Company Ltd. 
 
Figure 6. History and evolution of medicines information (MI) to patients in Finland since the 1960s. 
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Since the early 1990s, patients’ self-management and responsibility for 
their own medication, medication monitoring and the shared-decision-
making between patients and HCPs has been emphasised (Figure 6).43 The 
first effort to shift from medicine-centred counselling to more individual and 
tailored counselling was taken through a national campaign in community 
pharmacies in 1993–1996.17,18,43,131 The Questions to Ask about Your 
Medicines campaign (QaM), called Kysy lääkkeistä in Finnish, was adapted 
from the WHO EuroPharm Forum’s programme.131,132 The campaign was an 
attempt to encourage medicine users to ask about their medicines by creating 
awareness of what they should know about their medicines (five core 
questions).131 Community pharmacies were encouraged to provide patient 
counselling training for their staff and to set national and local standards for 
medication counselling. During the QaM campaign, pharmacists’ counselling 
became more customised and more empathy was shown toward the patients. 
Additionally, pharmacists started to more spontaneously provide MI both 
orally and written. However, a discrepancy was found in the priority content 
of MI between consumer and community pharmacists: pharmacists 
emphasised technical aspects, such as repeating the label information and 
explaining how to store the medicine at home, while the consumers primarily 
wanted to learn about therapeutic effects of their medications, particularly 
about interactions, ADRs and therapeutic effects.136 Furthermore, the non-
participatory observations of medication counselling content in community 
pharmacies indicated the content to be limited, varying by the therapeutic 
group.137 These findings and experiences with the QaM campaign laid the 
foundation for the development of new tools, databases and continuing 
education assisting community pharmacists in their counselling practice. 
The most intensive period in the strategic development of medication 
counselling in community pharmacies occurred in the early 2000s when the 
TIPPA Project (2000–2003) was carried out to enhance MI provided by 
community pharmacists (Figure 6).14,17,26 TIPPA Project and its consequent 
projects in 2004–2019 have promoted the shift from traditional paternalistic 
medication counselling culture towards patient-centred approach, 
empowerment and respecting patients autonomy. Furthermore, it has aimed 
at strengthening the role of community pharmacies in the medication use 
process and as part of social and healthcare. 
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It became evident during the first phase of the TIPPA Project in 2000–
2003 that not all of the problems that medicine users experience with their 
medications can be solved by counselling, but require a more comprehensive 
approach.17 Thus, the next phase of the project in 2004–2007 focused on 
developing collaborative medication review procedures and related 
competences for pharmacists (Figure 6).17 As a result, a standardised 
comprehensive medication review (CMR) procedure and related qualification 
training were created through this project.138-140 Since then, the collaborative 
medication review procedures involving pharmacists have diversified and 
evolved in various settings, particularly in geriatric care in Finland.141-146 
The third phase of development that emerged from the TIPPA Project, 
called Apila Project (2012–2015) focused on community pharmacists’ 
contributions to patient and medication safety (Figure 6). It was linked to the 
national implementation programme of the first Finnish Patient Safety 
Strategy 2009–2013 established by the Ministry of Social Affairs and 
Health.147 The national implementation programme, called 
Potilasturvallisuutta taidolla in Finnish, was run by the National Institute of 
Health and Welfare during 2011–2014.148 
Apila Project encouraged community pharmacies: 1) to ensure safe 
medication practices within their outlets, and 2) to assist home care and other 
primary care units, as well as social service units, to ensure medication safety 
in their practice. For these purposes, community pharmacies were 
recommended to actively use a wide range of tools, such as a self-audit tool for 
assessing safe medication practices, adopted and validated from the US 
Institute for Safe Medication Practices’ (ISMP) Medication Safety Self-
Assessment (MSSA) tool,149 electronic databases assisting in medication 
reviews by identifying, for example, interactions, anticholinergic and 
serotonergic load and potentially inappropriate medications for older adults. 
Furthermore, the Association of Finnish Pharmacies launched a new 
electronic reporting system for reporting prescribing and dispensing errors 
identified in community pharmacies.  
The most recent phase of the TIPPA Project, called TIPPA 3 Project 
(2016–2019) continued with the goals of the previous projects to strengthen 
the contributions of community pharmacists in promoting rational medicine 
use and to give pharmacists a more visible part of the medication use process 
(Figure 6).150 TIPPA 3 Project was, in particular, planned to support the 
Rational Pharmacotherapy Action Plan (2018–2022) established by the 
Ministry of Social Affairs and Health as part of the Strategic Programme of 
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Prime Minister Juha Sipilä’s Government (2015–2019).28,151 One of the major 
strategic goals of the Government Programme was a national reform of social 
and health services system.151 
Another remarkable national long-term effort to promote rational 
pharmacotherapy was primarily targeted at primary care physicians. The goal 
of the ROHTO (1998–2008) was to influence physicians’ prescribing 
behaviour by promoting implementation of the Current Care Guidelines, 
called Käypä hoito -suositukset in Finnish (Figure 6).152 ROHTO was initiated 
as a 4-year programme (1998–2001), and was then changed to an 
independent unit operating under the Ministry of Social Affairs and Health 
(Centre for Pharmacotherapy Development ROHTO). The centre was merged 
to the National Institute of Health and Welfare in 2009.153 
Since the 2000s, the Internet and other electronic information sources 
have improved access to health information and MI among consumers, for 
example by making statutory PLs available online and increasing online MI 
services for consumers (Figure 6).18,154 In the 1990s, before online pharmacies 
were allowed in Finland, community pharmacies started to establish MICs 
and provide call-centre-based MI services to their customers. The first 
national call centre was established by the University Pharmacy (YA) in 1996, 
which has since grown to multi-channel MI services with high magnitude 
(Figure 6).18 Another national call centre (The Kuopio Medicines Information 
Centre KLIK) was established by the University Pharmacy of the University of 
Kuopio (currently the University of Eastern Finland) in 2001.155 It contracted 
private community pharmacies so that their clients could call the centre when 
they had medication-related problems (e.g., beyond opening hours). During 
2012–2014, KLIK operated under the name The National Pharmaceutical 
Information Centre, which was jointly owned by the University of Eastern 
Finland and Pharmaceutical Information Centre. Since 2015, The National 
Pharmaceutical Information Centre has been owned by the Pharmaceutical 
Information Centre. Since 2017, the call centre has served only HCPs through 
online services. 
Online pharmacies have been allowed in Finland since 2011 and they are 
obliged to ensure rational medicines use by providing MI to patients while 
dispensing and selling prescription and non-prescription medicines online 
(Figure 6).156,157 
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2.2.3 STRATEGIC DEVELOPMENT OF MEDICINES INFORMATION IN 
FINLAND DURING THE 2010s 
 
As the previous chapters indicate, MI has been a special priority in Finland for 
a long period of time in terms of medicines policy, research and practice 
development. The most recent developments during this decade have been 
based on the Medicines Policy 2020 established by the Ministry of Social 
Affairs and Health in 2011 as an outcome of an intensive stakeholder 
cooperation.3 Medicines Policy 2020 document is in line with the strategic 
guidelines for social and health policy by 2015 established by the Ministry of 
Social Affairs and Health in 2006.158 MI was prioritised in medicines policy 
because numerous MI sources and databases were available for medicine 
users and HCPs, but there was a lack of coordination between actors in the 
production and utilisation of different information sources in social and 
health services.3 
In 2011, the Finnish Medicines Agency Fimea was given a mandate to 
launch a long-term national programme to coordinate MI practices and to 
develop a national MI strategy. The national MI strategy was developed in 
cooperation with stakeholder representatives, including patient 
organisations, universities, pharmacies, and professional associations in 
medicine, pharmacy and nursing (Figure 7).159-161 Moreover, previous studies 
and experiences of MI practices and existing MI strategies in other EU 
member states were utilised.128,162 Guided by these studies and experiences, 
along with the recommendations of the Pharmaceutical Forum for strategic 
development of MI,25 Fimea published Finland’s first MI strategy, Rational 
Use of Medicines through Information and Guidance – Medicines 
Information Services: Current State and the Strategy for 2020, covering the 
years 2012–2020 in February 2012.22 
The ultimate goal of the national MI strategy is to have well-informed 
patients who adhere to their medications (Figure 8).22 This strategic goal is in 
line with the Chronic Care Model,163,164 which was quite extensively piloted in 
Finland in the beginning of the 2010s (i.e., at the time the national MI strategy 
eatablihed) as a potential basis for a new social and health services system.165 
The model puts the patient into the center and encourages creation of 
structures and processes that support self-management of chronic diseses.  
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Figure 7. Development of the first national medicines information (MI) strategy in Finland. 
 
The primary target of the national MI strategy is patients with long-term 
medication. The main phases and actions of different HCPs involved in the 
medication use process are illustrated in Figure 8. Patients have a statutory 
right to be informed about the reasons and effects of their treatment, 
alternative treatment forms and their effects and other factors which may 
affect the decision to select the treatment.23 The aim is strengthen patients’ 
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involvement in their own care and enhancing adherence. The national MI 
strategy has 6 main goals with 37 proposals for the actions (Table 3).22 The 
primary values of the national MI strategy are to promote patient-centredness 
and multidisciplinary practices. Achieving the strategic goals requires 
engagement of the stakeholders in pharmaceutical sector and their willingness 
to implement the goals of the strategy in practices.  
 
 
 
Figure 8. Medication use process for patients with chronic diseases as illustrated in the 
Finnish national medicines information (MI) strategy by 2020.22  
 
  
 
Table 3. Strategic goals, objectives and proposals for the actions of the Finnish national medicines information (MI) strategy 2012–2020.22 
 
 
MAIN  
STRATEGIC  
GOALS 
 
OBJECTIVES PROPOSALS FOR THE ACTIONS 
1. To establish  
a multidisciplinary  
MI network  
in Finland 
1. Establishing a national MI 
network 
 
1. Establish a MI network in order to increase cooperation, a more systematic approach and greater multidisciplinarity in developing 
MI activities and to promote collaboration between public and private sectors. 
2. Incorporating research and 
follow-up in MI activities 
2. To direct the activities of the MI network, the following will be assessed: the need for information among HCPs, the need in the 
different sectors and the effectiveness of medication counselling and guidance. 
3. Participating  
in international initiatives 
 
3. Assess the applicability of international models and MI tools for use in Finland. 
2. To ensure 
that HCPs 
utilise reliable 
information 
sources and 
services 
4. Increasing awareness of 
reliable information sources 
4. Produce summaries of pharmacotherapies. 
 
5. Produce evaluations and summaries of the therapeutic and economic value of medicines for HCPs and patients. Encourage greater 
utilisation of evaluated evidence. 
 
6. Improve the availability of MI in Swedish for HCPs. 
 
7. Establish an effective information management system for crisis situations and pharmacovigilance-related information to ensure 
that all HCPs can be contacted during the same day. 
 
5. Improving the accessibility 
and  
usability of MI 
8. Ensure through basic and complementary education that HCPs are aware of the various information sources and databases and are 
able to use them. 
 
9. Develop electronic clinical decision support systems and integrate them into existing information systems. 
 
10. Ensure easy access to SmPCs. Improve the quality of SmPCs in the EU. 
 
11. Produce a MI formulary in Finnish based on generic names. 
 
6. Utilising experts and 
existing specialist services 
12. Evaluate opportunities for networking and coordination of activities between the stakeholder currently providing MI services. 
 
13. Evaluate and monitor the quality of MI disseminated by stakeholders providing MI services. 
 
14. Increase awareness of and collaboration between Clinical Pharmacology and Clinical Pharmacy services. 
• Develop Clinical Pharmacology and Clinical Pharmacy services and ensure access to them everywhere in Finland, for instance 
by creating  
• A network-type consultations service for HCPs. 
• Shift the focus of ward pharmacy activities from medicines logistics towards clinical pharmacy: medication review and 
medication counselling for patients (e.g., admission interview, review of admitted patients’ medication, medication counselling 
on discharge together with a physician and a nurse). 
 
15. Step up collaboration in producing hospital-specific internal Standard Operating Procedures an in disseminating these SOPs and 
best practices in pharmacotherapy. Opportunities to utilise guidelines and practices from other countries should also be evaluated. 
 
 
 
 
 
  
3. To ensure 
a high level of 
medicines 
expertise and 
multi-
disciplinarity 
in healthcare 
7. Improving medicines  
expertise and developing training 
in medication counselling 
16. Develop basic and complementary education for all professional groups. 
• Develop existing syllabuses and ensure that physicians and other HCPs are well prepared for reading, assessing and applying 
published research, treatment guidelines and assessments of the therapeutic an economic value of medicines. 
• Increase the practical application of theoretical knowledge in clinical pharmacy teaching for pharmacy students. 
• Further develop medicines expertise among nurses and ensure equal skills everywhere in Finland. 
• Further develop practical nurses’ medicines expertise. 
8. In basic and complementary 
education emphasising a patient- 
centred attitude, a multi-
disciplinary approach and support 
for patient self-management 
17. Ensure that basic and complementary education for all groups of professionals contain multidisciplinary courses. Teaching should 
address at least the following areas: a patient-centred approach and support for self-management, tailored medication counseling, a 
multidisciplinary approach, and increasing awareness of the competence of one’s own professional group among other groups of 
professionals. 
18. Consider special groups: MI should be included in the basic and complementary education of sign language interpreters and 
interpreters working with immigrants. 
4. To base 
medication 
counselling on 
national 
guidelines and 
local agreements 
9. Harmonising the provision  
of medicines counselling  
in healthcare 
19. Increase collaboration between pharmacies and healthcare units and encourage more local agreements on monitoring long-term 
treatments. Medication counselling practices should also be agreed on. 
20. Define quality and structural standards for medication counselling and assess the possibility to document and monitor medication 
counselling. 
10. Using MI to support  
the provision of pharmacotherapy  
in various settings 
21. Ensure that units have unit-based pharmacotherapy plans that also include MI activities. 
22. Ensure that persons providing pharmacotherapy have access to MI. 
11. Ensuring medication  
counselling in self-care 
23. Support the work of professionals by producing evidence-based treatment guidelines concerning self-medication and self-care 
and integrate these info existing treatment guidelines wherever possible. 
24. Incorporate guidance for self-care and self-medication into the national self-care programme. 
25. Assess and monitor the quality of MI and medication counselling available from online pharmacy services and pharmacy service points. 
5. To ensure that 
medicine users 
utilise reliable 
information 
sources and 
services 
12. Ensuring the availability of 
reliable MI 
26. Increase collaboration between patient organisations and other stakeholders in this field to improve MI. 
13. Promoting the readability  
and usability of PLs 
27. Further enhance package leaflet readability and contents in the EU. 
14. Producing MI  
in minority languages and for 
other special groups 
28. Produce MI in Swedish. 
29. Produce MI for special groups (immigrants, deaf and hard of hearing, visually impaired, elderly, children, patients with public 
health problems). 
15. Increasing the use of 
information and communications 
technology  
to disseminate MI 
30. Incorporate general MI for citizens into other social affairs and healthcare information in the SADe Projecta. 
31. Link general MI, including information on medicines currently used by the patient, to patient-specific information in the 
National Archive of Health Information’s ePrescription system. 
32. Create a list of links to reliable sources of MI or establish a quality label. 
33. Develop and promote the visibility and participation of HCPs in social media. 
6. To achieve a 
high level of 
health literacy 
among the general 
public 
 
16. Promoting health literacy  
among children and adults 
 
 
34. Promote the use of the DARTS checklistb, developed to help assess whether MI is reliable, among the public and in school teaching. 
35. Carry out a multidisciplinary population-level campaign on the safe and appropriate use of medicines. 
36. Update MI webpages to produce a generic source of MI for the general public. 
37. Ensure that the appropriate use of medicines and MI literacy continue to be included in the Core Curriculum for basic education. 
• Create national medicines education guidelines for schools in which the appropriate use of medicines is integrated into a wider 
educational context.  
• Encourage medicines education collaboration between schools and the healthcare system and develop guidelines and material to 
support HCPs giving medicines education lessons. 
• Ensure teaching material is provided for special groups such as sign language uses. 
 aNational program for accelerating electronic services and democracy (2010–2015) by the Ministry of Finance, bA five-item tool to assess the quality of online MI. 
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2.2.4 IMPLEMENTATION OF THE NATIONAL MEDICINES 
INFORMATION STRATEGY 
 
The National Medicines Information Network (MI Network) was established 
in September 2012 to support the implementation of the national MI strategy 
(Table 4, Figure 9).159 The aim of the MI Network is to increase national and 
international multidisciplinary cooperation in the promotion of reliable MI 
and MI services and in assessing their effectiveness. Fimea has overall 
responsibility for coordinating the MI Network’s activities. The activity of the 
MI Network is based on the collaboration of the Coordination Group and four 
working groups (Figure 9). The proposed actions (n=37, Table 3) of the 
national MI strategy were divided between the working groups in 2012 when 
the MI Network was built up. The MI Network consists of a wide range of key 
stakeholder representatives involved in providing and producing MI (Table 
4). At the network-building phase, a total of around 110 stakeholders 
representing about 50 organisations participated in the MI Network. Such a 
network is unique both in Finland and internationally. 
 
Table 4. Stakeholder groups represented in the Finnish National Medicines Information  
Network during 2012–2020. 
 
STAKEHOLDER GROUPS 
Community pharmacies 
Educational units: universities, polytechnics, vocational institutions and continuing education units 
Primary healthcare centres 
Hospital pharmacies and dispensaries 
Patient associations and organisations 
Pharmaceutical industry organisations 
Public administrations 
Scientific societies 
Student associations 
Trade and professional unions and organisations 
University hospitals and hospital districts 
 
Implementation of the national MI strategy is divided into three 
operational periods (2012–2014, 2015–2017, 2018–2020). Stakeholder 
representatives are selected at the beginning of each operational period. The 
MI Network is open and public, and new member organisations or members 
can be suggested by anyone. Each stakeholder decides what is their 
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contribution to the activities of the MI Network and development projects. No 
resources have been allocated to the MI Network by the government or Fimea, 
other than the salary of the coordinator of the MI Network. All the documents 
produced in the MI Network, such as working groups’ action plans, reports 
and meeting memos, are available freely online.166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Structure of the National Medicines Information (MI) Network and purposes and  
main objectives of the working groups (WG). 
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MEDICINES 
INFORMATION  
TO HEALTHCARE 
PROFESSIONALS 
WG 
 
• Develops MI 
activities, 
multiprofessional  
cooperation and  
the provision of 
MI  
in healthcare 
• Promotes multi-
professional  
cooperation with 
the Education WG 
 
 
MEDICINES 
INFORMATION  
TO PATIENTS WG 
 
• Provides 
information on 
reliable MI sources 
to patients  
• Promotes 
cooperation and 
development of 
patient-focused 
material 
• Promotes patients’ 
self-management 
and empowerment 
 
 
RESEARCH WG 
 
• Promotes MI 
research and 
collaboration 
between MI 
researchers 
• Identifies key 
areas and topics 
of MI research 
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The Coordination Group consists of representatives from all key 
stakeholders from the pharmaceutical sector, HCPs and patient organisations. 
The group promotes and coordinates the development of MI, monitors 
development projects and comments on their progress. Communications 
Team assists the Coordination Group and transmits information between the 
working groups. The team includes communication experts from the 
stakeholders involved in the MI Network. 
The Research Working Group includes stakeholders who carry out 
research on MI. The group does not perform the research itself, but it 
promotes the research and collaboration in this field and outlines key research 
areas and topics related to MI at national level. 
The Education Working Group is a forum for teachers working in 
education units for HCPs (e.g., universities, polytechnics, vocational 
institutions, complementary educations units) educating current and future 
professionals in medicine, nursing and pharmacy. Members of the group 
develop solutions to promote a multidisciplinary approach and MI activities 
in basic and continuing education taking into account working life needs. 
The Medicines Information to Healthcare Professionals Working 
Group consists of HCPs from various stakeholders (e.g., universities, 
healthcare units, scientific societies, national authorities, trade 
organisations). The aim of the group is to develop MI activities, 
multiprofessional cooperation and the provision of MI at practical level in 
healthcare. 
The Medicines Information to Patients Working Group comprises 
stakeholders from patient organisations, pharmacies, pharmaceutical 
industry, trade unions and national authorities. The group provides 
information on reliable MI sources to patients and promotes cooperation and 
development of patient-focused MI material. Activities of the group 
strengthens support for self-management and patient empowerment. 
The Medicines Information Forum is a multidisciplinary seminar which 
brings together the users and producers of MI. The Forum aims to promote a 
wide-ranging debate on the current status and challenges of developing MI. 
The Forum is carried out once a year in autumn and it is open for public. 
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2.2.5 RESEARCH TO GUIDE AND EVALUATE THE IMPLEMENTATION 
OF THE NATIONAL MEDICINES INFORMATION STRATEGY 
 
Research has been an integral part of the activities of the MI Network.22 
Information obtained through periodic evaluations of the national MI strategy 
and other research coordinated by the MI Network has guided the national MI 
strategy’s implementation (Figure 10). Research has been organised by 
establishing the first national MI research strategy in 2014.167 Table 5 presents 
the finalised studies and projects under the national MI research strategy 
during a 10-year period of 2009–2019.87,128,159-162,168-176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aUpdated for each operational period. 
 
Figure 10. Operations and evaluation of the national medicines information (MI) strategy. 
 
 
 
 
 
 
 
I operational period 
2012–2014 
  
II operational period 
2015–2017 
III operational period 
2018–2020 
EVALUATION 
 
National 
MI Network 
was  
established  
in September 
2012 
 
First 
National 
MI research 
strategya 
was 
published  
in 2014 
 
Interviews 
for members of the 
National MI Network 
in spring 2015 
OPERATIONS 
  
National MI Network 
meeting and group 
discussions  
in autumn 2017 
Survey for members 
of the  National MI 
Network 
in spring 2019 
 
• Research and collaboration projects 
• Activities for implementing the national MI strategy 
coordinated by the National MI Network 
 
     
 
National 
MI strategy 
was 
published  
in February 
2012 
    2012             2013             2014            2015             2016             2017             2018             2019             2020 
   
Table 5. Studies related to the national medicines information (MI) strategy and its implementation in Finland during 2009–2019. Information in this table is 
based on the review published previously.177 
 
 
STUDIES SUPPORTING DEVELOPMENT OF THE NATIONAL MEDICINES INFORMATION STRATEGY 
 
Authors 
Publication yearRef. 
(Type of publicationa) 
Study 
year 
Aspects studied Study population Method Key findings 
Salonen 2010162  
(M) 
2009 Role of MI in the national 
legislation, activities taken 
in developing MI practices 
nationally and coordination 
of MI to patients 
Medicines regulatory 
authorities in the EU member 
states (n=27), response rate 
63% 
Cross-sectional 
online survey 
The national health information/MI strategy was published in the UK, Italy and Germany in 2009. The 
development of MI targeted to the public emphasised the use of information technology, which had been 
utilised in different countries by publishing online PLs, developing MI websites for consumers, electronic MI 
services and quality certificates. To support the development of the Finnish national MI strategy, it is 
important to consult stakeholders producing MI at a national level and medicine users about their thoughts of 
good practices and development needs in MI. 
Young 2010128  
(O) 
2009–
2010 
Experiences on the 
implementation of the UK’s 
national health information 
strategy and the Finnish 
stakeholders’ views and 
future expectations of the 
new national MI strategy in 
Finland 
The UK’s national health 
information strategy, “Better 
Information, Better Choices, 
Better Health”, published in 
2004 and key stakeholders of 
MI in Finland 
Document 
analysis and 
interviews 
Effects of a 3-year national health information strategy of the UK on MI and MI services were positive, 
although not all 25 activities of the strategy were implemented completely. Political support as well as the 
availability of funding and support from stakeholders contributed to this success. The strategic activities for 
which planning, and implementation had already been started before the publication of the strategy were the 
best implemented. Finnish stakeholders emphasised that MI has been a focus for authorities in Finland since 
the 1990s and has been improving since then. Despite this Finland has never had a national strategy for MI. It 
is likely that the use of a strategy would further improve MI to patients. Stakeholder involvement will be key 
to the planning and implementation stages of a new national MI strategy. 
Hämeen-Anttila  
et al. 2012160 (P) 
2011 Role of stakeholders as 
producers of MI, views on 
coordination of MI and 
good practices, challenges 
and development needs in 
Finland 
Stakeholder representatives 
(n=28) from patient 
organisations, universities, 
pharmacies and professional 
associations in medicine, 
pharmacy and nursing 
Interviews Stakeholders emphasised the need to increase multiprofessional collaboration in the development of MI and 
to develop MI services for the public sector. Deficiencies were demonstrated in the access of MI, 
pharmacotherapy competence and teaching medication counselling in basic and in continuing education 
among HCPs. The receipt of reliable MI in different social and healthcare environments among patients and 
HCPs was presented as a challenging issue by the stakeholders. 
Hämeen-Anttila 
et al. 2013159 (P) 
Luhtanen 2012161 (M) 
 
STUDIES SUPPORTING ACTIVITIES OF THE NATIONAL MEDICINES INFORMATION NETWORK 
 
Järvinen et al. 
2013171  
(O) 
2000–
2013 
Description of the current 
MI practices in Finland and 
the research areas to be 
addressed in the future 
Original peer-reviewed 
publications conducted in 
Finland 2000–2013 (n=116) 
Systematic 
review 
Research on MI has been conducted in Finland from many different perspectives and topics, especially from 
community pharmacies’ and pharmacists’ point of view as well as from the MI sources and needs of different 
patients groups. Public's health and MI literacy, MI needs and sources of HCPs and the use of electronic MI 
sources have been the least studied. Obstacles in the use of reliable MI among HCPs, effectiveness of MI and 
MI needs among special patient groups (e.g., the deaf, the blind, immigrants, the elderly) should be 
researched in further studies. 
Hämeen-Anttila  
et al. 2019169  
(P) 
 
2000–
2017 
Effectiveness of patient 
counselling and WMI 
targeted to patients 
Systematic reviews (n=6) and 
original peer-reviewed studies 
(n=16) published in 2000–
2017 
Review MI has had a primarily positive effect on patients’ adherence and knowledge about medicines. Effects of WMI 
seemed to be contradictory. There was only limited evidence on the economic impact of MI and effects of MI 
on patient satisfaction and quality of life. 
Pajunen 2017178  
(M) 
2002–
2014 
Long-term trends in the 
receipt of MI among 
adolescents and young 
adults medicine users 
People aged 15–29 
participated in the national 
health behaviour studyb in 
2002,2005, 2008–2014 
Nationwide 
repeated cross-
sectional 
survey 
Physicians, pharmacists and PLs were the main MI sources throughout the study period. The receipt of MI 
decreased most from PLs (45% to 31%) and physicians (40% to 30%) while increased most from the Internet 
(4% to 17%). The proportion of medicine users who did not receive MI from any of the sources increased from 
29% to 42% during the study period. 
Ryhänen 2013179  
(U) 
2013 Feasibility of the 
assessment tools on the 
quality of MI for consumers 
International assessment tools 
for quality of MI (n=7) 
Report There are various effective tools for assessing the quality of MI for consumers. The tools have often used the 
same evaluation criteria, but there were also differences. The most commonly used criteria were topicality, 
authors, sponsors, correctness of information, links and references used. 
   
 
STUDIES GUIDING DEVELOPMENT OF MEDICINES INFORMATION DURING STRATEGY PERIOD 2012–2019 
 
Authors 
Publication yearRef. 
(Type of publicationa) 
Study 
year 
Aspects studied Study population Method Key findings 
Junnila 2015170  
(M) 
1999–
2013 
Long-term trends in the 
receipt of MI among ageing 
medicine users 
People aged 55–64 
participated in the national 
health behaviour studyb in 
1999,2002,2005, 2008–2013 
(n=6644) 
Nationwide 
repeated cross-
sectional 
survey 
Physicians, community pharmacies and PLs were the main MI sources throughout the study period. The 
receipt of MI decreased most from physicians (61% to 46%) while increased the most from the community 
pharmacies (27% to 43%) and the Internet (1% to 12%). The proportion of ageing medicine users who did not 
receive MI from any of the sources increased from 19% to 23% during the study period. 
Pakarainen 2015173 
(M) 
2013 MI needs and sources of 
practical nurses working in 
atypical areasc 
Members of the Finnish  
Union of Practical Nurses 
(n=666) 
Cross-sectional 
online survey 
PLs, the medical database (in Finnish: Terveysportti) and colleagues were the most common MI sources for 
practical nurses. Practical nurses were mostly satisfied with the current MI sources, but MI is not always 
available when needed. More information was needed about the interactions and ADRs. Nurses need further 
training on the use of MI sources and the application of knowledge in practice. 
Hämeen-Anttila 
2014168 (O) 
2014 Needs and sources of MI 
among medicine users 
Participants were collected 
through the websites and 
email lists of patient 
organisations and community 
pharmacies (n=2489) 
Cross-sectional 
online survey 
PLs (90%), pharmacists (83%), physicians (72%) and the Internet (68%) were the most common MI sources 
among medicine users using the Internet. Young, highly educated and people with long-term medication, such 
as patients with neurological or orphan diseases, reported needing more MI. Need for MI was highest when 
physician prescribed a new medicine (76%) or when a new medicine was started at home (51%). More 
information was needed on interactions with other medicines (79 %) and ADRs (83%). One-third (33%) 
reported conflicting information received from different sources as a major challenge in utilising MI. 
Hämeen-Anttila 
et al. 201887 (P) 
Pietilä 2015174 (M) 
Vornanen 2016176 (M) 
Kuosmanen 2015172 
(M) 
2014 Health and MI literacy, 
information-seeking 
behaviours and MI sources 
of adolescents  
Adolescents aged 18–20 
studying in the Finnish 
vocational schools (n=20) 
Group 
discussions and 
individual 
vignette-based 
solution tasks 
The Internet, PLs and parents were the primary sources of information on medicines-related questions for 
young people. The Internet and nurses were the most commonly used sources on health-related questions. 
Health and medicines information-seeking among young people was influenced by experience of symptoms, 
previous experiences, situation in life, social environment, access to information, sensitivity of the topic and 
reliability of information. 
 
STUDIES ASSESSING IMPLEMENTATION OF THE NATIONAL MEDICINES IFORMATION STRATEGY 
 
Unpublished work 
in progress,  
University of Helsinki 
2015 Assessment on 
implementing the goals and 
the activities of the Finnish 
national MI strategy after 
the first operational period 
Stakeholder representatives  
of the National Medicines 
Information Network 
(n=79/111), 
participating rate 71% 
Semi-
structured 
interviews 
The activities of the MI Network were assessed to be meaningful and necessary during the first operational 
period (2012–2014) of the national MI strategy in spring 2015. The strategic goals had become more concrete 
and activities in MI more coordinated. Moreover, networking has promoted communication and 
multiprofessional collaboration between different stakeholders. Networking under working groups has 
inspired multiple research and development projects. Lack of resources was considered to cause challenges 
for implementing the national MI strategy. 
Urpelainen 2018175  
(B) 
2017 Assessment on 
implementing the goals and 
the activities of the Finnish 
national MI strategy after 
the second operational 
period 
Stakeholder representatives  
of the National Medicines 
Information Network 
(n=41/110),  
participating rate 37% 
Workshop 
discussion 
notes 
At the end of the second operational period (2015–2017) of the national MI strategy, the performance of the 
MI Network was still assessed to be successful. The most challenging goals were the use of reliable MI sources 
among medicine users and public’s health and MI literacy. Due to the digitalisation and the increased use of 
electronic information sources, awareness and availability of reliable and user-friendly information sources 
should be developed further along with medicines education. 
aB=Bachelor’s thesis, M=Master’s thesis, O=Other research report, P=Peer-reviewed article, U=Unpublished report; b“Health Behaviour and Health among the Finnish Adult Population” was a national study 
conducted by the Finnish National Institute for Health and Welfare during 1978-2014, cHome care and social welfare units.
2 Review of the literature 
40 
The progress of the implementation of the national MI strategy has been 
regularly evaluated by Fimea at the end of each operational period (Figure 
10).177 The evaluation of the first operational period (2012–2014) was carried 
out by interviewing all members of the MI Network in spring 2015. Data from 
group discussions conducted as part of the MI Network meeting in autumn 
2017 were used to evaluate the second operational period (2015–2017). The 
evaluation of the third operational period (2018–2020) was recently 
conducted by surveying the members of the MI Network in spring 2019. 
In addition to evaluating progress in implementing actions, the 
performance of the MI Network as a facilitator of the implementation has been 
regularly evaluated throughout the strategy process. The preliminary results 
of the evaluation of the functionality of the MI Network in 2015, by the author 
of this dissertation, have been published in 2017 (see International 
Pharmaceutical Federation FIP: Medicines Information, Strategic 
Development, page 25, Table 5)16 (see also Appendix 1: Questions 5 and 6). 
 
2.2.6 ACHIEVEMENTS IN THE IMPLEMENTATION OF THE NATIONAL 
MEDICINES INFORMATION STRATEGY BY 2019 
 
One of the most significant achievements in the implementation of the 
national MI strategy has been the establishment of the MI Network shortly 
after the national MI strategy was published.177 The multiprofessional MI 
Network has proven to be highly functional and to have actively facilitated the 
launch of many key actions of the national MI strategy (Table 6). Among the 
most important actions implemented so far are: 1) Tunne lääkkeesi (Know 
your medicines), a Facebook site targeted at consumers for guiding rational 
medicine use and the use of reliable MI sources in managing medications, and 
2) Lääkehoidon päivä (Pharmacotherapy Day), an annual national awareness 
campaign targeted at consumers and HCPs for promoting rational 
pharmacotherapy. Carrying out both these actions involves a wide range of 
stakeholders and the goal is highlight practical tools and resources for making 
medicine use rational and safe. These actions have been recently integrated 
into the national implementation campaign of the Rational 
Pharmacotherapy Action Plan28 by the Ministry of Social Affairs and Health. 
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Table 6. Examples of actions taken by the National Medicines Information Network within 
seven years since the launch of the national medicines information strategy in 2012. 
 
MAIN STRATEGIC GOALS EXAMPLES OF ACTIONS 
1. To establish  
a multidisciplinary MI network 
in Finland 
• The National Medicines Information Network has been active since 2012  
with five working groups. 
2. To ensure that HCPs utilise 
reliable information sources 
and services 
• List of reliable and useful MI sources targeted to different HCPs (e.g., 
physicians, pharmacists, nurses) were published. 
3. To ensure a high level of 
medicines expertise and 
multi-disciplinarity  
in healthcare 
• Multiprofessional forum for pharmacotherapy teachers has been 
organised three times since 2014 (In Finnish: Lääkehoidon opettajien 
moniammatillinen foorumi). 
4. To base medication 
counselling on national 
guidelines and local agreements 
• Clinical Practice Guidelines for self-medication was published in 2016 (In 
Finnish: Käypä Hoito -suositus: Itselääkitys). 
5. To ensure that medicine users 
utilise reliable information 
sources and services 
• One-day national event for patients and HCPs to enhance rational  
pharmacotherapy has been organised every year since 2012  
(In Finnish: Lääkehoidon päivä). 
• Medicines Information Forum for patients and HCPs that brings together  
users and producers of MI has been organised every year since 2012 
(In Finnish: Lääkeinformaatiofoorumi). 
• Facebook website for directing consumers to use reliable MI sources was 
published in 2016 and is maintained by the National Medicines 
Information Network (In Finnish: Tunne lääkkeesi -Facebook-sivu). 
6. To achieve a high level of 
health literacy among  
the general public 
• During 2014–2016, pharmacy students held medicine education lessons 
for schoolchildren in 203 schools around Finland. 
2.3 USE OF MEDICINES INFORMATION SOURCES               
IN ADULTS – INTERNATIONAL PERSPECTIVE 
This section presents the current evidence on the use of MI sources among the 
adults using medicines obtained from a systematic literature search. The 
origin of the review was to gather background information for the Study II 
which examined long-term trends in the receipt of MI among Finnish adult 
population during the 2000s (see Chapters 4.2, 5.2 and 6.1.2). Hence, the 
ultimate aim of this review was to find if there were longitudinal studies 
describing long-term trends in the use of MI sources at population level. 
Furthermore, factors affecting MI-seeking behaviour are described based on 
the included studies. 
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2.3.1 SYSTEMATIC LITERATURE SEARCH 
 
The review is based on a systematic literature search using predetermined 
inclusion and exclusion criteria (Table 7). Only studies that met clearly the 
predetermined inclusion criteria were included in the review. A systematic 
search was conducted to obtain a comprehensive understanding on the topic 
in question. 
 
Table 7. Inclusion and exclusion criteria for the systematic literature search. 
 
 
INCLUSION CRITERIA 
 
 
EXCLUSION CRITERIA 
 
Population  
Participants aged 18–65 years Participants aged under 18 years or over 65 years 
Medicine users People not using medicines 
Study focus  
MI sources actually used Study did not focus on MI sources used 
The following topics were excluded: seeking information 
about healthcare services, food and nutrition 
information, travel health advice and information 
about someone else's medicines; usability of online 
MI; receipt of MI has not been clearly separated from 
health information; receipt of MI among the illiterate 
or people with limited literacy skills; and research 
focused on only one source of information, e.g., the 
Internet. 
Context  
Study conducted in developed economya Conference abstracts, editorials, narrative reviews, 
     doctoral theses, Master’s or other theses Full original research articles or  
systematic reviews and meta-analysis 
Published in peer-reviewed international scientific 
journal in English 
 
All types of interventions and research methods  
Time  
Study has been conducted and published  
within Jan 1, 2000 – May 31, 2018 
Study has been conducted and published before 2000 
aCountry selection was based on the classification by the United Nations.180 
 
One researcher (the author of this thesis) performed the literature 
search using an international bibliographic database MEDLINE® (Proquest) 
(Figure 11). The following search terms were used: medicines/drug 
information, receipt/receive, search/seek, and medicines/drug information 
source. Studies conducted during the course of 2000–2018 were included in 
the review. Included studies were content-analysed and categorised according 
to study country, study year and year of publication, aspects studied, study 
population, setting, study methods used, and key findings related to the use of 
MI sources. 
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Figure 11. A flow diagram of the study selection process for the systematic literature search. 
 
2.3.2 CHARACTERISTICS OF THE STUDIES 
 
A total of 27 studies met the inclusion criteria (Tables 8 and 9).30,87,115,181-204 
Nearly half of the studies (n=11) were carried out in European countries (Table 
8).87,183,190,193-197,199-201 Two studies were multinational115,189 and nine were 
national.87,187,188,193-196,199,200 A cross-sectional survey was the most dominant 
study method (n=14).87,115,182,184-186,189,190,192,194-196,199,201 HCPs (e.g., physicians, 
pharmacists, nurses), relatives, friends and the Internet were the most 
commonly studied MI sources. 
 
 
 
 
 
 
 
 
Final inclusion: 
27 articles 
Excluded by title or abstract: 
1952 citations 
 
Found from reference lists or 
manually added: 
5 articles 
 
Excluded after reading full-text: 
687 articles 
 
Full-text assessment for eligibility: 
709 articles 
 
Search results:  
2661 citations 
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Table 8. Characteristics of the studies (n=27) on the use of medicines information sources  
among adult population. 
 
 
CHARACTERISTICS (n)Ref. 
 
Country  
    Finland (n=8)87,193-196,199-201  
   Australia (n=7)30,185,187,188,191,192,202  
   USA (n=4)181,184,198,204    
   Canada (n=3)182,186,203  
   Multinational (n=2)115,189  
   UK (n=2)190,197  
   The Netherlands (n=1)183  
Year of publication  
   2000–2004 (n=4)186,191,197,198  
   2005–2009 (n=8)181,182,193-195,199,202,203  
   2010–2014 (n=14)30,115,183-185,187-190,192,196,200,201,204  
   2015–2018 (n=1)87  
Study population  
   Specific medicine user groups (n=11)115,181,182,189,192,194,198-201,203  
    Heterogenous medicine user groups (n=10)30,87,185,187,188,190,191,193,195,202 
    Medicine users with a chronic disease (n=6)113,183,186,196,197,204 
Study method  
   Survey, cross-sectional (n=14)87,115,182,184-186,189,190,192,194-196,199,201  
   Qualitative interview (n=6)181,183,193,198,202,204  
   Focus groups (n=2)30,197  
   Mixed-method (n=2)191,203  
   Telephone survey, cross-sectional (n=2)187,188  
   Survey, repeated, cross-sectional (n=1)200  
MI sources included in the study  
   Physician, specialist (n=27)30,87,115,181-204  
   Pharmacist (n=24)30,87,115,181,182,184,185,187-203  
   Internet (n=22)30,87,115,181,184-190,192-196,198,200-204  
   Relatives, friends (n=21)30,87,115,181,183-186,189-196,198-201,203 
   Nurse, midwife (n=17)87,115,181,184,185,189-198,200,203  
   Package leaflet (n=15)30,87,115,184,185,187-196  
   Books, magazines, newspapers (n=14)87,115,181,184,185,190-196,198,203 
   Radio, television, media (n=12)87,115,181,185,193-196,199-202 
   Telephone services, call centres, medicines information centres (n=7)87,115,189,193-196 
   Advertisements (n=6)181,192-196  
   Health food store (n=6)115,191,194-196,203  
    Other written patient informationa (n=6)87,181,184,185,191,202  
   Support groupsb (n=4)184,186,193,202  
   Medical book, drug handbook, health journal (n=3)87,186,193 
   Pharmaceutical company (n=3)188,193,197  
   Hospital (n=2)188,191  
   Drug regulatory authority (n=1)193  
   Seminars, talks (n=1)185  
n=number of studies; a Brochures, labels, newsletters, posters, product inserts, written patient information leaflet 
provided by healthcare organisation; b Patient organisations and societies, peers and other individuals. 
  
Table 9. Studies published in 2000–2018 on the use of medicines information (MI) sources among adult population (n=27) according to the publication year. 
 
 
STUDIES ON THE USE OF MEDICINES INFORMATION SOURCES AMONG ADULTS USING PARTICULAR MEDICINE (n=11) 
 
Authors 
Publication yearRef. 
Country 
Study 
year 
Aspects studied Study population Setting Method Key findings related to the use of MI sources 
Sleath et al.  
2003198 
USA 
2000 Patients’ sources of 
antidepressant 
information 
Antidepressant 
users, n=81 
Female 79% 
19-83 years 
Community 
pharmacies (n=8) 
in central North 
Carolina 
Individual 
interview 
Most commonly reported sources were pharmacists (58%), primary care physicians (51%), 
mental specialists (41%), friends and family members (32%) and the Internet (19%). Younger 
patients were significantly more likely to report receiving antidepressant information from the 
Internet than older patients. 
Wathen et al. 
2006203 
Canada 
 
 
 
 
2002–
2003 
Information seeking 
behaviour and decision-
making regarding 
menopause, hormone 
replacement therapy and 
use of complementary 
and alternative medicines 
Current or former 
hormone 
replacement 
therapy users, 
n=285 
Female 100% 
45-65 years 
Southwestern 
Ontario 
Individual 
interview 
and local 
cross-
sectional 
survey 
Women’s information-seeking behaviour and choice of different information sources differed 
according to decision they were making. Most of the women (85%) reported their physician as 
their most frequently used source of information when they decided to start hormone 
replacement therapy. Most of the women (90%) used multiple sources of information before 
making their final decision. 
Närhi et al.  
2007194 
Finland 
2005 Sources of MI used by 
analgesic users 
Analgesic users, 
n=502 
Female 50% 
15–64 years 
Nationwide National 
cross-
sectional 
survey 
Analgesic users reported physicians (35%), PLs (33%) and community pharmacists (33%) as their 
most common sources of MI. Almost half (49%) of the analgesic users did not report any HCPs 
(physician, pharmacist, nurse) as their source of MI. Gender impacted to the choice of source of 
MI. 
Tiihonen et al. 
2007199 
Finland 
2003 Information sources 
about hormone 
replacement therapy 
among women 
Hormone 
replacement 
therapy users, 
n=315 
Female 100% 
Nationwide; 
community 
pharmacies from 
each hospital 
district (n=15) 
National 
cross-
sectional 
survey 
Physicians and the media were the most common sources of information concerning benefits 
(74% vs. 56%) and ADRs (45% vs. 78%) of hormone replacement therapy. Only 3% of the 
respondents reported that they had received information from the pharmacy concerning both 
benefits and adverse reactions of hormone replacement therapy. 
Baldwin et al. 
2008181 
USA 
 
 
– Patients’ receipt of 
information about the 
medicines they use, and 
patients’ preferred role 
orientation associated 
with MI-seeking 
behaviour 
Blood pressure 
medicine users, 
n=189 
Male 97% 
66 years (mean) 
Medical centres 
(n=2) in Iowa City 
and Minneapolis, 
and community-
based outpatient 
clinics (n=4) 
Individual 
interview 
Patients reported receiving information on their blood pressure medicines most commonly 
from the Internet, community pharmacists and brochures. A more patient-centred role of 
which was associated with: 1) a greater likelihood to seek MI, 2) seeking MI from a greater 
number of information sources, and 3) initiating a conversation with HCPs about their 
medication. 
Black et al.  
2008182 
Canada 
2008 Patients’ preferences, 
satisfaction and 
perceived stigma related 
to community 
pharmacists 
Psychotropic 
medicine users, 
n=79 
Female 60% 
42 years (mean) 
Mental health 
outpatient clinics 
(n=4) in Halifax 
Multicentr
e cross-
sectional 
survey 
Psychiatrists, pharmacists and family physicians were the most commonly used sources for 
information on psychotropic medicines among patients receiving psychotropic medicines. 
Ngo et al.  
2010192 
Australia 
 
 
– Patients’ perceptions and 
understanding on the 
appropriate use of non-
prescription ibuprofen 
Non-prescription 
ibuprofen users, 
n=183 
Female 76% 
18 years or older 
Community 
pharmacies (n=8) 
in South Australia 
and the Northern 
Territory 
Multicentr
e cross-
sectional 
survey 
One-third of the respondents (36%) reported receiving MI from their physician or pharmacist, 
whereas 32% received information from friends or relatives, and 26% from advertisements. 
Most patients (65%) did not seek medical advice before using non-prescription ibuprofen. Most 
patients (66%) sometimes or never read PLs. 
 
  
Authors 
Publication yearRef. 
Country 
Study 
year 
Aspects studied Study population Setting Method Key findings related to the use of MI sources 
Tiihonen et al. 
2010200 
Finland 
 
 
 
2001, 
2007 
Information sources 
among women using 
hormonal contraceptives 
and the influences of 
sources on women’s 
attitudes and perceptions 
Hormonal 
contraceptive 
users, n=700 
(n=264 in 2001 
and n=436 in 
2007) 
Female 100% 
26 years (mean) 
Nationwide; 
university 
pharmacies across 
Finland (n=17 in 
2001, n=18 in 
2007) 
National 
repeated 
cross-
sectional 
survey 
The most common source of information on the benefits of hormonal contraceptives was the 
physician (43% in 2001 vs. 63% in 2007) and the most common sources of information on ADRs 
were friends and relatives in 2001 (43%) and physician in 2007 (35%). In 2007, one-sixth of 
respondents reported the Internet to be an important source of information on benefits (16%) 
and ADRs (17%) of hormonal contraceptives. 
Tiihonen et al. 
2011201 
Finland 
 
 
2009 Experiences, perceptions 
and information sources 
among women using 
hormone therapy 
Hormone therapy 
users, n=281 
Female 100% 
59 years (mean) 
Community 
pharmacies 
owned by the 
University 
National 
cross-
sectional 
survey 
Women reported the physician (91%) as their most common source of information on the 
benefits of hormone therapy, whereas the media (54%) was the most common information 
source on ADRs of hormone therapy. A relatively small number of respondents reported the 
Internet or pharmacy as an important source of information on the benefits (12% vs. 6%) and 
ADRs (14% vs. 7%) of hormone therapy. 
Hämeen-Anttila  
et al.  
2013189 
Multinationala 
 
 
 
2011–
2012 
Needs of MI and MI 
sources for pregnant 
women in various 
countries 
Pregnant women 
(n=5090) and 
women with 
children less than 
25 weeks 
(n=2002), n=7092 
Female 100% 
20-38 years 
Countries from 
Eastern Europe 
(n=5), Western 
Europe (n=6), 
Northern Europe 
(n=4), Americas 
(n=3) and 
Australia 
Online 
cross-
sectional 
survey 
The most commonly used information sources for women were physicians (73%), the Internet 
(60%), pharmacists (46%) and nurses or midwives (33%) when all participating countries were 
considered. Respondents used three information sources on average. There were differences in 
the information sources used in different countries. 
Hämeen-Anttila  
et al.  
2014115 
Multinationala 
 
 
 
 
2011–
2012 
Use of MI sources, 
consequences of 
conflicting information 
and factors associated 
with these objectives 
among pregnant women 
Pregnant women 
(n=5090) and 
women with 
children less than 
25 weeks 
(n=2002), n=7092 
Female 100% 
20-38 years 
Countries from 
Eastern Europe 
(n=5), Western 
Europe (n=6), 
Northern Europe 
(n=4), Americas 
(n=3) and 
Australia 
Online 
cross-
sectional 
survey 
Most of the pregnant women (84%) reported using more than one source (mean 3 sources) for 
seeking information on medicines use during pregnancy. Over one-fifth (23%) of the 
respondents using multiple MI sources stated that information received was conflicting, leading 
to the decision not to use medicines during pregnancy (44%), chose to rely on one MI source 
and ignore the conflicting one (33%), sought a new information source (30%), became anxious 
(25%) and did nothing (3%). 
 
STUDIES ON THE USE OF MEDICINES INFORMATION SOURCES AMONG HETEROGENEOUS MEDICINE USER GROUPS (n=10) 
 
Newby et al.  
2001191 
Australia 
– Medicines use, MI-
seeking behaviour, 
satisfaction and 
understanding of the 
information received, and 
barriers and facilitators of 
information-seeking 
Medicine users 
and people who 
care for someone 
who uses a 
medicine, n=786 
Female 56% 
18 years or older 
Households in the 
Hunter region in 
New South Wales 
Individual 
telephone 
interview 
and 
follow-up 
in-depth 
interview 
Physicians (46%) and pharmacists (23%) were the most common sources of MI. Most 
participants had received information from one source. A total of 93% were satisfied with the 
information they had received. However, 42% did not seek information and did not want to 
seek information about their medicines. There were many reasons why people do not seek MI, 
such as limited access to information sources or lack of awareness of other sources apart from 
HCPs. 
 
 
 
 
  
Authors 
Publication yearRef. 
Country 
Study 
year 
Aspects studied Study population Setting Method Key findings related to the use of MI sources 
Närhi  
2007193 
Finland 
2005 Medicine users’ source of 
MI and the perceived 
reliability of these 
sources 
Prescription and 
non-prescription 
medicine users, 
n=704 
Female 55% 
15-74 years 
Nationwide Individual 
telephone 
interview 
Respondents reported PLs (74%), physicians (68%) and pharmacists (60%) as their most 
common sources of MI, and these sources were considered to be the most reliable sources in 
every age group. One-fifth (20%) of the respondents reported using the Internet as a source of 
MI. Half of the respondents (49%) mentioned two to four sources of MI. 
Närhi et al.  
2007195 
Finland 
2005 Sources of MI among 
adult medicine users 
Medicine users, 
n=2348 
Female 61% 
15-64 years 
Nationwide National 
cross-
sectional 
survey 
Physicians (61%), pharmacists (49%) and PLs (44%) were the most common sources of MI. Of 
the respondents, 9% reported that they had used the Internet as a source of MI. Women 
reported more sources and they seemed to use more written and non-professional sources 
than men. Older people seemed to use HCPs as their source, while younger people preferred 
the Internet. 
Tio et al.  
2007202 
Australia 
2004 Mi sources used by 
patients 
Medicine users, 
n=110 
Female 66% 
42-67 years 
Community 
pharmacies (n=3) 
in Brisbane 
Individual 
interview 
The most frequent MI sources cited by the patients were physicians (83%), written information 
(82%) and pharmacists (78%). The physician was identified as the predominant source of 
information for prescription medicines (37%), the pharmacist for non-prescription medicines 
(32%) and written information obtained from the supermarket (26%). 
Carter et al.  
2013185 
Australia 
2008–
2009 
Patients’ MI seeking 
behaviour and developing 
a scale for measuring MI-
seeking behaviour 
Patient using 
multiple 
medicines, n=910 
Female 50% 
≥18 years 
Community 
pharmacies and 
medication 
management 
services around 
Australia 
National 
cross-
sectional 
survey 
Patients primarily sought MI from physicians, pharmacists and PLs. A new MI seeking behaviour 
(MISB) scale was developed which provide a useful tool for both practice and research. 
Information-seeking was the most intense among respondents who had recent changes in their 
medicine regimen and worries about their medicines. 
Krska et al.  
2013190 
UK 
– Hospital patients’ use of 
PLs or other MI sources 
about ADRs 
Hospital patients, 
n=1218 
Female 51% 
18 years or older 
National Health 
Service hospitals 
(n=6) in North 
West England 
Local 
cross-
sectional 
survey 
Less than half of the respondents (42%) usually read PLs and 19% never read PLs. Over half 
(56%) of the patients never sought more information about possible ADRs of their medicines. 
Patients searched additional information from HCPs (51%) and from the Internet (29%). 
Hamrosi et al.  
201230 
Australia 
2008 Medicine users’ opinions 
on their WMI needs and 
barriers and facilitators to 
provision and use of WMI 
Prescription 
medicine users, 
n=62, Female 61% 
18 years or older 
Residents of New 
South Wales 
Focus 
groups 
Less than half of medicine users had received WMI. Many wanted WMI to supplement the 
verbal MI they received but not to replace it. WMI was used to facilitate informed decision, 
ascertain medicine suitability and review intructions. PLs were considered technical and too 
long. 
Hamrosi et al. 
2014187 
Australia 
2009 Medicine users’ 
preferences for MI 
provision and barriers 
and facilitators to the 
utilisation of MI 
Prescription 
medicine users, 
n=1000 
Female 52% 
18 years or older 
Nationwide Cross-
sectional 
telephone 
survey 
PLs (68%) and computer-generated information from physician or pharmacist (54%) were the 
most preferred MI sources among medicine users. Almost half (44%) of medicine users wanted 
spoken MI from their physician of pharmacists, and only a small percentage (13%) seek MI from 
the Internet. 
Hamrosi et al. 
2014188 
Australia 
2009 Medicine users’ 
awareness and use of 
WMI for prescription 
medicines 
Medicine users, 
n=226 
Female 52% 
18 years or older 
Nationwide Cross-
sectional 
telephone 
survey 
Community pharmacists (88%), PLs (86%) and physicians (70%) were the main MI sources 
reported by medicine users. Most consumers (69%) reported receiving MI for their prescription 
medicines. Half (47%) of medicine users received MI every time they received a new medicine. 
Hämeen-Anttila 
et al.  
201887 
Finland 
2014 Internet as a source of MI 
compared to other 
sources of MI 
Prescription and 
non-prescription 
medicine users, 
n=2489 
Female 85% 
Nationwide Online 
cross-
sectional 
survey 
PLs (90%), pharmacists (83%) and physicians (72%) were more common MI sources than the 
Internet (68%). Internet use for MI was associated with female gender, age < 65 years, higher 
education, daily use of the Internet and continuous use of vitamins or herbals. 
  
 
STUDIES ON THE USE OF MEDICINES INFORMATION SOURCES AMONG MEDICINE USERS WITH A CHRONIC DISEASE (n=6) 
 
Authors 
Publication yearRef. 
Country 
Study 
year 
Aspects studied Study population Setting Method Key findings related to the use of MI sources 
Chen et al.  
2001186 
Canada 
2000 MI sources among cancer 
patients and physicians 
Cancer patients, 
n=191 
Female 64% 
17-77 years 
Cancer care 
hospital (n=1) in 
Toronto 
Local 
cross-
sectional 
survey 
Physicians were the primary MI source for the majority (83%) of cancer patients. Only 7% of 
patients reported having sought MI on the Internet in 2000. 
Raynor et al.  
2004197 
UK 
– Patients’ perspectives on 
MI and views on the PLs  
Asthmatics, n=23 
Female 52% 
13-82 years 
Community 
pharmacies (n=6) 
in Leeds, North of 
England 
Focus 
groups 
HCPs in primary care were the main information source for asthmatics. Information on 
interactions primarily came from community pharmacists. Individualised information was 
valued. PLs were perceived as being less helpful than face-to-face advice. 
Carpenter et al. 
2011184 
USA 
– Vasculitis patients’ most 
commonly used MI 
sources and perceived 
credibility of information 
sources 
Vasculitis 
patients, n=232 
Female 69% 
21-82 years 
Patients were 
recruited through 
multiple sources, 
such as patient 
conferences and 
disease-specific 
collaborative 
networks 
Online 
cross-
sectional 
survey 
Physicians were the most frequently used MI sources for both men and women. Women 
received MI from the Internet and PLs more often than men, whereas men receive MI from 
spouse, partner or nurse more often. Physicians, the Internet, pharmacists and other vasculitis 
patients were perceived as the most credible sources of MI for both genders. 
Pohjanoksa-Mäntylä 
et al.  
2011196 
Finland 
2005 Sources of MI used by 
people with and without 
mental disorders 
People with 
mental disorders 
(n=228) and 
without mental 
disorders 
(n=2120), n=2348 
Female 61% 
15-64 years 
Nationwide National 
cross-
sectional 
survey 
Physicians (83% of the people with mental disorders vs. 59% of the people without mental 
disorders), pharmacists (56% vs. 49%) and PLs (53% vs. 43%) were the most common MI 
sources. People with mental disorders sought more frequent MI from the Internet than people 
without mental disorders (15% vs. 8%). The most commonly respondents used two to four MI 
sources. 
Zukoski et al.  
2011204 
USA 
2005–
2006 
Primary information 
sources, types of 
information sought and 
barriers to accessing 
information 
People living with 
HIV/AIDS, n=16 
Female 44% 
18 years or older 
Rural three-
county area in 
Oregon 
Individual 
interview 
Two-thirds of participants reported their local HIV/AIDS physician as their primary source of MI. 
The second primary source of MI was the Internet. A community-based organisation who 
contacted patients individually and health department caseworker were also reported as 
essential MI sources. Patients reported barriers to seeking MI, such as fear, stigma, concern 
about disclosure and feelings of futility and anger. 
Bults et al.  
2012183 
Netherlands 
2011 Patients’ information-
seeking about Q fever 
vaccination  
Patients with 
specific 
cardiovascular 
diseases, n=413 
Female 39% 
70% older than  
60 years 
Municipal public 
health service 
(n=1) in the south 
of the 
Netherlands 
Individual 
interview 
The most frequently reported sources for information about Q fever vaccination were general 
physicians (60%), family (32%), specialists (13%) and friends (13%). Of the respondents, 30% 
had actively sought information about Q fever vaccination. Respondents aged 60 years or 
younger (39%), those with a higher educational level (42%), and those employed (41%) more 
often sought information. 
aRespondents from Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, the Netherlands, Norway, Poland, Russia, Serbia, Slovenia, South America, Switzerland, UK and USA. 
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2.3.3 KEY FINDINGS OF THE STUDIES 
 
MI sources for medicine users have diversified in the last few decades (Table 
9).30,87,115,181-204 Medicine users increasingly seek MI from multiple sources, 
and they receive MI from more than one information source, such as HCPs 
(e.g., physicians, pharmacists, nurses), traditional media (e.g., television, 
radio, newspapers), the Internet, specific patient-directed information 
sources (e.g., PLs, telephone services), and personal contacts (e.g., family, 
friends, peers).  
 
MEDICINES USERS’ MOTIVES FOR SEARCHING MEDICINES INFORMATION 
 
Medicine users search information about their medicines for multiple reasons 
(Table 9).30,182,191 Usually, people seek information to obtain advice when 
changing medicine or confirming information from other sources. 
Information is also needed for reviewing instructions of HCPs, assisting in 
informed decision making and clarifying questions not raised during 
prescribing or dispensing. People tend to choose information sources which 
they perceive as the most reliable and appropriate for their purposes. Patients’ 
trust in physicians and pharmacists is the main reason for asking advice from 
them. Additionally, they choose their information source based on their 
perceptions of the severity or importance of their health condition. Medicine 
users aged 60 years or younger, those with a higher educational level and with 
a job and those with recent changes to their medication or worries about their 
medicines commonly seek MI more often than other people.183,185 
Sometimes medicine users do not consider it necessary to seek more 
information about their medicines.30,191 They might not have encountered any 
problems with their medicines or they believe that they are generally healthy. 
They may also trust their HCPs (e.g., pharmacist or physician) so that they 
have no need for a second opinion or complementing information on what 
their HCP has told them earlier about their medications. 
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USE OF MEDICINES INFORMATION SOURCES AMONG SPECIFIC MEDICINE 
USER GROUPS 
 
Studies focused on the use of MI sources among women on hormone 
replacement therapy or using oral contraceptives state that the majority of 
them primarily receive information from their physician when considering to 
start or stop using the hormone replacement therapy (Table 9).199-201,203 The 
physician is also the most common source when asking in regard to the 
benefits of systemic hormone replacement therapy, whereas the media and 
physician are commonly used information sources for ADRs.199 Only a small 
percentage (3–6%) of hormone replacement therapy users consider a 
pharmacist as an important source of information on hormone replacement 
therapy. Similar findings have been obtained in women on hormonal 
contraceptives.200 The physician is the most common information source 
concerning the benefits of hormonal contraceptives, and physician, friends 
and relatives are the most common information sources relating to the risks 
of hormonal contraceptives. Only a small percentage (2–3%) of the hormonal 
contraceptive users consider pharmacy as the most important information 
source to receive information about the benefits of hormonal contraceptives.  
Similar findings have been observed in studies with other medicine user 
groups.115,181,189,192,194,198 People using antidepressants or psychotropics 
primarily receive information about their medication from the physician, 
psychiatrist or pharmacist.181,198 Moreover, almost one-fifth (19%) of 
antidepressant users seek MI from the Internet.198 The most common MI 
sources for patients using prescription or non-prescription analgesics are 
HCPs such as physicians and pharmacists, and PLs.192,194 People commonly 
receive information about their blood pressure medicines from the Internet, 
pharmacists and different type of written leaflets and brochures.181 According 
to the multinational studies, a majority of pregnant women are most likely to 
receive information about their medicines from physicians, the Internet and 
pharmacists.115,189 
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USE OF MEDICINES INFORMATION SOURCES AMONG HETEROGENEOUS 
MEDICINE USER GROUPS 
 
Generally, consistent findings from the studies involving heterogeneous 
medicine user groups are that physicians, community pharmacists and PLs 
are the most common MI sources regardless of the research method, the study 
year, the research population or the country in which the research has been 
conducted (Table 9).30,87,185,187,188,190,191,193,195,202 However, the use of 
information sources varies between prescription and non-prescription 
medicine users.188,191,202 Physicians, pharmacists and PLs are the main 
information sources of prescription medicines, and, respectively, pharmacists 
are information sources from which medicine users receive information about 
non-prescription medicines.  
Despite the fact that most medicine users want information about the 
medicines they use, only about half (47%) reported receiving MI every time 
they received a new medicine, and less than half (40%) received MI when 
collecting a repeat prescription for a regular medicine.188 Although the PLs are 
among the most commonly used MI sources, not all medicine users will read 
them.190 For example, 42% of the hospital patients reported that they usually 
read PLs for medicines prescribed, whereas almost one-fifth (19%) of the 
patients reported that they never read the PLs. 
 
USE OF MEDICINE INFORMATION SOURCES AMONG MEDICINE USERS  
WITH A CHRONIC DISEASE 
 
The use of MI sources has been diversely studied among medicine users 
having a chronic disease, such as asthma,197 cancer,186 cardiovascular 
diseases,183 HIV,204 mental disorders196 or vasculitis (Table 9).184 People with 
asthma actively seek MI from a variety of sources, commonly from HCPs in 
primary care along with practice and clinic nurses.197 Pharmacists are the 
primary source of medicine interactions among asthmatics. They value 
individualised information and PLs are generally seen as less helpful than 
face-to-face counselling which could be tailored to the patient needs and 
abilities.  
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The majority (83%) of cancer patients receive MI from their 
physician.186 Seeking MI from the Internet is rare (7%) among cancer patients. 
Physicians (60%) and family members (32%) are the most frequently reported 
sources for advice regarding Q fever vaccination among patients with 
cardiovascular disease.183 Among patients living with HIV reported their 
physician, the Internet and specific people from a community-based 
organisation as their most common sources of MI.204 People with a mental 
disorder use their physician (83%), pharmacist (56%) and PLs (53%) as their 
primary MI source.196 The Internet was used as a source of information by 15% 
of people with a mental disorder. Vasculitis patients receive MI most 
frequently from physician and the Internet which they also consider as the 
most reliable information sources.184 
 
NUMBER OF INFORMATION SOURCES USED BY MEDICINE USERS 
 
The number of MI sources used by medicine users has increased slightly since 
the beginning of 2000s, when information was usually obtained from a single 
source (Table 9).191 Nowadays medicine users usually receive or seek MI from 
two to four information sources regardless of age.115,189,193,196,198 Medicine users 
who use the Internet as a source of information seek information on average 
from three different websites.87 
 
THE INTERNET AS A SOURCE OF MEDICINE INFORMATION 
 
The use of the Internet as a source of MI varied depending on the study 
population, the study method used and the study country (Table 
9).87,186,187,190,193,195,196,198,202,203 Based on the cross-sectional questionnaires and 
interviews, 8-29% of medicine users seek MI from the Internet,186,187,190,193,195, 
196,198,202,203 whereas, according to an online survey in Finland, 68% of 
respondents reported having used the Internet when searching for MI.87 
However, many patients are concerned about the quantity of information on 
the Internet or do not know how to assess the quality and reliability of 
information obtained from the Internet.30,202,203  
The Internet use as an MI source is associated with female gender, age 
less than 65 years, polytechnics, college or university degree, and daily use of 
the Internet.87 Patients commonly search for MI from health portals (56%), 
search engines (43%) and pharmacy websites (41%). Some patient groups use 
certain websites more often than other patient groups for searching MI, such 
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as people with mental disorders. In doing so, they use pharmacy websites 
(50%) and discussion forums (32%), and patients with thyroid diseases use 
commercial health portals (42%) and discussion forums (26%). Some 
patients, such as asthmatics, do not see the Internet as particularly useful.197 
They consider that MI found from the Internet is ambiguous or unreliable, or 
the Internet offers too much information. 
 
BARRIERS TO RECEIVING MEDICINES INFORMATION 
 
Patients may encounter barriers when receiving or seeking information on 
their medicines (Table 9).30,186,191,204 Such barriers may be due to the patients 
themselves (e.g., lack of confidence or necessary communication skills, 
difficulty in understanding the information provided, lack of positive HCP-
patient relationship or a feeling of powerless within this relationship, lack of 
awareness of other information sources than HCPs), HCPs (e.g., providing 
insufficient information, lack of time or interest to provide information) or 
other reasons (e.g., limited access to HCPs). Moreover, patient’s educational 
limitations, language barriers and lack of literacy may influence to desireness 
to seek or receipt WMI.30 Specific barriers for HIV positive patients are the 
impediments of seeking information such as stigma, fear, embarrassment and 
frustration. 
 
SATISFACTION WITH AND RELIABILITY OF THE INFORMATION RECEIVED 
 
Half of the medicine users (48%) are satisfied with MI they received in general 
(Table 9).191 However, not all medicine users consider that they receive enough 
information about their medicines from HCPs, such as 47% of cancer patients 
have reported.186 Hormone replacement therapy users consider the receipt of 
information about their medicines from their physician is very (57%) or 
somewhat (31%) useful.203 Moreover, while many medicine users want WMI, 
many of those have reported that WMI should be more patient-centred, less 
ambiguous and easier to undertand.30 
Medicine users consider physicians (31–99%), pharmacists (36–99%) 
and PLs (40–98%) as the most reliable information sources in all age 
groups.193,202 Medicine users under 50 years (45%) rely more on MI found 
from the Internet than older (≥ 50 years) medicine users (24%).193 Both men 
and women rate their family members as the least credible source.184 
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2.3.4 FACTORS AFFECTING MEDICINES INFORMATION SEEKING 
BEHAVIOUR 
 
 
Studies showed multiple factors affecting MI-seeking behaviour (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Factors affecting medicines information-seeking behaviour. 
 
Women seek information more often and use more information sources 
than men to obtain information about medicines they use.183,194 Men typically 
receive MI from their physicians more often than women, and women receive 
MI from other sources (e.g., pharmacists, PLs, the Internet, newspapers and 
books).87,184,194-196 
Young people are more likely to seek MI from the Internet than older 
age groups.87,193,195,196,198 In contrast, older people are likely to use HCPs, 
especially physicians, as their MI source, and they rely on interpersonal 
contact with HCPs more than younger people for receiving MI.185,193,195,196 
Young people are more likely to obtain information about prescription 
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medicines from nurses, relatives and friends than older counterparts.200 
However, younger people (≤30 years) commonly receive information about 
adverse reactions of hormonal contraceptives from a physician, friends and 
relatives, while older people find the media as the most important information 
source for that.200 
People with a higher level of education (university or higher degree) are 
more likely to search MI, especially from the Internet, compared to people 
with a lower level of education.87,183,196 Respectively, less educated (≤9 years) 
people are more likely to receive information from nurses, family members or 
friends than higher educated people.87,196,198 
Morbidity and medicines use also affect the receipt of MI. The more 
diseases people have, the more they use different information sources to 
receive MI.196 Diabetics and people with mental or thyroid diseases more 
commonly receive advice and counselling from nurses compared to other 
information sources.87 Respectively, people with cardiovascular disease or 
musculoskeletal system disease use PLs more than other sources to receive 
MI. Patients with three or more prescription or non-prescription medicines in 
use receive MI more from HCPs than those using less medicines. 
The receipt of MI and use of different information sources may vary 
between countries. Pregnant women in Northern Europe (66%) received less 
information from their physician than pregnant women living in other 
countries (on average 78%).189 On the other hand, pregnant women in 
Northern Europe (50%) and Australia (49%) preferably use midwives and 
nurses for information, whereas their counterparts in North America (27%) 
and in Eastern Europe (14%) contact these HCPs much less frequently. The 
pharmacist as a MI source is rarely used in South America (23%) compared to 
other countries (50% on average). Eastern Europeans (75%), especially 
Russians (90%), use the Internet as a source of MI. 
 
2.3.5 QUALITY OF THE STUDIES AND LIMITATIONS 
 
To provide a comprehensive picture of the use of MI sources among adult 
medicine users, all the studies that met the inclusion criteria were included in 
the review. The quality of the studies in the review described above was not 
systemically assessed. Studies were carried out fairly evenly over the study 
period of 2000–2018. Size of the study population varied greatly between 
studies and in accordance with study methods. One-third of the studies 
examined heterogeneous medicine user groups and it was not possible to 
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identify what medicines the patients were using. Therefore, the findings of 
these studies could not be compared to the studies involving patients taking 
certain medicines or patients with specific chronic diseases. 
Research was conducted in various settings. Variation in study settings 
may affect the study results, for example patients recruited from the hospitals 
may use different information sources than those recruited from the 
community pharmacies. Some of the studies were performed locally and some 
were at a national level. Almost half of the studies were from different 
European countries. Furthermore, the review included only the studies 
carried out in developed countries.180 These aspects should be taken into 
account in generalising the results as MI practices vary between the countries 
and continents, such as use and accessibility of the WMI and Internet. 
Multiple research methods had been used, but almost all had applied a single 
cross-sectional study design. Only one study compared the results from 2 
years covering a 7-year period.200 There is a need for studies with long-term 
population-based trend analysis on the use of MI sources among medicine 
users as none of these studies applied a longitudinal study design.
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3 AIMS OF THE STUDY 
The objective of this study was to examine medicines information (MI) 
practices and policies in Finland during the 2000s. The ultimate goal was to 
collect and provide information to assist in strategic development of MI 
(Studies I and II) and to evaluate the implementation of the national MI 
strategy (Study III) in Finland. Sub-studies (I–III) and their linkage to the 
strategic development of MI in Finland is presented in Figure 13. 
 
The specific objectives of the study were: 
 
1) To identify focus areas and gaps in MI research in Finland during the 
2000s in order to develop and steer MI research and practices in the 
future ( (I) 
 
2) To examine long-term trends in the receipt of MI among Finnish 
adult medicine users in order to be addressed when developing MI 
practices and sources to consumers (II) 
 
3) To investigate well-implemented actions and actions needing 
development in the medication use process for patients with chronic 
diseases to evaluate the implementation of the national MI strategy 
three years after its launch in 2015 (III) 
 
These objectives were addressed in three independent studies of the thesis, 
resulting in three international peer reviewed scientific publications (I–III)
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Figure 13. Studies (I–III) and their linkage to the national medicines information (MI) 
strategy in Finland. 
First Finnish MI strategy was published in 201222 
 
• In 2012, the National MI Network was established to support  
the implementation of the national MI strategy.  
• The National MI Network coordinates MI research activities and 
compiles the strategy for MI research nationally 
 A need for gathering information on previous studies on MI 
carried out in Finland and the development needs of MI practices. 
First national MI research strategy was published in 2014 
• The first period of the national MI strategy (2012–2014) ended  
at the end of 2014. 
• A mid-term evaluation of the strategy progress was needed. 
• One of the strategic goals is to improve the quality and  
availability of MI to patients. 
• Information is needed on the long-term trends in the receipt of  
MI among the adult population. 
 
STUDY I 
A systematic literature 
review on MI research 
conducted in Finland 
in the 2000s 
 
 
 
STUDY II 
A repeated cross-sectional 
survey (1999–2014) on the 
receipt of MI among the 
Finnish adults 
 
STUDY III 
An evaluation study 
conducted by interviewing 
the members of the National 
MI Network in spring 2015  
 
 KEY BACKGROUND FACTORS IN THE DEVELOPMENT OF  
THE FINNISH MEDICINES INFORMATION STRATEGY BY 2020 
 
ACTIONS IN THE EUROPEAN UNION 
 
 
 
 
 
 
 
 
 
ACTIONS IN FINLAND 
 
 
 
 
 
 
 
 
A need for a national MI strategy 
2002: High Level Group on Innovation 
and Provision of Medicines (G10 Medicines 
Group) published recommendations to 
improve the quality and access of MI  to 
patients24 
2008: European High Level 
Pharmaceutical Forum published 
recommendations for the national MI 
practices and coordination25 
2006: Ministry of Social Affairs and 
Health published strategic guidelines  
for social and health policy by 2015158 
 
2011: Ministry of Social Affairs and 
Health published alignments  
for medicines policy by 20203 
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4 MATERIALS AND METHODS 
This study applied both quantitative and qualitative research methods. The 
study utilised the methods commonly used in social sciences and policy 
research. Each sub-study (I–III) is based on its own data (Table 10). 
 
Table 10. Materials and methods used in the Studies I-III. 
 
 
4.1 MEDICINES INFORMATION RESEARCH IN FINLAND (I) 
 
4.1.1 DESIGN AND SETTING (I) 
 
A systematic literature review was conducted in order to understand the 
medicines information (MI) practices in Finland in the 2000s that could be 
utilised as a basis for implementing the national MI strategy and targeting 
actions of the National Medicines Information Network (MI Network). The 
ultimate aim was to identify research topics and gaps related to MI. The 
Finnish Medicines Agency Fimea carried out a comprehensive inventory of 
STUDY STUDY AIMS METHODS DATA SOURCE ANALYSIS 
I 
To identify focus areas and 
gaps in MI research in 
Finland 
Systematic 
literature 
review 
Original peer-reviewed studies 
(n=126) related to MI research  
in Finland, published between  
1 January 2000 and 30 June 2016 
Qualitative 
content analysis 
II 
To examine long-term 
trends in the receipt of MI 
among Finnish adults 
Repeated  
cross-
sectional 
postal 
population 
survey 
Responses from Finnish adult 
medicine users (n=18862) to  
the postal survey ‘Health Behaviour 
and Health among the Finnish Adult 
Population’ by the National 
Institute for Health and Welfare, 
covering responses from years 
1999, 2002, 2005, 2008–2014 
Quantitative 
analysis: 
descriptive 
statistics and 
logistic 
regression 
III 
To investigate how the 
ultimate goal of the 
national MI strategy on a 
well-informed patient with 
a long-term medication 
has been achieved 
Qualitative 
interviews 
Members of the National 
Medicines Information Network 
(n=79) after the first operational 
period of the national medicines 
information strategy (2012–2014) 
in 2015 
Qualitative 
content analysis 
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existing MI research in 2013.171 In this study, the review was updated to cover 
research up to June 30, 2016, and the included articles were qualitatively 
analysed. 
 
4.1.2 DATA COLLECTION AND EXTRACTION (I) 
 
Predetermined inclusion and exclusion criteria were used for the data 
collection and extraction (Study I: Table 1). Original peer-reviewed studies 
related to MI research in Finland and published in English or in Finnish 
between January 1, 2000 and June 30, 2016 were included in the review. The 
study material was collected from two international databases, Medline and 
Scopus, and from a Finnish database, Medic, using keyword screening criteria 
with the assistance of information specialists (Figure 14, Study I: Figure 1). 
The search was supplemented by articles found in the reference lists of the 
included studies. To identify relevant articles and research lines, MI experts 
and researchers were consulted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. A PRISMA flow diagram of the study selection process. (I) 
 
 
Search results: 1554 citations 
(Medic n=284, Medline n=766, Scopus n=504) 
Excluded by title or abstract: 1324 citations 
 
Full-text assessment for eligibility: 230 articles 
 
Excluded articles after reading full-text: 
 114 review articles or did not meet the inclusion criteria 
 40 duplicates 
 
Final inclusion: 126 articles 
 
Manually added articles: 
 44 articles found from reference lists or recommended 
by experts 
 6 monograph dissertations (not indexed in databases) 
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The preliminary selection of the articles was carried out by Fimea’s 
research group that prepaired an inventory on MI research conducted in 
Finland during 2000–2013.171 The literature search and the selection of the 
articles was repeated in 2016 and extended to cover the time period until June 
30, 2016. At least two authors independently reviewed full-text articles for 
inclusion and exclusion. Disagreements were resolved through discussion and 
consensus with the third researcher or within the study group. The Cochrane 
Handbook for Systematic Reviews and the PRISMA Guidelines was followed 
in conducting the review and reporting findings when appropriate.205,206 A 
detailed description of the inclusion and exclusion criteria, the key search 
terms and an example of the search strategy is provided in Original 
publication I (Study I: Figure 1, Table 1 and Appendix A). 
 
4.1.3 QUALITATIVE CONTENT ANALYSIS (I) 
 
Included studies were content analysed according to MI practices identified, 
trends over time in research methodology and theory. First, studies were 
classified and then content analysed according to the main objectives of the 
national MI strategy.22 Following this, the sub-themes were inductively 
formulated to reflect the objectives of the included studies. Studies may have 
focused on more than one aspect, and therefore, some of the studies were 
categorised under several main themes and sub-themes. 
After categorising the studies, they were summarised using an 
extraction table addressing the aims of the review (Study I: Appendix B). 
Characteristics extracted included year of publication, aspects studied, 
research method, study participants or subjects and key findings. Data were 
extracted by two authors and approved by the other research group members. 
4.2 TRENDS IN THE RECEIPT OF MEDICINES INFORMATION 
AMONG THE ADULT POPULATION (II) 
4.2.1 DESIGN AND SETTING (II) 
 
The study was performed as an indicator to identify long-term trends and 
potential gaps in the receipt of MI among the adult Finnish population that 
should be addressed when improving MI practices during the strategic 
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development of MI nationally. In particular, the study focused on the use of 
the Internet as a source of MI during the study period. 
The data were derived from the annual national health behaviour survey 
Health Behaviour and Health among the Finnish Adult Population 
conducted between 1978 and 2014 by the National Institute for Health and 
Welfare (formerly the National Public Health Institute).207 This national 
survey has its origins in the North Karelia Project, started in 1972.208 The 
project aimed to comprise etiology and factors related to the high prevalence 
of cardiovascular diseases in Finland, and regional differences in the 
prevalence and associated mortality. This survey was established to perform 
as an indicator for changes in population health and related risk factors, such 
as smoking, food and alcohol consumption and physical activity. It has been 
repeated every year in identical form to yield comparable results. The survey 
instrument included a standard set of structured questions supplemented by 
other questions over the years. One of the added questions was the one used 
in this study concerning the receipt of MI from different sources available for 
the public and medicine users in Finland. The question related to MI was 
added to the survey instrument in 1999.209 
 
4.2.2 SURVEY INSTRUMENT AND DATA COLLECTION (II) 
 
The survey used in this study was conducted as a repeated cross-sectional 
postal survey using each year a new nationally representative sample 
(n=5000) of the Finnish working age population of 15–64 years old.207 The 
sample has been derived from the Population Register Centre of Finland 
which is a government-based register where all Finnish citizens and 
permanent residents are required to be registered.207,210 Three reminders were 
sent each year to maintain a response rate high enough for generalisable 
results.211 Data from the years 1999, 2002, 2005, 2008–2014 were compared 
as these are the years when the survey included the question on the receipt of 
MI. 
Receipt of MI on medicines in use was the main outcome measure used 
(Figure 15). The question was followed by a list of MI sources available for 
consumers in Finland at the time of the study. Respondents could indicate 
from the list as many information sources as applicable. It was not possible to 
report other sources than those listed in the survey. 
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Figure 15. The question concerning the receipt of medicines information from various 
sources included in the “Health Behaviour and Health among the Finnish Adult Population” 
survey.207 
 
Socio-demographic variables used in this study were gender, age and 
education. Health-related variables used were respondents’ medicine use and 
diagnosed diseases. Medicine use was assessed by the question presented in 
Figure 16. This question was followed by a list of commonly used prescription 
and non-prescription medicines for common chronic and acute diseases. 
Respondents could indicate from the list as many medicines as they had been 
using within 7 days prior to the survey without the possibility to report any 
other medicines than those mentioned in the list. The medicines use within 
the past 7 days was used as a measure in order to control recall bias.212 
 
 
 
 
 
 
 
 
 
 
                 
 
 
Figure 16. The question concerning medicine use in the “Health Behaviour and Health 
among the Finnish Adult Population” survey.207 
 
In the past year (12 months), have you received information on the medicines you have used? 
 
1) No 
2) Yes, where? 
Yes                                                                                 Yes 
from a physician…………………………….. 1 from relatives, friends…………….………… 1 
from a community pharmacy…………. 1 from the Internet………………….………….. 1 
from a package leafleta………………….. 1 from advertisements……………………..... 1 
from a public health nurse,  from radio, TV…………………….……………. 1 
a registered nurse…………..………….. 1 from health food stores…………………… 1 
  from telephone services…………………… 1 
  
aAdded to the survey in 2002. 
 
Have you used any tablets, powders or other medicines within the past week (7 days)? 
         Yes                             Yes 
blood pressure medication………………..... 1 antidepressantsb……………………………..… 1 
cholesterol medication………………….…….. 1 preparations containing vitamin Dc…… 1 
insulina………………………………………………... 1 other vitamin preparationsc……………… 1 
diabetes medicationa…………………………... 1 cough medication………………………..…... 1 
painkillers for headache………………………. 1 cholesterol medication…………………..… 1 
other painkillers…………………………………… 1 hormone replacement therapy 
contraceptives (oral)………………………….… 1  for women…………………………………….. 1 
sedatives……………………………………………… 1  medication for erectile dysfunction..... 1 
sleeping pills………………………………………… 1 
 
aAdded to the survey in 2005,aAdded to the survey in 2002, bAdded to the survey in 2005, cVitamin and mineral 
preparations were specified for vitamin D preparations and other vitamins in 2011. 
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Diagnosed diseases were determined by the question presented in 
Figure 17. This question was followed by a list of chronic and acute diseases 
common in Finland. Respondents could indicate from the list as many 
diseases as they had been suffering from within the year prior to the survey 
without the possibility to report any diseases other than those mentioned in 
the list. 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
Figure 17. The question about diagnosed diseases in the “Health Behaviour and Health 
among the Finnish Adult Population”survey.207 
 
4.2.3 QUANTITATIVE ANALYSIS (II) 
 
Statistical analyses were performed using the Statistical Package for Social 
Sciences software (IBM SPSS Statistics for Windows, Released 2016, Version 
24.0. Armonk, NY: IBM Corp.). Respondents who reported using at least one 
medicine during the 7-day time-frame prior to the survey were included in the 
analysis as medicine users. 
Respondents were divided into predetermined groups by socio-
demographic (gender, age, education) and health-related (number of 
medicines in use, number of diagnosed diseases) variables (Study II: Table 1). 
Trends in the receipt of MI from different information sources and the number 
of MI sources used by the respondent were counted for each study year of 
1999, 2002, 2005, 2008–2014. The significance of the change in the receipt 
of MI between the study years was analysed with logistic regression (Study II: 
Table 2). Analyses were adjusted for potential confounding factors (i.e., age, 
gender, education, number of medicines in use and number of diagnosed 
 
Have you had any of the following diagnosed diseases or diseases treated by the physician  
within the past year (12 months)?   
         Yes                                                            Yes 
high blood pressure, hypertension……….. 1 digestive illness  
diabetes………………………………………….……. 1 (gastritis catarrh, gastritis, ulcer)……. 1 
coronary disease, angina pectoris  high blood cholesterola…………………..…  1 
 (=chest pain during exercise)………….…. 1 cancerb……………………………………………… 1 
rheumatoid arthritis…………………………….. 1 depressionb………………………..…….………. 1 
degenerative disk disease,  other mental health disorderb…………… 1 
 other back illness………..…………………….. 1 cholesterol medicationb………………….… 1 
chronic bronchitis,  hay or allergic rhinitisc…………………….… 1 
 pulmonary emphysema..…………………… 1 food allergyc……………………………………… 1 
asthma…………………………………………………. 1    
 
aAdded to the survey in 2002, bAdded to the survey in 2005, cAdded to the survey in 2008. 
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diseases). The receipt of MI from different sources was calculated by gender, 
age, number of medicines in use and number of diagnosed diseases for each 
study year. 
4.3 IMPLEMENTATION OF MEDICATION USE PROCESS            
FOR PATIENTS WITH CHRONIC DISEASES (III) 
4.3.1 DESIGN AND SETTING (III) 
 
This study was conducted as part of the evaluation of the national MI 
strategy’s implementation (Figure 10). The study investigated how the 
national MI strategy’s key goal of a well-informed patient with a long-term 
medication plan had been achieved after the first 3-year operational period 
(2012–2014). Medication use process refers to an operative chain of actions 
starting with the diagnosis and prescribing the medication followed by 
dispensing, medication counselling and medicine use and ending in 
monitoring of the effects of the medication (Figure 8, Study III: Appendix B).  
The medicine use process with the patient at the center (Figure 8) was 
chosen as a target of the national MI strategy’s evaluation. A pragmatic 
approach was applied in the evaluation in order to understand the impact of 
interactions, nonlinear relationships and multi-level influence in the medicine 
use process.213 Data were collected by semi-structured interviews. In order to 
find out a comprehensive view of study question, all members of the MI 
Network were invited to interviews (purposive sampling). Instead of aiming 
to reach data saturation, the aim was gather the views of all stakeholders in 
the MI Network. During the first operational period of the national MI 
strategy, the MI Network had 111 members representing 53 stakeholder 
organisations. An invitation to participate in the interview was sent to all 
members of the MI Network via email, and a more detailed information letter 
related to the study was sent to those who agreed to participate. The interviews 
were conducted within the period from January to June, 2015 (Figure 10). 
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4.3.2 DATA COLLECTION AND INTERVIEW GUIDE (III) 
 
In order to gather a comprehensive understanding of stakeholders' views, 
interviews were carried out as individual, pair and group interviews. 
Interviews were conducted as face-to-face, by telephone and as video 
conferencing. The form of the interview was decided upon convenience of the 
participants from each stakeholder. One moderator (the author of this thesis) 
facilitated and audiotaped all interviews with permission from the 
participants.  
A semi-structured interview guide with two main themes and eight sub-
themes (Appendix 1) was developed by the research group following the goals 
of the national MI strategy.22 The interview guide was pre-tested in two 
interviews with six participants to ensure the face and content validity of the 
interview protocol. Based on the pilot test study, no significant changes were 
made, and, therefore, the data from the pilot interviews were included in the 
study. The interviews focused on two main themes pertaining to: 1) reaching 
the goals and implementing the actions of the national MI strategy and 2) 
actions taken by the MI Network. 
This study focused on the results of the first theme, which concentrate 
on the ultimate goal of the national MI strategy of well-informed and adherent 
medicine users with chronic diseases, and how this goal had been achieved by 
the point of the interview in spring 2015 (Figure 18, Appendix 1: Question 4). 
The figure of the medication use process illustrating this ultimate goal in the 
national MI strategy was shown to the participants of the interviews to 
stimulate discussion and focus it on the core of the national MI strategy 
(Figure 8). 
 
 
 
 
 
 
 
Figure 18. The question used in the interview about the implementation of the medication 
use process aiming at well-informed and adherent medicine users with chronic diseases 
during the first operational period of the national medicines information strategy by 2015 
(Appendix 1). 
 
 
If you consider the figure of the medication use process for a patient with chronic 
disease: 
1) what are the most crucial actions that have been implemented ? 
2) what actions should be focused on in the future in order to achieve  
the goal of a well-informed, adherent patient or medicines user ? 
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4.3.3 ANALYSIS OF THE QUALITATIVE DATA (III) 
 
The interviews were analysed by applying the Framework Method.214 The 
analysis was performed using both deductive and inductive content analysis 
through seven stages (Figure 19, Study III: Figure 1). One researcher was 
responsible for the analysis (the author of this thesis), and another researcher 
verified the analysis to confirm dependability and confirmability of the 
study.215  
The figure of the existing medication use process (Figure 8)22 was used 
as a basis for an analysis matrix. To strengthen the credibility of the analysis, 
the Framework Method was chosen as a theoretical method because of its 
systematic and flexible approach.214 This method has its origins in social policy 
research where it has been used extensively since the 1980s. Currently, the 
Framework Method is an increasingly popular in the management and 
analysis of qualitative data, also in medical and health research.  
A new conceptual framework model of the medication use process was 
developed based on the existing medication use process model (Figure 8)22 
and complemented by participants’ views identified from the interviews. The 
data from different types of interviews were combined and mentions were 
counted. One researcher (author of this thesis) read the transcripts 
independently and created code categories and summaries (Figure 19). 
Another researcher verified the codings by reviewing the coded texts and 
crosschecking the coding categories created by the first researcher. Any 
discrepancies of interpretation were discussed within the research group. The 
content and structure of concepts created by content analysis were presented 
clearly and systematically with the quotations from various participants to 
indicate conformability and objectivity (Study III: Appendix C). In the 
conceptual model building, it was useful to use the breakdown of the data to 
macro, meso and micro levels.216 The profession or stakeholder group was not 
specified during the analysis, as the aim was to obtain an overall 
understanding of the implementation of medication use process rather than 
to compare views between professions or stakeholders. 
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Figure 19. Qualitative content analysis process applying the Framework Method.214 (III)
Stage 1: Transcription 
Interviews were transcribed verbatim by a company specialised in converting  
to written text qualitative research data 
Stage 4: Developing an analytical matrix 
An analytical matrix and main categories were developed deductively according  
to the existing model of medication use process (Figure 8) 
New main and sub-categories emerged inductively from the 
interviews ere added to the matrix 
Stage 5: Applying the analytical matrix 
Main and sub-categories and codes were indexed to the analytical matrix 
Stage 3: Coding 
Single words, sentences or groups of sentences related to study questions were coded  
by one researcher (the author of this thesis) 
Stage 2: Familiarisation with the data 
Each transcript was repeatedly read by one researcher (the author of this thesis)  
while listening to the audiotapes 
Stage 6: Charting data into the analytical matrix (indexing) 
Codes were classified into the main categories, and the encoded data were charted into 
a spreadsheet which had been generated from the analytical matrix 
Stage 7: Interpreting the data 
Participants’ perceptions identified from the interviews were assembled as a new 
theoretical concept of medication use process 
Encoded data were verified by another researcher, and any 
differences of interpretation were discussed within the research group  
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The results are presented in a new conceptual model illustrating well-
implemented actions and  actions needing development in the medication use 
process. The model was constructed by categorising the themes into three 
operational levels, namely the infrastructure (macro) level, HCP (meso) level 
and patient (micro) level. The conceptual framework applied to combine the 
functions of primary care with the dimensions of integrated care was utilised 
in categorising the data in these levels.216 The number of encodings for each 
theme was counted according to the mentions by each participant.  The new 
conceptual model is presented in two different ways: 1) as two separate figures 
showing well-implemented actions and actions needing development in the 
medication use process (Study III: Figures 3 and 4), and 2) as a summary 
figure based on these separate figures (Figure 24). 
 
4.4 RESEARCH ETHICS 
All study procedures were conducted according to good ethical and scientific 
practice.217  
Study I was conducted as a systematic literature review. As the study 
was based solely on published peer-reviewed original research articles and no 
primary data were collected, the ethical approval was not required.217 
Study II was based on the secondary analysis using routinely collected 
and fully anonymised survey data. Permission to use the data was obtained 
from the National Institute for Health and Welfare. Ethics approval was not 
applicable, because anonymous surveys are exempt from ethical approval in 
Finland.217 Responding to the survey was voluntary and considered as giving 
informed consent. No personal identifiable information was collected.  
Study III was performed as qualitative interviews. The study plan was 
presented and approved by the MI Network. The study was deemed to be 
exempt from requiring approval from the research ethics committee as the 
participants were informed in writing about the interview in advance and they 
volunteered to participate in the study.217 Furthermore, each interviewee was 
informed prior to the interview that the data would be used for research 
purposes and that data are anonymised in order that no interviewee can 
subsequently be identified. The interviewees were able to stop the interview at 
any time and refuse to participate in the study, but no one refused.  The 
recordings and interview notes were digitally stored and were accessible only 
to the research team. The material was anonymised after the literation in 
order to protect the identity of the participants. 
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5 RESULTS 
This chapter summarises the key findings of the Studies I–III. 
5.1 MEDICINES INFORMATION RESEARCH IN FINLAND (I) 
5.1.1 CHARACTERISTICS OF THE STUDIES (I) 
 
A systematic literature search identified 126 original studies covering a broad 
variety of approaches and themes (Table 11, Study I: Table 2). Included studies 
were categorised into 6 main themes according to the Finnish national 
medicines information (MI) strategy.22 Patient counselling in different 
settings (36% of all studies, n=45/126) was the most commonly studied main 
theme (Figure 20, Study I: Table 2). MI literacy (n=13) and MI policies and 
strategies (n=3) were the least commonly studied main themes. Furthermore, 
included studies were compiled according to 15 inductively generated sub-
themes (Table 11, Study I: Table 2). The most commonly studied sub-themes 
were patient counselling in community pharmacies (n=24), MI sources among 
different patient groups (n=22) and MI sources among healthcare 
professionals (HCPs) (n=22). MI literacy in adults (n=2), development of the 
national MI strategy (n=2) and evolution of MI regulation in the EU (n=1) 
were the least commonly studied sub-themes. A more detailed description on 
the characteristics of the included studies is provided in Original publication 
I (Study I: Appendix B). 
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Figure 20. Medicines information studies (n=126) according to the main themes of the 
national medicines information strategy22 and publication year. The same study may have 
had more than one sub-theme, and therefore the study may have been categorised under 
more than one main theme. (I) 
 
Most of the studies were published in international journals (76%, 
n=96/126). The annual publication rate had remained relatively stable 
throughout the study period of 2000–2016 (Figure 20, Study I: Figure 2). In 
the early 2000s (2000–2004), almost half of the publications (45%, n=18/40) 
were related to patient counselling in different settings (Theme 1), and a 
quarter (25%, n=10/40) concerned MI sources and needs of HCPs (Theme 4). 
Since then, the research has shifted towards MI sources and needs of medicine 
users (Theme 2), and patient counselling and pharmacotherapy competence 
of HCPs (Theme 3). MI literacy (Theme 5) and MI policies and strategies 
(Theme 6) have emerged as new research topics in the 2000’s. 
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Table 11. Summary of the original studies (n=126) related to medicines information (MI) which have been conducted in Finland during 2000–2016 organised as 
six themes derived from the goals of the national medicines information strategy.22 The same study may have had more than one sub-theme, and therefore 
the study may have been categorised under several themes. (I) 
 
 
THEME 1. PATIENT COUNSELLING IN DIFFERENT SETTINGS (n=45) 
 
Sub-themes (n) Aspects studied (n)Ref. Key findings related to MI 
Patient counselling  
in community 
pharmacies (n=24) 
Implementation of the national patient 
counselling development project  
(TIPPA Project) (n=9)26,76,120,218-223 
Multiple actions and tools for developing and assessing patient counselling in community pharmacies were applied during the TIPPA Project 
2000–2003. Novel in-house training and professional development practices were established to improve pharmacists’ patient counselling 
skills and understanding of concordance and therapeutic alliance in their communication with medicine users. Patient counselling specific 
quality assurance instrument was developed. 
Patient counselling among different patient  
groups (n=14)137,224-236 
Patient counselling by community pharmacists was recognised as important, but the content and amount of MI varied between different 
patient groups and according to therapeutic class. Pharmacists were found to have false assumptions (“myths”) on OTC customers' need for 
patient counselling. Electronic counselling services provided by community pharmacies started to become common in the early 2000s. 
Patient counselling as a tool for preventing  
medication errors (n=1)237 
Physicians considered patient counselling to be the most important action of community pharmacists to reduce medication errors. 
Patient counselling  
in hospitals  
(n=8) 
Patient counselling among different patient 
groups (n=7)238-244 
WMI improved patient education, interaction between HCPs and patients and HCPs’ readiness for patient counselling. Patients were generally 
satisfied with counselling in hospitals, but they were dissatisfied with counselling on ADRs and lack of emotional support. Lack of time was 
reported as most commonly barrier to patient counselling among HCPs. Patients’ interest in receiving MI is related to their willingness to 
participate in medical decision-making. 
Documentation of patient counselling  
in surgical care (n=1)245 
The need for patient counselling descriptor codes for the Finnish Classification of Nursing Interventions (FiCNi) was identified in surgical care 
in order to document patient counselling provided and the feedback given by patients. 
Patient counselling 
in MICs, call centres 
and telephone 
services 
(n=8) 
Telephone and online counselling (n=8)73,246-252 
Utilisation of telephone and online patient counselling services was not common at the population level, but these MI sources were regarded 
as valuable, particularly for some patient groups such as people using psychotropics. Telephone services provided by physicians proved to be 
useful in resolving patients’ DRPs. 
Influence of patient 
counselling  
on medicines use 
(n=6) 
Influence of patient counselling among different 
patient and medicine user groups (n=6)230-232,253-255 
Community pharmacists can improve asthma patients’ treatment and clinical outcomes by enhanced counselling. WMI did not enhance 
compliance or efficacy of escitalopram treatment among people with depression. One-time counselling of the aged with benzodiazepines and 
other fall-risk-increasing medicines decreased the number of long-term and regular use of benzodiazepines and related medicines. User 
satisfaction is strongly associated with information provided at the time the levonorgestrel-releasing intraurine system is inserted. 
Theoretical 
approaches  
to patient 
counselling 
(n=6) 
Theoretical and practical models/methods  
related to patient counselling (n=6)74,76,120,219,233,256 
 
The USP Medication Counseling Behavior Guidelines were suitable for evaluating and learning community pharmacists' counselling skills. The 
EUPC Method was found to be a useful tool for learning patient counselling skills targeted at people with chronic diseases. Paternalism and 
patient autonomy were applied as philosophical approaches to reflect MI from community pharmacies before the TIPPA Project (2000–2004) 
followed by the implementation of concordance-based counselling practice. Long-term personal support and applied empowerment to self-
management to long-term therapy among diabetics improved the results of diabetes care outcome measures. 
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THEME 2. MEDICINES INFORMATION SOURCES AND NEEDS AMONG MEDICINE USERS (n=25) 
 
Sub-themes (n) Aspects studied (n)Ref. Key findings related to MI 
MI sources among 
different patient 
groups 
(n=22) 
MI sources among different patient 
groups (n=19)90,115,189,193-196,199-201,236,241,257-263 
Consistently in all studies, HCPs, especially physicians, pharmacists and nurses, and PLs were identified as the most common MI sources among 
patients. Receipt of MI from pharmacists and the Internet has increased during the last few decades. The use of the Internet was more 
common among people with mental disorders and young people. 
Quality of online antidepressant  
information (n=1)264 
The quality of antidepressant information on websites was relatively good and correct, but not always comprehensive. 
Readability and content of PLs of  
OTC medicines (n=1)197 
The overall readability of the PLs was good, and the quality of content was not directly associated with the readability.  
Influence of patient information booklet provided 
to support patient counselling among women  
with menorrhagia (n=1)265 
The information booklet influenced treatment choices among women with menorrhagia but did not increase the number of surgical 
procedures used, improve knowledge, or influence satisfaction or anxiety. 
MI needs among  
different patient 
groups 
(n=11) 
MI needs reported by different patient  
groups (n=11)90,189,199,240,241,257,258,261,263,266,267 
Patients most commonly reported the need for information on ADRs, interactions and effects of medicines. Antidepressant users seek online 
MI to obtain a second opinion, verify information received from PL, preparing to visit the physician and hearing peer experiences. The majority 
of pregnant women need MI during pregnancy, especially women with medical problems and lower health literacy. 
 
THEME 3. HEALTHCARE PROFESSIONALS’ COMPETENCE IN PATIENT COUNSELLING AND PHARMACOTHERAPY (n=25) 
 
Patient 
counselling 
competence 
(n=13) 
 
Competence in basic pharmacy  
education (n=7)224,256,268-272 
Structured guidelines and criteria were recognised as useful tools for assessing, teaching and giving feedback on pharmacy students’ patient 
counselling and communication performance. Lack of adequate knowledge about mental health disorders was found in a six-country study. In 
Finland 36% of pharmacy students reported patient-related barriers to patient counselling for people with mental disorders. The EUPC Method 
helped pharmacy students to counsel chronically ill patients. The method was comprehensive and easy to use. 
Competence among pharmacists (n=4)138,139,219,273 
In-house training, long-term continuing education and online education positively influenced patient counselling competence among 
pharmacists. One of the successful achievements was a comprehensive medication review (CMR) competency of community pharmacists 
through a 1.5-year programme. 
Educational interventions (n=2)274,275 
In-house training improved pharmacists' counselling skills and knowledge of asthma management. Online education of nurses positively 
influenced on patients and their family members' satisfaction with patient counselling. 
Pharmacotherapy 
competence 
(n=12) 
HCPs' and HCP students' competences (n=10)276-285 
Nurses and nursing students found pharmacology to be a difficult topic and considered their own skills to be insufficient. Public health nurses 
were generally familiar with the vaccination recommendations and contraindications, but also found areas of competence where they needed 
more training. In managing successful vaccinations, both strengthening and weakening factors must be considered. 
Teaching pharmacotherapy in nursing schools 
(n=2)286,287 
Nursing teachers rated their competence in teaching pharmacotherapy as good in the late 1990s, but the content and amount of 
pharmacotherapy teaching varied between undergraduate nursing programmes in Finnish polytechnic schools even in 2010. They evaluated 
that their best competence was in teaching the implementation of pharmacotherapy and the worst in teaching pharmacology. 
 
  
 
7
4
 
 
THEME 4. MEDICINES INFORMATION SOURCES AND NEEDS AMONG HEALTHCARE PROFESSIONALS (n=23) 
 
Sub-themes (n) Aspects studied (n)Ref. Key findings related to MI 
MI sources among 
HCPs 
(n=22) 
Implementation of national clinical  
practice guidelines (n=13)230,288-298 
HCPs, especially physicians, were generally familiar with the national and local clinical practice guidelines, although the level of 
implementation varied. The majority of physicians considered the guidelines to be useful in clinical decision-making. For example, during the 
MIKSTRA Infectious Disease Program in 1998–2003, the prescribing of antibiotics changed for the better following the national clinical practice 
guidelines, treatment durations shortened, and clinical outcomes improved. 
Quality assessment and development of MI 
sources and services (n=6)299-304 
HCPs were satisfied with the quality of MI services provided by hospital pharmacy, such as telephone services. A MI database to support 
patient counselling and pharmacy protocol for patient counselling were prioritised features in developing future information technology 
systems for community pharmacies. Information content on ADRs varied between PLs of different brands of the same active substance. 
Implementation of local clinical practice  
guidelines (n=2)305,306 
Local clinical practice guidelines were well known among physicians, but lack of time limited their use in practice. Physicians familiar with  
the guidelines were more active in offering practical support. 
Community pharmacy as a source of MI for 
physicians (n=1)307 
Physicians identified and solved DRPs during repeat prescribing more effectively if they received the patient information from the community 
pharmacists. 
MI needs  
among HCPs  
(n=2) 
MI needs reported by HCPs (n=2)302,308 
Home care nurses’ access to MI was varied. Information on interactions, ADRs, doses, dosages, effects and use of medicines was  
commonly needed as reported by hospital nurses and physicians. 
 
THEME 5. MEDICINES INFORMATION LITERACY (n=13) 
 
Children's 
medicines education 
(n=11)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Development and implementation of  
national children's medicines education 
programme (n=10)309-319 
Children’s understanding about medicines was somewhat superficial. Teachers’ attitudes and beliefs towards medicines influenced their 
willingness to teach about medicines. The majority of primary and comprehensive school teachers were willing to teach children about 
medicines. Teachers considered teaching about medicines as being important to be included in the national health education curriculum, and 
they reported the need for support in teaching the rational use of medicines. Online medicines education materials developed for school 
teachers and children were useful. Online education materials for teachers should contain a simple structure and ready-to-use materials. The 
medicines education project was useful for pharmacy students to learn useful skills and competences. 
Pictograms to support MI for children (n=1)314 Most of the children understood USP’s pictograms correctly, but the context in which pictograms were tested influenced on the  results. 
MI literacy 
in adults 
(n=2) 
Seeking and assessing online MI among people 
with depression (n=2)90,320 
Studies yielded a model for MI seeking on the Internet among people with depression. A five-item quality assessment tool for MI (called 
DARTS) was proved to be easy to use and understand. 
 
THEME 6. MEDICINES INFORMATION POLICIES AND STRATEGIES (n=3) 
 
Development of the 
national MI strategy  
(n=2) 
Stakeholders’ perspectives on development 
needs of MI practices for developing 
the national MI strategy (n=2)159,160 
Key stakeholders in MI considered that better coordination of MI, balancing between Internet-based sources and tailoring patient information 
is needed in developing MI at national level. 
Evolution of MI 
regulation  
in the EU  
(n=1) 
Statutory requirements for SmPCs and PLs  
in 1965-2002 (n=1)19 
Incorporation of SmPCs and PLs into marketing authorisations of medicinal products has helped to make the EU’s pharmaceutical 
legislation more public health oriented. 
n=number of studies
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Included studies applied a variety of research methods (Figure 21, Study 
I: Figure 3). A cross-sectional survey was most commonly used single research 
method (88%, n=51/126),76,115,120,189,194-196,199,201,218,223,224,228,229,235,237,238,240,243,244, 
253,256,259,261,262,266,270,272,277,279,280,282,286-292,294,297,299-305,318,319,321 and most of these 
studies were nationwide (n=30).76,120,194-196,199,201,218,223,228,229,235,237,243,253,259,279, 
280,286-290,297,305,321 A qualitative study design was applied in more than half of 
the studies (54%, n=68/126).19,73,74,90,137-139,159,160,193,219-222,225-227,230-234,239,241,242, 
245-252,254,255,257,258,260,261,263-265,267-269,273-275,278,281,285,293,295,298,306-317,320,322,323 
Document analysis (n=18),19,73,74,138,219,245-252,264,267-269,323 mixed-methods 
(n=17)139,159,160,220,226,227,233,241,278,281,293,298,306,311,312,316,317 and qualitative 
interviews (n=17)90,194,222,239,257,258,260,263,273,293,308-310,313-315,320 were the most 
commonly applied research methods. An intervention was carried out in 12 
studies, of which six were randomised and had a control group.230-232,242,254,255, 
265,274,275,285,295,307 A more detailed description on the study methods of the 
included studies is provided in Original publication I (Study I: Appendix B). 
 
 
 
Figure 21. Medicines information studies (n=126) categorised according to the research 
method and the publication year. (I) 
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5.1.2 KEY FINDINGS AND GAPS IN THE METHODOLOGY AND 
THEORY OF MEDICINES INFORMATION RESEARCH (I) 
 
In Finland, MI practices have been widely investigated and multiple 
approaches have been covered in MI research during the 2000s (Table 11, 
Study I: Appendix B). Most of the studies were descriptive. Only six studies 
applied a theory, and they were all conducted in a community pharmacy 
context.74,76,120,219,233,256 Three studies applied theories to patient counselling 
(i.e., autonomy and paternalism in MI from community pharmacies, 
community pharmacists’ attitudes toward concordance, empowerment in 
self-management of type 2 diabetes).74,120,233 A theoretical model to patient 
counselling behaviour (i.e., USP Medication Counseling Behavior Guidelines) 
was applied in two studies.76,219 One study applied a practical method for 
structuring patient counselling in community pharmacies for patients with 
long-term medications (i.e., EUPC Method).256 
 
RESEARCH ON PATIENT COUNSELLING IN DIFFERENT SETTINGS 
 
More than a third of the studies related to patient counselling in different 
settings (Table 11, Study I: Appendix B).73,74,76,120,137,218-256,322 The largest line of 
research has been patient counselling in community pharmacies.76,120,137,218-
237,322 A national patient counselling development project, the TIPPA Project 
(2000–2003), has been one of the major contributors to the modernisation of 
patient counselling culture in Finnish community pharmacies.76,120,218-223,322 
The change from traditional paternalistic patient counselling performance 
towards empowerment and respecting patient autonomy has been actively 
supported by launching nationally the USP Medication Counseling Behavior 
Guidelines.76,219,221 A more practical method, the EUPC Method, has later been 
introduced to structure patient counselling with patients having long-term 
medications.256 Studies in different patient groups have concluded that MI 
provided by community pharmacists has been recognised as important, but 
the content and amount of MI varied between patient groups and according 
to therapeutic class.137,226,229-232,236 There was not found sufficient studies to 
show clearly that patient counselling has an influence on appropriateness of 
medicine use.230-232,253-255 Only a few studies have been conducted in this 
respect and they have indicated improvements in treatments and clinical 
outcomes among asthmatics due to the counselling provided by community 
pharmacists.230-232 
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Patient counselling and MI services provided by hospitals238-245 and 
medicines information centres (MICs)73,246-252 have been less commonly 
studied topics (Table 11, Study I: Appendix B). Cross-sectional surveys in 
specialised care patients have stated that patients have generally been 
satisfied with the counselling provided by HCPs in hospitals.238,243,244 The lack 
of time and emotional support from HCPs have most commonly been 
identified as barriers to receiving MI from HCPs in hospitals.240,243,244 Studies 
focused on MI services provided by MICs and call centres have revealed that 
the use of telephone and online patient counselling services has not been 
common when assessed at the population level but these MI sources have been 
regarded as valuable, particularly for some patient groups, such as 
psychotropic users.73,246,248-252 Telephone counselling services provided by 
physicians proved to be useful in resolving patients’ drug-related problems 
(DRPs).247 
 
RESEARCH ON HEALTHCARE PROFESSIONALS’ COMPETENCE IN PATIENT 
COUNSELLING AND PHARMACOTHERAPY 
 
Studies related to competence of HCPs have primarily been focused on 
pharmacists’ and pharmacy students’ competence in patient counselling and 
nurses' and nursing students’ competence in pharmacotherapy (Table 11, 
Study I: Appendix B).138,139,219,224,256,268-287 Competence studies on patient 
counselling have recognised structured guidelines and criteria, e.g., USP 
Medication Counseling Behavior Guidelines, as useful tools for assessing, 
teaching and giving feedback on pharmacy students’ patient counselling and 
communication performance.268-271 Moreover, a practical patient counselling 
method, EUPC Method, has proven to be useful for pharmacy students in 
counselling chronically ill patients.256 In-house training, long-term continuing 
education and online education have positively influenced patient counselling 
competence of practising pharmacists.138,139,219,273,275  
Studies on pharmacotherapy competence have shown that the content 
teaching hours in pharmacotherapy training still varied in the 2010s between 
undergraduate nursing programmes in polytechnic schools although teachers 
self-rated their competence in teaching pharmacotherapy as good already by 
the late 1990s (Table 11, Study I: Appendix B).286,287 Practising nurses and 
nursing students found pharmacology as difficult topic and considered their 
own skills to be insufficient.276,283-285 Vaccination was the most widely studied 
single competence area among HCPs, especially in nursing.277,279,280 
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RESEARCH ON MEDICINES INFORMATION SOURCES AND NEEDS AMONG 
MEDICINE USERS AND HEALTHCARE PROFESSIONALS 
 
Consistently all studies focused on MI sources of medicine users, physicians, 
pharmacists, nurses and package leaflets (PLs) have been identified as the 
most common MI sources among patients and medicine users (Table 11, Study 
I: Appendix B).90,115,189,193-196,199,200,236,257-260,262,263 The Internet has become a 
more common source of MI over the last few decades, especially among young 
people and certain patient groups, such as people with mental 
disorders.90,193,195,263 Studies on MI needs among patients have shown that they 
commonly have needs for additional information on adverse drug reactions 
(ADRs), interactions and proper medicine use, e.g., 
administration.90,199,240,241,257,258,261,263,267 
The implementation of the national and local clinical practice guidelines 
has been the most commonly studied topic related to MI sources used by HCPs 
(Table 11, Study I: Appendix B).229,288-298,305,306,321 HCPs, especially physicians, 
have generally been familiar with the national clinical practice guidelines in 
the early 2000s, although the level of implementation has varied.289,291-
294,298,321 A majority of physicians considered the clinical practice guidelines as 
being useful in clinical decision-making, such as in prescribing antibiotics as 
shown in the MIKSTRA Infectious Disease Program (1998–2003). The MI 
needs of HCPs have been explored only in two studies which have been 
conducted in home care or a hospital context.302,308 
 
RESEARCH ON MEDICINES INFORMATION LITERACY 
 
MI literacy research has primarily been focused on children’s medicines 
education, particularly in schools as part of health education (Table 11, Study 
I: Appendix B).90,309-320 These studies revealed that children have only 
superficial knowledge about medicines.309,317 There is some evidence that 
pictograms may support counselling on medicines among children but the 
context in which pictograms are used may affect the understanding of 
pictograms.314 School teachers considered teaching about medicines to be 
important and they were willing to teach about medicines, but they need more 
support in teaching medicines-related topics.310,313,316,318 Teachers found 
online medicines education to be useful if the education materials are simple 
and ready-to-use.310,312 Studies on MI literacy in adults have shown that people 
with depression are generally critical of MI retrieved from the Internet and 
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they are commonly able to recognise inaccurate or non-evidence-based 
information from the discussion forums.90,320 A five-item quality assessment 
tool for MI (called DARTS) was created by the Finnish Medicines Agency 
Fimea in 2007 and it has proved to be easy to use and understand.320 
 
RESEARCH ON MEDICINES INFORMATION POLICIES AND STRATEGIES 
 
MI policies and strategies have only been studied to a limited extent with 
research primarily focusing on the first Finnish national MI strategy (Table 11, 
Study I: Appendix B).19,159,160 Studies on the development of the national MI 
strategy stated that the key stakeholders identified multiple strengths, 
challenges and opportunities in MI practices. Better coordination of MI, 
balancing between Internet-based sources and tailoring patient information 
were highlighted as the most important issues.159,160 A study of statutory 
requirements in Summary of Product Characteristics (SmPCs) and PLs has 
shown that the incorporation of SmPCs and PLs into marketing authorisation 
of medicinal products has helped to make the EU’s pharmaceutical legislation 
more public health oriented.19 
 
5.2 TRENDS IN THE RECEIPT OF MEDICINES INFORMATION 
AMONG THE ADULT POPULATION (II) 
5.2.1 CHARACTERISTICS OF THE STUDY POPULATION (II) 
 
In the annual health behaviour population survey, Health Behaviour and 
Health among the Finnish Adult Population, the number of respondents 
varied by year from 2545 to 3371, and the response rate decreased from 67% 
in 1999 to 53% in 2014 (Study II: Table 1). Of the total responses (n=29465) 
64% were from medicine users (n=18862, ranging by year from 58% to 68%). 
The gender distribution of the respondents who reported using medicines 
remained the same throughout the study period, 61–64% being female. The 
annual mean age varied between 41 and 45 years. The respondents most 
commonly used one medicine, ranging from 63% in 1999 to 54% in 2014 
(included prescription and non-prescription medicines). More than a third of 
the medicine users reported having at least one diagnosed disease of the 
diseases listed in the survey instrument, increasing from 37% in 1999 to 59% 
in 2014. A more detailed description on the characteristics of the study 
population is provided in Original publication II (Study II: Table 1). 
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5.2.2 KEY RESULTS ON THE RECEIPT OF MEDICINES INFORMATION 
AMONG MEDICINE USERS (II) 
 
Medicine users reported physicians, community pharmacists and PLs as their 
most common MI sources throughout the study period (Figure 22, Study II: 
Figure 1). These information sources were the most common despite gender, 
age, number of medicines in use or number of diagnosed diseases (Appendix 
2-5, Study II: Appendix A and B). The Internet was still a relatively rare MI 
source when considering the entire adult population, although its use as an 
MI source increased most being 1% in 1999 and 16% in 2014 (Figure 22, Study 
II: Figure 1). In contrast, the receipt of MI from physicians (62% to 47%) and 
PLs (44% to 34%) decreased most. The receipt of MI from community 
pharmacists (46% to 45%) and nurses (14% to 14%) remained relatively stable. 
Detailed results are provided in Original publication II. 
 
 
 
Figure 22. Trends in the receipt of medicines information among medicine users (n=18862)  
in 1999–2014 (percentage of the respondents who reported use of at least one prescription 
or non-prescription medicine within 7 days prior to the survey). (II) 
 
 
n=18862 
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The greatest changes occurred in the receipt of MI from the physician 
among women, people aged 55–64 years, people using two or more medicines 
and medicine users with one or more diagnosed diseases (Appendix 2-5, Study 
II: Appendix A and B). In these groups, the receipt of MI from the physician 
decreased by 18–26%. On the other hand, the receipt of MI from the Internet 
increased in all medicine users regardless of gender, age, number of medicines 
in use or number of diagnosed diseases. The greatest increase (16–20%) was 
in women, people under 24 years, people with two or more medicines and 
medicine users with three or more diagnosed diseases. Receipt of MI from PLs 
decreased in all medicine users, most commonly among people under 24 
years, people with one or two medicines in use and medicine users without 
diagnosed diseases. The decline in these groups varied between 12% and 22%. 
The number of people who did not report any information sources about 
their medication increased regardless of gender, age number of medicines in 
use or diagnosed diseases (Appendix 2-5, Study II: Appendix  A and B). In 
1999, 4% of the medicine users reported not receiving MI from any of the 
sources listed in the survey, while, remarkably, this proportion had increased 
to 28% in 2014 (Figures 22 and 23, Study II: Figure 2). Men, medicine users 
under 45 years, people using one or two medicines and medicine users without 
any diagnosed diseases were the most common groups in which this appeared. 
In 1999, 17% of the medicine users did not report any HCPs (e.g., physicians, 
community pharmacists or nurses) as their MI source, and this proportion 
had grown to 38% by 2014. 
The number of MI sources from which medicine users reported 
receiving MI changed over the study period 1999–2014 (Figure 23, Study II: 
Figure 2). The most noticeable decreases occurred in those who reported 
receiving MI from one (47% to 21%) or two (30 % to 22%) sources. The 
number of medicine users receiving MI from more than two sources increased 
moderately. As the number of medicines in use or the number of diagnosed 
diseases increased, the number of different MI sources increased. 
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Figure 23. Number of medicines information sources from which the adult medicine users 
had received information on the medicines they used in 1999–2014. (II) 
 
 
5.3 IMPLEMENTATION OF MEDICATION USE PROCESS            
FOR PATIENTS WITH CHRONIC DISEASES (III) 
5.3.1 CHARACTERISTICS OF THE STUDY POPULATION (III) 
 
In total, 79 out of 111 members of the National Medicines Information 
Network (MI Network) participated in the study (participation rate 71%) 
related to the implementation of medication use process in patients with 
chronic diseases (Study III: Table 1). Participants represented 42 out of 53 
stakeholder organisations. Most of the participants were pharmacists (43% of 
all participants, n=34/79), physicians (22%, n=17/79) and nurses (15%, 
n=12/79). Educational units were the most commonly represented 
stakeholder group (24% of the stakeholder organisations, n=10/42), including 
universities, polytechnics, vocational institutions and continuing education 
units. A detailed description of the study participants is presented in the 
Original publication III (Study III, Table 1). 
 
n=18862 
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Altogether, 43 semi-structured interviews were conducted as individual 
(n=22), pair (n=11) and group interviews (n=10). Interviews were conducted 
as face-to-face (n=34), by telephone (n=5), as video conferencing (n=3) or as 
face-to-face and video conferencing (n=1). In total, 3–6 participants attended 
the group interviews at a time. Four interviews included participants from 
several stakeholder organisations. 
 
5.3.2 KEY FINDINGS ON THE IMPLEMENTATION OF MEDICATION 
USE PROCESS AND A NEW CONCEPTUAL MODEL (III) 
 
A new conceptual framework model was compiled based on the views of the 
stakeholders on the well-implemented actions and actions needing 
development in the medication use process among patients with chronic 
diseases (Figure 24, Study III: Figures 3 and 4). The new model includes ten 
main categories, of which seven were derived deductively from the previous 
medication use process (Figure 8)22: 1) patient, 2) starting the medication, 3) 
advice and guidance by nurses, 4) medication counselling in the community 
pharmacies, 5) implementing the medication use process in home care and 
social care, 6) treatment monitoring and 7) specialist services. The following 
three categories were inductively derived from the data: 8) management of the 
entire medication use process, 9) patient information transfer and electronic 
health records (EHRs) and 10) multiprofessional collaboration. All the 
inductively derived categories were at the infrastructure level (macro). 
Half of the stakeholder representatives (52%) recognised well-
implemented actions and almost all of the study participants (94%) indicated 
actions needing development at all levels (macro, meso, micro) in the 
medication use process (Figure 24, Study III: Figures 3 and 4). The 
stakeholders raised far more actions for development than well-established 
practices in the medication use process (211 vs. 68 mentions, respectively).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=a summative of number of the single interviewee's mentions; aAll prescriptions have been electronically prescribed in Finland since 1 January 2017, be.g., clinical pharmacology consultation services and CMRs. 
Figure 24. Stakeholders’ views on well-implemented actions and actions needing development in the medication use process for patients with chronic diseases. 
Categories derived deductively are marked as blue (n=7) and categories emerged inductively from the stakeholders’ interviews are marked as green (n=3). (III) 
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Well-implemented  
actions (n=2) 
• Multiprofessionality: 
consisting of good local 
multiprofessional 
models for patients 
with chronic diseases 
(n=2) 
 
Actions needing 
development (n=23) 
• Roles of HCPs: HCPs do 
not know the roles or 
competences of other 
HCPs (n=7), lack of 
common agreements of 
the roles between HCPs 
(n=4) 
• Communication: 
conflicting information 
provided by HCPs (n=4), 
lack of ways to 
communicate between  
HCPs (n=3) 
• Multiprofessionality: 
underutilisation of 
existing local 
multiprofessional 
models and good 
practices in 
collaborations (n=2), 
lack of trust between 
HCPs (n=1), 
discontinuation of 
previously existing 
national programmes 
for long-term diseases, 
e.g., asthma network 
(n=1) 
 
 
Well-implemented 
actions (n=0) 
• No mentions 
 
Actions needing development (n=13) 
• Specialist services: unfamiliarity or limited use (n=4), lack of coordination (n=1), 
challenges in identifying the patients who need consultation with a clinical 
pharmacologist (n=1) 
• Dose dispensing services: high costs (n=3) or availability is low (n=1) for patients 
• Medication review services: challenges in carrying out medication reviews 
elsewhere than in community pharmacies, e.g., home care (n=1), 
pharmacies need to develop medication review services (n=1), patient’s 
updated medication list available from an electronic prescription system 
have replaced the need for a comprehensive medication review (CMR) (n=1) 
 
Well-implemented actions (n=4) 
• Most of the patients are able to seek MI and they have 
a good level of knowledge of their disease and long-
term medication (n=4) 
 
 
 
Well-implemented 
actions (n=0) 
• No mentions 
Actions needing development (n=24) 
• Coordination and organisation of medication use process: weaknesses in every phase 
of the process (n=10), patients are not involved with the planning and/or development 
of their medication (n=3), shortcomings in organising medication use process (n=2), 
lack of a permanent partnership between patient and HCPs (n=2), fragmented thinking 
model in primary care without seeing patient's overall situation (n=2) 
• Communication: Inadequate competence of HCPs to communicate with patients (n=1) 
• Place of treatment: treatment practices vary by place of 
treatment (public vs. private) or by patient group (n=2), 
medications prescribed in specialised care cannot be re-
prescribed/continued in primary health care (n=1), HCPs 
working on healthcare cannot work with clients of social 
care even they are in the same building, e.g., pharmacist 
specialised in medication reviews (n=1) 
 
Well-implemented actions (n=4) 
• Electronic prescribinga: 
prescriptions are better accessible 
through the electronic prescribing 
system, and it is possible to see 
what medicines have been 
prescribed to the patient in 
different healthcare units (n=3) 
• Electronic health records (EHRs) 
enable better transmission of 
patient information (n=1) 
 
Actions needing  
development (n=33) 
• Patient information transfer: 
transition of patient information 
accurately and unambiguously 
between healthcare units (n=8), 
security of patient information 
transfer (n=2) 
• EHRs: difficulties in finding 
information from multiple 
databases (n=4), challenges with 
medication interaction systems 
(n=3), unavailability of patient 
information for every HCP (n=2), 
incompleteness of patient 
information (n=1) 
• Electronic prescribing: lack of 
understanding of patient’s overall 
medication(n=3), prescribing or 
renewal of prescriptions is time-
consuming (n=1), same medicine 
has been prescribed several times 
(n=1), difficulties in maintaining an 
updated medication list (n=1), 
database does not indicate which 
medicines are actually being used 
(n=1), lack of online banking 
identifiers to access the electronic 
prescription database in patients 
(n=1) 
• Electronic documentation: Lack of 
documentation of given MI and 
information about patient’s health 
status, condition and diseases 
(n=3) 
• Patients need more information 
and electronic MI sources at each 
phases of the medication use 
process (n=2) 
 
Actions needing development 
(n=9) 
• Inadequate support for 
adherence to medication (n=4) 
• Variation in guidance (n=3) 
• Advising on self-medication  
and (n=1) identification of  
interactions (n=1) 
Well-implemented actions (n=14) 
• Implemented relatively well (n=6),  
best in special care (n=3) 
• Advising on the use of medicines  
• (n=2) 
• Nurses treat and provide guidance  
from the patient’s point of view 
(n=2) 
• Nurses are dedicated to work (n=1) 
Actions needing development (n=27) 
• Lack of adherence or motivation to medication (n=6) 
• Information and communication: inability or 
unwillingness to communicate with HCPs (n=5), 
deficiencies in searching for reliable information (n=3), 
providing information to patients with different 
backgrounds (n=3), difficulties in remembering or 
understanding of information received (n=2), lack of 
written information (n=2), HCPs have challenges in 
identifying patients who want or need information (n=2) 
• Lack of updated medication list or care plan (n=3) 
• Inability to recognise of changes in their own health 
(n=1) 
 
 
MICRO LEVEL 
Patient 
 
 
TREATMENT MONITORING 
 
Well-implemented actions (n=3) 
• Role of community pharmacists has been increased 
(n=2) 
• Monitoring in special medical care at moderate level 
and regular contacts with the treatment unit (n=1) 
 
Actions needing development (n=20) 
• Medication lists are not systemically monitored (n=5) 
• Reasons for inadequate monitoring: prolonged 
prescription for two years and refilling a prescription 
via email without seeing physician (n=3), variation in 
monitoring practices in home care and at pharmacies 
(n=2), patient information is hard to find or combine 
from multiple databases (n=2), lack of time (n=2), 
patients’ experiences ignored in monitoring (n=2), lack 
of monitoring medicines interactions (n=1), lack of 
supporting adherence to follow-up treatment (n=1) 
• Monitoring is only conducted when ADRs occur or 
patient points out the problem itself (n=2) 
  
IMPLEMENTING THE MEDICATION USE PROCESS IN HOME CARE AND SOCIAL CARE 
 
Actions needing development (n=34) 
• Inadequate competences of practical 
nurses in pharmacotherapy (n=9), to 
provide MI (n=5), in identification of ADRs 
(n=3), in treatment monitoring (n=2) 
• Lack of multiprofessional teams (n=2) 
• Practical nurses’ deficiency to engage 
their work and understanding the 
importance of their role in the 
medication use process (n=2) 
 
• Inadequacy in practical nursing education (n=6) 
• Varied practices in home care (n=4), e.g., continuous 
turnover of nurses in home care and scarcity of visits 
by a physician causing problems with the monitoring 
patients' health status in home care (n=1) 
 
 
STARTING THE MEDICATION 
 
 
Actions needing development (n=17) 
• Physician's overly short appointment times (n=6) 
• Patient-related factors: patient is nervous or 
embarrassed to receive information (n=5) 
• Identification of drug interactions (n=3) 
• Access to primary care in non-acute cases (n=2) 
• Lack of permanent patient-physician partnerships (n=1) 
 
 
MEDICATION COUNSELLING  
IN THE COMMUNITY PHARMACIES 
 
Well-implemented actions (n=26) 
• Implemented well or moderately (n=17) 
• Pharmacies are  well-specialised in supporting 
adherence among certain patient groups (n=5) 
• Pharmacy is the primary source of MI for 
public (n=2) 
• Counselling is customised and instructions 
provided by physician/ nurse are repeated 
once again at community pharmacies (n=2) 
 
Actions needing development (n=11) 
• Provided inadequate or too much information 
(n=5) 
• Supporting adherence to therapy (n=3) 
• Lack of counselling about medicines 
interactions (n=2) 
• Deficiencies in perceiving the patient's overall  
situation (n=1) 
 
Well-implemented actions (n=1) 
• Basic knowledge on 
medication administration 
are good among practical 
nurses (n=1) 
Well-implemented 
actions (n=14) 
• Implemented well or 
reasonably well 
(n=12) 
• Best implemented in 
special care (n=2) 
5 Results 
85 
 
At infrastructure (macro) level, stakeholders presented only a few well-
implemented actions related to patient information transfer and EHRs (n=4 
mentions of being well-implemented) and multiprofessional collaboration 
(n=2), while none of the stakeholders mentioned management of the entire 
medication use process (n=0) or specialist services (n=0) (Figure 24, Study 
III: Figure 3). Numerous actions needing development were identified, of 
which the patient information transfer between care units or when the patient 
is transferred from one care unit to another and limited availability of EHRs 
assisting in medication risk management in clinical practice were the main 
concerns (Figure 24, Study III: Figure 4). Stakeholders mentioned that some 
HCPs do not have access to complete patient information, such as laboratory 
results, and they have difficulties in finding information from various 
databases. Furthermore, many stakeholders emphasised that the 
management of the entire medication use process has not been implemented 
well as patients are not sufficiently involved in the planning of their own 
medication. Collaboration between different HCPs was found to be one of the 
major development needs in the infrastructure level, such as lack of awareness 
and mutual agreements on the roles between different HCPs. 
At the HCP (meso) level, stakeholders perceived medication counselling 
in the community pharmacies, starting the medication and advice by nurses 
as the best implemented actions (Figure 24, Study III: Figure 3). All 
stakeholders participated in the study agreed that the biggest challenges are 
found in implementing the medication use process in home care and social 
care (Figure 24, Study III: Figure 4). Inadequate education and variation in 
competence among practical nurses were considered as weakening factors for 
the implementation of safe and high-quality medication for patients with 
chronic diseases. Stakeholders also expressed various concerns related to 
treatment monitoring, such as monitoring is not commonly conducted 
systematically, and that patients do not have reconciled medication lists. 
At patient (micro) level, stakeholders shared very few well-implemented 
actions in the medication use process (Figure 24, Study III: Figure 3). They 
considered that patients with long-term medications know how to search 
information about their medication and seem to have the best knowledge of 
their disease and medication, although stakeholders highlighted that this is 
not the case among all patients. Patients’ lack of motivation or adherence to 
treatment and inability or unwillingness to communicate with HCPs were the 
most commonly mentioned development needs (Figure 24, Study III: Figure 
4). Patients do not always have a reconciled medication list or a care plan, 
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which may not only challenge HCPs at the point of prescribing and dispensing 
medicines, but also patients while using medicines. Additionally, patients’ 
limited skills in searching reliable MI and insufficient medication counselling 
to particular patient groups, such as the deaf, people with vision impairment 
and using multiple medications, were among identified as areas needing 
attention 
 
5.4 SUMMARY OF THE KEY FINDINGS 
 
The systematic review found that research related to MI has been carried out 
from various perspectives over time and has been applied by multiple study 
methods during the 2000s in Finland (Study I). Most of the included studies 
were qualitative or cross-sectional surveys, and they were mainly descriptive 
without a theoretical framework. Patient counselling in community 
pharmacies was largest research line. One of the major contributors to the 
modernisation of patient counselling culture in Finnish community 
pharmacies was achieved during the national TIPPA Project (2000–2003). 
However, there was not found clear evidence to present that patient 
counselling has an influence on appropriateness of medicine use. In addition 
to studies conducted with pharmacy personnel, research was conducted 
mainly from the perspective of HCPs, such as competences in 
pharmacotherapy among nurses. Studies conducted on consumers focused 
commonly on MI sources used by medicine users. The implementation of the 
national and local clinical practice guidelines were the most commonly 
studied topics related to MI sources used by HCPs, but the MI needs of HCPs 
had not been widely explored. MI literacy research concentrated primarily on 
children’s medicines education, but MI literacy in adults had not been studied. 
Least studied topic was MI policies and strategies. 
Based on the survey of long-term trends in the receipt of MI, physicians, 
community pharmacists and PLs were the main MI sources among adult 
Finnish medicine users during the 2000s (Study II). The receipt of MI from 
physicians and PLs decreased most and increased most from the Internet, 
whereas the receipt of MI from community pharmacists and nurses remained 
relatively stable. The more the patient had medicines in use or diagnosed 
diseases, the more the patient received MI from multiple information sources. 
The proportion of medicine users who did not report receiving MI from any 
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sources grew by sevenfold and the proportion of those who did not report 
receiving MI from any of HCPs more than doubled during the 2000s. 
According to the stakeholders’ interviews on the implementation of the 
medication use process among patients with chronic diseases, the best 
implemented actions were medication counselling at community pharmacies, 
starting the medication by physicians and guidance by nurses (Study III). 
Stakeholders recognised far more actions needing development at all 
implementation levels in the medication use process. Inadequacy in 
implementing the medication use process in home care and social care, 
patient information transfer between healthcare units, use and accessibility of 
EHRs, lack of knowledge or common agreements on the roles of HCPs, and 
lack of systematically conducted treatment monitoring were among the major 
development targets. Furthermore, poor patient involvement during the 
entire medication use process was a concern reflecting lack of motivation or 
adherence to treatment and inability or unwillingness to communicate with 
HCPs. A further concern was that patients do not always have reconciled 
medication lists or treatment plans, which may challenge not only HCPs at the 
point of prescribing and dispensing medicines, but also patients while using 
medicines at home. Additionally, patients’ limited skills in searching reliable 
health information and MI were identified as areas needing attention. 
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6 DISCUSSION 
6.1 KEY FINDINGS OF THE STUDIES I-III 
The research related to the national medicines information (MI) strategy 
carried out in this doctoral dissertation forms a unique entity with a wide 
coverage in terms of the time frame and MI research areas. The findings of 
this dissertation have assisted in understanding the roots and development of 
current MI practices in Finland, and the next steps to be taken in order to 
ensure that the strategic goal of well-informed medicine users will be 
achieved. 
Among the most striking findings of this dissertation is the one 
indicating that an increase in the diversity of MI sources available do not 
necessarily lead to a better coverage of medicine users receiving MI on the 
medicines they are taking. The shift “from paper to cyber” may not 
automatically reach all medicine users. Increasing the use of electronic MI 
sources in the population seems to be a surprisingly slow process. Receipt of 
MI among medicine users still appears to be strongly heavily reliant on 
physicians, community pharmacists and package leaflets (PLs). 
The available MI research in Finland has focused on investigating MI 
practices in community pharmacies and the long-term development efforts 
undertaken in this context since the 1990s. Surprisingly little research has 
been conducted on physicians’ MI practices, although they are among the 
primary MI sources, especially for ageing people and long-term medicine 
users. Another almost unresearched area is the empowerment of medicine 
users and its impact on self-management and outcomes of 
pharmacotherapies. This relates to understanding the medication use process 
from the medicine users’ perspective. 
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6.1.1 DEVELOPMENT NEEDS OF MEDICINES INFORMATION 
PRACTICES IN FINLAND AS INDICATED BY RESEARCH 
CONDUCTED SINCE 2000 (I) 
 
The systematic review on MI research conducted in Finland since 2000 (Study 
I) provides a comprehensive overview of the research areas covered and 
methodology applied. The review found that MI research forms a well-
established research area which applies a variety of research methods, albeit 
most of the studies have been descriptive and small-scale, and lacking a 
theory-base. Despite the fact that many of the studies have been carried out 
somewhat a long time ago, some of them have laid the foundation for recent 
and long-term development of MI practices in Finland, particularly in 
community pharmacies. The research has guided the implementation of 
patient-centred counselling first in routine dispensing,14,17,26,131,137 and more 
lately as an essential part of collaborative medication reviews.140,324-326 These 
communication practices on medications are currently being extended to 
other healthcare settings in Finland, particularly to hospitals as part of 
pharmacist-conducted medication history taking, reconciliation and 
reviews.76,120,144,145,218,221,322,327 
This systematic review also revealed that medication counselling in 
community pharmacies was the most widely studied topic in MI research in 
Finland since the beginning of 2000s.76,120,137,218-237,322 Patient counselling 
services have been proactively developed in Finnish community pharmacies 
since 1983 when pharmacists were given a statutory obligation to provide 
counselling to patients.14,17,26,43 Since then, the development of patient 
counselling competence among pharmacists has been supported by multiple 
educational interventions which have been evaluated.14,17,26,131 The most 
intensive development period was actualised over the initiation phase of the 
national TIPPA Project in the early 2000s, which also reflects the intensity of 
patient counselling research in this phase.76,120,138,139,218-223,322 
The quality of MI provided by community pharmacists has shown 
improvement, e.g., in pseudo customer studies regularly conducted since the 
late 1990s.221 However, the most recent pseudo customer study conducted by 
the Finnish Medicines Agency Fimea in 2018 focusing on OTC counselling by 
community pharmacists still indicates the need for improvement in terms of 
clinical content and standardisation of quality.328 The same seems to apply to 
medication counselling by other healthcare professionals (HCPs) although 
evidence is scarce, as shown in this systematic review. Consequently, more 
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attention should be paid to improving personal medication counselling and 
using different modes of communication for that purpose, including Internet-
based applications that are easily available to consumers, e.g., in smart 
phones. The priority of personal medication counselling has been 
demonstrated in, for example, an intervention study among chronic myeloid 
leukaemia (CML) patients.329,330 
Patients’ receipt of MI from various sources has also been broadly 
explored in Finland. Few studies have directly focused on empowerment and 
supporting a more active role for patients which has been a strategic goal in 
medicines policy nationally and internationally during the last few 
decades.3,22,24,25,28 There is great deal of evidence indicating that physicians, 
pharmacists and statutory PLs have remained as primary MI sources among 
the Finnish adult population for a long period of time.90,115,189,193-196,199-
201,236,241,257-263 Similar findings have been obtained from other countries 
during the 2000s (see Chapter 2.3).30,115,181-192,197,198,202-204 More research is 
needed on consumers’ MI-seeking strategies and behaviours as people are 
expected to become more empowered in searching for MI from various 
sources easily available to them, particularly via electronic information 
sources. 
Appraising the quality of MI found from different sources requires 
sufficient health information and MI literacy skills.25 This is an area that has 
been in the national MI strategy, but which has not gained much attention in 
the implementation actions so far. Although literacy is at a high level in 
Finland, there is lack of research on health information and MI literacy among 
the population.90,172,320 Understanding literacy and health literacy have 
become more timely, because the Finnish population has recently become 
more diverse, through, for instance, immigration. This may have influenced 
both literacy and health literacy levels as it has done in other countries with a 
longer history of high-volume immigration.331-333 Other special populations 
whose health information and MI literacy skills should be better understood 
are adolescents and young adults, as well as older adults. Research into the 
availability and usability of MI that is especially suitable for older adults will 
become even more timely in Finland as our population is ageing and shifting 
towards electronic MI sources, which may be a greater challenge for older than 
for younger people. 
Based on the findings of the Study II, we should examine to what extent 
health information and MI literacy are contributing to the fact that large 
numbers of medicine users have not received information about medicines 
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they use (see Chapter 5.2). Previous studies, e.g., from Europe, suggest that 
health literacy is influenced by demographic status (e.g., age, gender), 
socioeconomic status (e.g., education, household income), social status, 
health status and use of healthcare services.332 The impact of these factors 
should be also investigated in Finland as our society is undergoing changes 
that may expand the proportion of the population with poor health 
information and MI literacy. 
Along with the consumer and medicine user approach, this systematic 
review provides insights into the use of MI sources among HCPs and their 
competence in patient counselling and pharmacotherapy. Research on the 
competence of HCPs has primarily focused on patient counselling skills 
among community pharmacists and pharmacy students,138,139,219,224,256,268-273,275 
pharmacotherapy competence among nurses and nursing students,276-285 and 
the use of national clinical practice guidelines among physicians.288,289,291-
295,297,298,321 There is still a lack of evidence on communication culture and 
pharmacotherapy competence for patient-centred and evidence-informed MI 
practices throughout the healthcare system. The use of theories and 
theoretical models, such as empowerment and concordance, as a tool for MI 
practice change should be also understood better and across various settings. 
Moreover, the actual use of novel online medication risk management tools in 
patient care should be investigated further as these tools are routinely 
available throughout healthcare and in community pharmacies in Finland. 
Based on preliminary experiences, the use of these tools is still limited 
compared to the potential they possess for improving quality and safety of 
medication.146,334,335 
Research has, to a marginal extent, on the effectiveness of MI in 
Finland230-232,253-255 and internationally (see Chapter 2.1). Further 
development is needed, especially in research methodology, to produce 
stronger evidence from this aspect. However, research should also shift 
towards assessing the impact of novel MI services on medicines use 
behaviours, self-management and therapeutic outcomes. There is a lack of 
recent comparative effectiveness studies to appraise the relative value of 
various MI practices and services, particularly between digital MI and HCPs 
as a MI source for consumers. Moreover, a robust body of evidence is missing 
on the use of electronic MI sources and services which apply modern 
information technology to clinical decision making and medication reviews. 
The findings of this systematic review have served as a foundation for 
the activities of the first national MI research strategy in Finland and in 
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following up its implementation.167 Moreover, the results of the review have 
also directed recent MI research, particularly under the national MI strategy22 
and the activities of the National Medicines Information Network (MI 
Network).166 The achievements of this review could serve as an example for 
other countries to systematically review existing MI research when 
establishing their own MI strategies.16,22,159 
 
6.1.2 TRENDS IN THE RECEIPT OF MEDICINES INFORMATION 
AMONG ADULT MEDICINE USERS IN FINLAND (II) 
 
The 15-year period (1999–2014) covered in Study II presents a unique 
conception on the change of consumers’ receipt of MI from various sources. 
According to the previous studies (see Chapter 2.3), this is the first 
population-based repeated cross-sectional survey examining long-term 
national trends in the receipt of MI among adult medicine users. The present 
study found that physicians, community pharmacists and PLs have prevailed 
as the main MI sources over the 2000s, which has been also shown in previous 
cross-sectional studies globally.30,115,181-192,197,198,202-204 Surprisingly, the use of 
the Internet as a MI source has grown only slowly at population level (from 
1% in 1999 to 16% in 2014) even though more than 90% of the Finns aged 16–
64 years were Internet users in 2014.336 The use of the Internet as a source of 
MI has not increased as of 2017, when 16% of Finnish adult medicine users 
still reported seeking MI on the Internet.337 
In the absence of longitudinal studies from other countries, cross-
sectional studies not generalisable to the entire population have indicated 
similar findings in using the Internet as a MI source among adult medicine 
users during the 2000s (see Chapter 2.3).186,198,202,203 However, some patient 
and medicine user groups have been found to search MI from the Internet 
more frequently than the adult population in general, such as people with 
chronic diseases or pregnant women.87,115,189  Nevertheless, these results 
cannot be applicable to the entire population or patient group in question due 
to the limited study samples or methods causing bias (e.g., targeted online 
survey, non-population-based). The receipt of MI from the Internet may have 
been over-estimated as part of the studies have targeted active Internet users. 
Consequently, this over-estimation may mislead health communication 
planning by ignoring importance of MI sources other than those accessible via 
the Internet. Thus, we could not solely count on the Internet-based MI sources 
and services if we want to reach the majority of the adult population. Further 
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population-based research is needed to ensure a more comprehensive 
understanding of the importance and usage patterns of the Internet as a MI 
source. In Finland, Fimea’s national population survey, Medicines Barometer, 
which will be conducted every second year, will provide such information in 
the future.337 
Unexpectedly, the study’s findings indicated that although the 
availability and the use of MI sources has diversified among the adult 
medicine users, a growing number of adults did not report receiving any MI. 
During the study period, the proportion of medicine users who did not report 
receiving MI from any of the listed sources grew sevenfold (4% to 28%) and 
the proportion of those who did not report receiving MI from any of the HCPs 
more than doubled (17% to 38%). In particular, MI received from physicians 
declined the most (9–26%) over the study period. These outcomes may imply 
that physicians are becoming less involved in actual patient care as the 
healthcare has become more fragmented. One reason for this could be that the 
time allocated for physician office visits has been shortened, leading to 
physicians having less time to focus on their patients’ medications.338-341 
Therefore, medicine users who were dependent on MI received from their 
physicians do not have that source available anymore. It also appears that 
community pharmacists have become more common MI sources for people 
with multiple medications instead of physicians, but nurses have not replaced 
physicians as a MI source. In the future, special attention should be paid to 
the receipt of MI among people with multiple diseases and medications, those 
who do not receive MI, and the ageing populations whose proportion is 
growing among the general population.  
As the study findings indicate, MI is not evenly distributed among 
medicine users. Women, people aged 45 years or older, people with three or 
more medicines in use and people with three or more diagnosed diseases 
received information on their medicines more often than other adult medicine 
users. These findings, covering a 15-year timeframe (1999–2014), are in line 
with the previous cross-sectional studies over the 2000s that were reviewed 
in Chapter 2.3 (Table 9). Moreover, factors that have been previously found 
to influence MI-seeking behaviours and the use of MI sources are education, 
ethnic background, income, employment, health status and medical history 
(see Chapter 2.3.4, Figure 12). Potential reasons and system-based root causes 
for differences in the receipt of MI among medicine users need to be addressed 
in future research. The results from Finland demonstrate that the availability 
6 Discussion 
94 
of a wide range of MI sources does not automatically guarantee their actual 
and evenly distributed use among medicine users.  
 
6.1.3 DEVELOPMENT NEEDS OF THE MEDICATION USE PROCESS OF 
PATIENTS WITH CHRONIC DISEASES (III) 
 
The first evaluation of the Finnish national MI strategy’s implementation at 3 
years after the launch was carried out by interviewing the stakeholders 
involved in the implementation of the strategy in 2015 (Study III). The 
interviews provided rich data to understand how the stakeholders perceived 
the ultimate goal of the national MI strategy, which was a well-informed and 
adherent medicine user with a chronic disease (see Chapter 2.2.3, Figure 8).22 
The overall notion based on the interviews was that it was hard for the 
participants to form an idea of the medication use process even though the 
figure illustrating it in the national MI strategy was shown to them in the 
interviews. 
Although numerous well-implemented actions in the medication use 
process were identified, the stakeholder representatives found even more 
actions needing development (see Chapter 5.3.2, Figure 24). The actions 
requiring development appeared at all levels of implementation, i.e., at 
infrastructure (macro), HCP (meso) and patient (micro) level. The dominant 
actions needing improvements at infrastructure level concerned the 
transmission of patient information within and between healthcare units, the 
availability of reconciled medication lists and other patient information in the 
electronic form, coordination of the entire medication use process, 
multiprofessional collaboration between HCPs, and defining the roles and 
responsibilities of patients and HCPs involved in the care process. These 
findings are in line with other recent observations from Finland.28,339,342-344 
The origin of the national MI strategy in 2012 was exclusively to improve 
coordination of MI and MI practices in healthcare.22 However, this first 
national MI strategy’s evaluation in 2015 has already revealed that MI and its 
receipt from various sources cannot be separated from the medication use 
process, nor can MI be separated from patient information. This was indicated 
by the finding that the availability of the reconciled medication list and/or 
individual treatment plans and electronic health records (EHRs) were highly 
prioritised by the stakeholders as actions to improve the management of the 
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entire medication use process which has also been described in earlier 
studies.329,345 A reconciled medication list is essential for HCPs and patients, 
for example the physician should review available patient information before 
encountering the patient and use the information gathered to determine what 
to talk over and agree upon in the treatment with the medicine user.15,26,329 
As reported by the stakeholders, the greatest challenges in 
implementing the medication use process emerge in primary care, especially 
in home care and social care units, such as in nursing homes. This means 
social and healthcare units providing care for older adults in the poorest 
conditions. HCPs’, especially practical nurses’, pharmacotherapy competence 
and skills in providing MI were recognised to be at an inadequate level, which 
has also been shown in previous studies.287,294-297 This result may reflect that 
the Finnish population is aging rapidly and the care system has not been 
sufficiently prepared for the growing need, for example, to train care 
personnel in geriatric pharmacotherapy to safely manage the medications. 
This is particularly the case for practical nurses, whose responsibility for 
medication management in geriatric care units has increased remarkably even 
though their pharmacotherapy training is limited. The same trend and 
challenges have been found in other research and development programmes 
in Finland and other countries.339,346 The challenges of safe management of 
medications and polypharmacy of older adults have been prioritised globally 
in the ongoing WHO Global Patient Safety Program Medication Without 
Harm.347 Further research should focus on geriatric care units in primary and 
social care to better understand the system-based root causes and 
contributing factors of actual and potential risks in the current medication use 
processes. 
In spite of the medicines policy initiatives and wide recognition of the 
importance of patient empowerment and involvement in healthcare during 
the 2000s,3,22 patient engagement in the medication use process was still 
being strongly communicated as an area for development by HCPs and 
representatives of patients in 2015. Stakeholders viewed that patients may not 
often actively discuss their medicines and drug-related problems (DRPs) with 
their HCPs. Communicative relationship between HCPs and patients is an 
imperative driver for patient involvement in decision making.348,349 Mutual 
communication is essential for sharing information and knowledge and giving 
the patient a sense of control and responsibility.350,351 HCPs should encourage 
patients to share experiences and concerns about their treatment and ensure 
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that patients receive MI throughout the process, not only when starting a new 
medication.349 Even though the number of MI sources available for patients 
has increased over the last few decades, the proportion of adult medicine users 
who received information about their medication from HCPs or any source 
had decreased remarkably during 1999–2014, as shown in Study II (see 
Chapter 5.2).  
It is worth remembering that a majority of the interviewees were HCPs, 
even where they represented the voice of patients, thus, the results are skewed 
to a professional opinion even from the patient perspective. Nevertheless, the 
results send a clear message that patients’ involvement in their long-term 
medication should be significantly increased. To be successful, research and 
actions should focus on patient approach in the implementation of long-term 
medications as only the patients themselves can describe the issues that 
matter to them affecting their motivation for treatment, success of self-
management and empowerment. Even people with poor health literacy want 
to know about their medications.352 Infrastructural factors leading to poor 
access to patient and MI and poor adherence, such as a lack of reconciled 
medication lists and treatment plans, along with lack of personal 
communication with care providers should be further investigated from a 
patient perspective.329,353 
Since this evaluation was conducted in 2015, deficiencies found in the 
infrastructure of the medication use process have been recognised in Finland 
in the ongoing Rational Pharmacotherapy Action Plan (2018–2022).28 The 
Government Program151,354 based action plan is intended to strengthen the 
actions at the infrastructure level which were minor in 2015. At the same time, 
it extends the scope of development towards the meta level, including health 
and medicines policy making that can facilitate infrastructural changes in the 
medication use process through information guidance, resource allocation 
and legislation.355 Furthermore, the description of the medication use process 
presented in this study supports patient involvement and serves as an useful 
framework for the training of HCPs by highlighting the roles and 
responsibilities of different actors in the medication use process. Most 
recently, the results of this study have guided ongoing compilation of the next 
national MI strategy for the years 2021–2026 in cooperation with the 
stakeholders. 
6 Discussion 
97 
6.2 STRENGHTS AND LIMITATIONS OF THE STUDIES I–III 
6.2.1 SYSTEMATIC REVIEW ON PEER-REVIEWED PUBLICATIONS (I) 
 
Study I provided a comprehensive overview of MI research in Finland during 
the 2000s. This systematic review deepened and updated the previous 
literature review.171 Although many of the studies were small-scale and 
descriptive, without theory base, they gave a multifaceted comprehension of 
the MI practices and their evolution in Finland over time. The literature search 
was conducted systematically from multiple appropriate databases (two 
international and one national) using predetermined inclusion and exclusion 
criteria. More than a third (n=44/126, 35%) of the included articles had not 
been originally found through the systematic literature search. They had been 
found from the reference lists of the included articles or recommended by 
experts and researchers. One of the reasons for the relatively high number of 
manually added articles may be the broad scope of the systematic literature 
search. Each of the six strategic goals of the national MI strategy could have 
made a scope of its own for a literature review. Furthermore, as a 
methodological strengths can be considered the fact that the preliminary 
selection of the articles was conducted by multiple researchers,22 and at least 
two researchers independently reviewed full-text eligible articles for inclusion 
and exclusion and achieved consensus on which studies to include. 
The study protocol followed the Cochrane Handbook for Systematic 
Reviews and the PRISMA Guidelines in conducting the review and reporting 
findings when appropriate.205,206 Included articles were qualitatively content 
analysed in more detail and data were extracted by two researchers and 
approved by the other research group members, which improves the 
comprehensiveness of the study.215 The validity of the analysis and 
interpretation was ensured by discussing the findings with some senior 
researchers who had been familiar with the research area in Finland for a long 
period of time. 
As the review solely includes full original peer-reviewed research 
articles, the grey literature (e.g., conference abstracts, theses except doctoral 
monographs) was excluded. Although grey literature would have deepened 
and extended the understanding of MI practices in Finland, such literature is 
mainly related to the same research areas as the articles included in this 
review. 
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6.2.2 REPEATED CROSS-SECTIONAL SURVEY AMONG FINNISH 
ADULT POPULATION (II) 
 
Study II enabled an examination of the trends on the receipt of MI among 
adult medicine users at the population level over time. The response rate of 
this repeated cross-sectional survey decreased from 67% to 53% during the 
study period (1999–2014) reflecting that the representativeness of the results 
to the entire population is getting weaker.207,356-364 Females were 
overrepresented (63% vs. 50% of the respective gender among the general 
population) throughout the study period.207,356-365 The youngest respondents 
(<35 years) were underrepresented and the oldest respondents (55–64 years) 
were overrepresented throughout the study period. The data did not contain 
the population segment of 65 years or older, which is a constantly growing 
demographic in Finland. Receipt of MI in this segment should be separately 
explored using other data. In comparison to the general population, people 
with the lowest level of education (≤9 years) were slightly underrepresented, 
and, accordingly, those with a higher education (>9 years) were slightly over-
represented throughout the study period. These facts should be considered 
when transferring the results for the Finnish adult population (15–64 years).  
The study was designed to indicate trends at the population level, not to 
indicate changes in the receipt of MI at the individual medicine user level. The 
study was conducted as a repeated cross-sectional survey without the cohorts: 
each study year a new nationally representative sample of 5000 Finns aged 
15–64 years was used. Thus, the survey each year was a cross-section of the 
Finnish adult population reflecting its health behaviours, morbidity, use of 
medicines and receipt of MI at that particular point of time. It was a conscious 
decision to first conduct a descriptive indicative trend analysis providing a 
foundation for further analysis that could go deeper in understanding the 
receipt of MI for example among various patient groups.  
In the survey instrument, the background question relating to the 
medicine use (Figure 16) has been drawn up in 1978 when the first survey was 
carried out. Since then, this question has remained the same to confirm 
comparability of the data between study years. In 1978, powders were a 
common dosage form, but in the future this question should be updated to 
reflect the most common current dosage forms. This survey was discontinued 
in 2014. Since then, the question about the use of medicines has been included 
in the Medicines Barometer population survey conducted by Fimea.337 
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The study provided information only on MI sources listed in the survey 
instrument that was compiled as comprehensively as possible (Figure 15). 
Prescription and OTC medicines were not specified separately. The survey 
instrument did not specify what kind of websites or other Internet-based MI 
sources medicine users had used for MI, nor did it specify the use of email or 
social media services such as chat. Moreover, the quality, validity or amount 
of the MI received were not explored in this study. Furthermore, the 
respondents were not distinguished according to their spontaneous activity in 
MI seeking. 
 
6.2.3 SEMI-STRUCTURED INTERVIEWS AMONG STAKEHOLDERS (III) 
 
Study III gathered stakeholder views on the implementation of the national 
MI strategy 3 years after its launch from a wide range of stakeholder 
representatives by use of semi-structured interviews. The pragmatic 
evaluation used in this study has been criticised that the approach is 
fragmented, lacking a developed philosophy, and there is limited practical 
descriptions on how to deal with complex and challenging interventions.366,367 
Based on these facts, there is a demand for this type of assessment that can 
serve as an example for the future evaluation of the national programs. Similar 
national long-term programs related to the strategic development of MI have 
been rare in other countries, i.a. examples can be found from the UK and the 
USA.16 Other countries could learn from this case and be encouraged to 
establish and evaluate their own national programs. 
A purposive sample of the stakeholders actively involved in 
implementing the national MI strategy ensured that all participants were 
familiar with and interested in the subject. The figure of the medication use 
process22 was shown during the interview in order to facilitate participants 
recollecting different areas of implementing the medication use process. The 
background of the stakeholders might influence the study results, such as 
education, organisation or work experience. Half of HCPs participating in the 
study were pharmacists, which may have skewed the results in recognising the 
medication counselling given by pharmacists to one of the most successful 
actions in the medication use process. There was, however, an absence of real 
patients with chronic diseases and long-term medications from the data as the 
patient voice distorts results. 
The open question technique (e.g., the question starts with ‘what’ or 
‘how’) was favoured in the interviews as such questions require participants 
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to answer more comprehensively.215 Pre-interviews were conducted to 
establish the credibility of the study. Additionally, the sample size was at a 
sufficient level for qualitative study as 79 out of 111 stakeholder 
representatives were interviewed (participation rate 71) representing 43 out 
of 53 organisations.368 The number of participants in the group interviews was 
reasonable (maximum six participants/interview) to allow everyone to 
express their opinions and experiences. The dynamics of the interviews may 
have been influenced by the fact that the interviews were conducted as 
individual, pair or group interviews. 
6.3 FURTHER RESEARCH 
Suggestions for further research topics related to developing MI practices and 
policy at national level are summarised in Figure 25. The research topics are 
based on the findings of the studies in this dissertation (Studies I–III), an 
updated version of the national MI research strategy,369 the interviews with 
the members of the MI Network in spring 2015 (Appendix 1) and the research 
topics related to MI included in the research strategy of the Rational 
Pharmacotherapy Action Plan (2018–2022).353  
In the future, MI research should shift towards larger research lines with 
a stronger theory base and study designs. More long-term trend and follow-
up studies should be conducted to deepen the understanding of the use and 
accessibility of MI sources among different patient groups (e.g., the ageing 
population, immigrants, patients with multiple medications and vulnerability 
related to socioeconomic factors, such as increasing poverty). Additionally, 
more population-based research is needed to, for example, gain a 
comprehensive understanding of the impacts and use of electronic MI, such 
as the Internet and social media. 
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Figure 25. Suggestions for further research as organised according to the main goals of the 
national medicines information (MI) strategy in Finland.22 
 
 
 
 
GOAL 1: To establish a multidisciplinary MI network in Finland 
• Organisation of MI and MI practices as part of the reform of the social welfare and healthcare 
services: implementation, baseline, follow-up and effectiveness studies 
• Follow-up for the actions of the National Medicines Information Network 
GOAL 2: To ensure that HCPs utilise reliable information sources and services 
• Current state of MI needs among HCPs 
• Use of MI sources among HCPs and utilisation of information sources in education 
• Use of electronic MI sources, clinical decision support systems and medication risk management 
tools among HCPs 
• Shortcomings and challenges in utilising MI and MI sources among HCPs 
• Awareness and availability of reliable MI sources among HCPs 
• Use of specialist services among HCPs, e.g., services by clinical pharmacologists 
GOAL 3: To ensure a high level of medicines expertise and multidisciplinarity in healthcare 
• Implementation of partnerships in medicine use in different healthcare settings 
• Incorporation of competences in multiprofessional practices, patient-centred medicines  
counselling, care support and MI tools into healthcare education programmes 
• Applications of existing good local multiprofessional practices in healthcare 
• Competences and challenges of practical nurses in medicine expertise 
 
 
 
GOAL 4: To base medication counselling on national guidelines and local agreements 
• Current state of medication counselling practices in different healthcare units and settings 
• Standardisation of medication counselling practices, e.g., in community pharmacies 
• Pharmacotherapy and medication counselling competences among HCPs (e.g., practical nurses)  
working in home care and social care units 
• Medication counselling and transition of patient information throughout the medication use  
process among patients with chronic disease 
GOAL 5: To ensure that medicine users utilise reliable information sources and services 
• The effectiveness of MI in patient care and the significance of MI received from various sources,  
such as the Internet and applications in smartphones 
• Patients’/medicine users’ MI-seeking strategies and behaviours 
• Patients’/medicine users’ awareness and availability of reliable MI sources and actions to promote 
patients to find these information sources 
• Reasons for increasing number of people who do not receive MI 
• Online counselling provided by HCPs and the use of electronic MI sources (e.g., the Internet,  
social media services) among patients 
• MI needs, suitable information channels for receiving MI and factors influencing on the receipt of MI  
in various patient groups, such as the ageing population, immigrants and patients with multiple 
diseases and medications 
GOAL 6: To achieve a high level of health literacy among the general public 
• Deeper understanding of health and MI literacy skills among different population and medicine user 
segments 
TOPICS FOR FURTHER RESEARCH IN DEVELOPING 
MEDICINES INFORMATION IN FINLAND 
7 Conclusions 
102 
 
7 CONCLUSIONS 
Based on the Studies I–III and the literature review of the dissertation, the 
following conclusions can be drawn: 
 
 Medicines information (MI) practices and policies have been widely 
developed and studied in Finland since the 2000s. After establishment 
of the national MI strategy in 2012 the coordination between 
stakeholders and their MI actions has improved. 
 Although multiple actions proposed in the national MI strategy have 
been implemented, the ultimate goal of well-informed and adherent 
patients had not yet been reached by the first follow-up in 2015. 
 The number and availability of MI sources targeted to consumers have 
increased during the 2000s. However, the shift “from paper to cyber” 
towards the use of electronic information sources has been moderate. 
Future research should focus on investigating awareness, accessibility 
and usability of electronic MI sources from the consumer and medicine 
user perspective, as well as their integration into the medication use 
process. 
 MI research should shift towards larger research lines with a stronger 
theory base and study designs. More long-term trend and follow-up 
studies should be conducted and the effectiveness of MI practices in 
different healthcare settings should be further investigated. 
 Healthcare professionals (HCPs) and package leaflets (PLs) still have 
dominating importance for adult medicine users in receiving MI 
despite the growing number of other MI sources available over time 
during the 2000s. 
 A growing number of adult medicine users did not receive MI from any 
information sources during the 2000s. The proportion of medicine 
users who did not report receiving MI from any of the listed sources 
grew by sevenfold and the proportion of those who did not report 
receiving MI from any of HCPs more than doubled. 
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 Medication use process of a chronically ill patient using long-term 
medication requires development at every level of implementation, 
namely at the infrastructure level (macro), HCP level (meso) and 
patient level (micro). 
 At the infrastucture level (macro), the major development 
needs concern coordination of care, transfer of patient 
information between healthcare units, availability of a 
reconciled medication list, and local and national agreements 
on tasks and responsibilities of patients and each HCP involved 
in the medication use process. 
 At the HCP level (meso), the most urgent development needs 
focus on the entire medication use process in primary care and 
social welfare units, particularly in geriatric care units where 
practical nurses’ competences do not meet their actual work 
responsibilities. 
 At the patient level (micro), the current medication use process 
lacks genuine patient-centredness, which is manifested by a 
lack of adherence, motivation and communication, and the 
inability of patients to retrieve information themselves. Patients 
on long-term medications need to be better involved in 
implementing their own treatment by improving empowerment 
and partnership, and by finding new ways to support self-
management and treatment commitment. 
 Many of the challenges identified in this evaluation study have 
been taken into consideration in the implementation of the 
national MI strategy since 2015, and the major challenges also 
in the Rational Pharmacotherapy Action Plan (2018–2022) 
established by the Ministry of Social Affairs and Health. 
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APPENDICES 
Appendix 1. Study III: An interview guide. 
THEME 1. IMPLEMENTATION OF THE NATIONAL MEDICINES INFORMATION 
STRATEGY AT NATIONAL LEVEL AND ACTIONS TAKEN IN YOUR OWN 
ORGANISATION 
 
The six strategic objectives of the national medicines information strategy used as a 
stimulus material.22 
 
1) How have the strategic goals described in the national medicines information 
strategy progressed nationally? 
 Which strategic goals have best been achieved at national level? 
 Which strategic goals have least been achieved at national level?  
 What has been the most significant thing that has been achieved at 
national level? 
 
2) What has been the significance/importance of the national medicines 
information strategy at:  
a) national level? b) international level?  
 
Are there other important strategic issues related to medicines information that 
should be taken into account and possibly lacking in the current national 
medicines information strategy? 
 
3) What is your organisation going to do based on the national medicines 
information strategy: 
a) in the near future? b) by 2020? 
 
4) If you consider the figure of medication use process for a patient with chronic 
disease: 
a) what are the most crucial actions that have been implemented? 
b) what actions should be focused on in the future in order to achieve  
the goal of a well-informed, adherent patient or medicines user? 
 
The figure of medication use process from the national medicines information 
strategy was shown to the participants during the interview.22 
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THEME 2. EXPERIENCES OF WORKING WITH THE NATIONAL MEDICINES 
INFORMATION NETWORK AND THE ROLE OF THE NETWORK AT NATIONAL LEVEL 
 
Organisational model of the National Medicines Information Network used as a 
stimulus material (sent to the participants in advance). 
 
NETWORK LEVEL 
 
5) What is the relevance of the National Medicines Information Network activity to 
the provision of medicines information and the implementation of the national 
medicines information strategy at national level? 
 What are the positive things the National Medicines Information Network 
has been brought at national level? 
 What are the positive things the National Medicines Information Network 
has been brought to your organisation? 
 What kind of development needs are at national level/at organisational 
level? 
 
WORKING GROUP LEVEL 
 
6) How did the participation in the working group/s affect your own work and/or 
your organisation? What has been working and what should be further 
developed? 
 What are the positive things that your participation in the National 
Medicines Information Network has brought to your job/your 
organisation? 
 What are the negative things that your participation in the National 
Medicines Information Network has brought to your job/your 
organisation? 
 How the information on the activities of the National Medicines 
Information Network has been shared within your organisation? 
 
7) How should research be directed to support the strategic development of 
medicines information practices in Finland? 
 
8) What kind of wishes you have for the National Medicines Information Network, 
working groups and coordination (i.e., Fimea)? 
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Appendix 2. Study II: Trends in the receipt of medicines information among men and women 
in 1999–2014 (percentage of the respondents who reported use of at least one prescription 
or non-prescription medicine within 7 days prior to the survey). 
 
 
 
 
                        
          
 
 
  
 
Appendix 3. Study II: Trends in the receipt of medicines information according to the age groups in 1999–2014 (percentage of the respondents who reported 
use of at least one prescription or non-prescription medicine within 7 days prior to the survey). 
 
 
    
           
 
 
 
 
 
  
 
Appendix 4. Study II: Trends in the receipt of medicines information according to the number of medicines in use in 1999–2014 (percentage of  
the respondents who reported use of at least one prescription or non-prescription medicine within 7 days prior to the survey). 
 
 
        
           
 
 
  
 
Appendix 5. Study II: Trends in the receipt of medicines information according to the number of diagnosed diseases in 1999–2014 (percentage of the 
respondents who reported use of at least one prescription or non-prescription medicine within 7 days prior to the survey). 
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